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ABSTRACT OF DISSERTATION

PEPTIDE-FUNCTIONALIZED MAGNETIC NANOPARTICLES FOR CANCER
THERAPY APPLICATIONS
Lung cancer is one of the leading causes of cancer deaths in the United States.
Radiation and chemotherapy are conventional treatments, but they result in serious side
effects and the probability of tumor recurrence remains high. Therefore, there is an
increasing need to enhance the efficacy of conventional treatments. Magnetic nanoparticles
have been previously studied for a variety of applications such as magnetic resonance
imaging contrast agents, anemia treatment, magnetic cell sorting and magnetically
mediated hyperthermia (MMH). In this work, dextran coated iron oxide nanoparticles were
developed and functionalized with peptides to target the nanoparticles to either the
extracellular matrix (ECM) of tumor tissue or to localize the nanoparticles in subcellular
regions after cell uptake.
The magnetic nanoparticles were utilized for a variety of applications. First, heating
properties of the nanoparticles were utilized to administer hyperthermia treatments
combined with chemotherapy. The nanoparticles were functionalized with peptides to
target fibrinogen in the ECM and extensively characterized for their physicochemical
properties, and MMH combined with chemotherapy was able to enhance the toxicity of
chemotherapy.
The second application of the nanoparticles was magnetically mediated energy
delivery. This treatment does not result in a bulk temperature rise upon actuation of the
nanoparticles by an alternating magnetic field (AMF) but rather results in intracellular
damage via friction from Brownian rotation or nanoscale heating effects from Neél
relaxations. The nanoparticles were functionalized with a cell penetrating peptide to
facilitate cell uptake and lysosomal escape. The intracellular effects of the internalized
nanoparticles alone and with activation by an AMF were evaluated.
Iron concentrations in vivo are highly regulated as excess iron can catalyze the
formation of the hydroxyl radical through Fenton chemistry. Although often a concern of
using iron oxide nanoparticles for therapeutic applications, these inherent toxicities were
harnessed and utilized to enhance radiation therapy. Therefore, the third application of
magnetic nanoparticles was their ability to catalyze reactive oxygen species formation and
increase efficacy of radiation. Overall, iron oxide nanoparticles have a variety of cancer
therapy applications and are a promising class of materials for increasing efficacy and
reducing the side effects of conventional cancer treatments.

KEYWORDS: iron oxide nanoparticles, peptides, magnetically mediated hyperthermia,
magnetically mediated energy delivery, reactive oxygen species
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Chapter 1 Introduction
Cancer is the second leading cause of death in the Unites States. Survival rates of lung cancer
are especially low with the 1- and 5-year relative survival rates at 44% and 17%, respectively.
These low survival rates are partially due to more than half (57%) of patients not being diagnosed
until the cancer has progressed to an advanced stage. In addition, current treatments (e.g.,
chemotherapy and radiation) result in severe side-effects. Therefore, there is a clear need to
improve current cancer therapies in order to prolong survival and reduce the toxic side-effects of
treatments.
Treatment of lung cancer via hyperthermia, the heating of tissue to 42-45 °C, in conjunction
with radiation and chemotherapy has resulted in synergistic effects in regard to efficacy of the
conventional treatment and has the potential to decrease the prevalence of toxic side effects (Genet,
Fujii et al. 2013). Current hyperthermia methods include whole body and regional hyperthermia.
Whole body hyperthermia is relatively invasive and results in greater toxic side-effects than
regional hyperthermia, but both have several disadvantages, including the burning of healthy tissue,
limited penetration of heat into the body, under-dosage of heat, and complications such as increased
heart rate and increased cardiac output (Zwischenberger, Vertrees et al. 2004, Issels 2008, Kumar
and Mohammad 2011). Magnetically-mediated hyperthermia (MMH), the heating of tissue using
heat generated by magnetic nanoparticles in the presence of an alternating magnetic field (AMF),
shows great promise in overcoming the limitations of current hyperthermia treatments due to the
ability of nanoparticles to deliver heat directly to the tumor site. Iron oxide nanoparticles are a class
of magnetic nanoparticles which have been previously studied due to their inherent
biocompatibility, magnetic properties, and lack of protein adsorption after proper coating (Laurent,
Dutz et al. 2011). Iron oxide nanoparticles have the ability to passively and/or actively target tumors
and, upon activation by an external alternating magnetic field, generate heat via multiple possible
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loss mechanisms: hysteresis, Néel paramagnetic switching, and friction from Brownian rotation
(Dennis, Jackson et al. 2009).
One of the main limitations to MMH is the difficulty in achieving a high magnetic nanoparticle
concentration within tumor tissue following intravenous injection of the nanoparticles. Properly
masking the nanoparticles with a biocompatible coating to improve stability, biocompatibility, and
circulation time has been used to improved tumor concentrations via passive targeting and
utilization of the enhanced permeation and retention (EPR) effect (Veiseh, Gunn et al. 2010, Wu,
Wu et al. 2015). Additionally, functionalizing the nanoparticle surface with active targeting ligands
has been shown to improve tumor targeting and retention of the magnetic nanoparticles
(Turcheniuk, Tarasevych et al. 2013, Singh and Sahoo 2014, Hola, Markova et al. 2015).
Despite extensive research, MMH treatment has yet to make its clinical debut. A recent focus
for magnetic nanoparticle research has been in magnetically mediated energy delivery (MagMED).
In this approach, cells internalize magnetic nanoparticles and when exposed to an AMF, the
nanoparticles locally delivery energy in the form of local heat dissipation, mechanical effects,
and/or surface reactivity without a measurable temperature rise (Kozissnik, Bohorquez et al. 2013).
MagMED treatment has been shown to elicit cellular responses such as lysosomal permeabilization,
increased mitochondrial reactive oxygen species (ROS) generation, opening of ion channels, and
apoptosis (Domenech, Marrero-Berrios et al. 2013, Sanchez, Diab et al. 2014, Connord, Clerc et
al. 2015).
The main focus of magnetic nanoparticles in biomedical research has been their ability to
deliver energy to increase the regional temperature in response to an AMF, but recent focus has
shifted to understanding the mechanisms of MagMED toxicity, such as the generation of ROS. Iron
oxide nanoparticles can catalyze the Haber-Weiss reaction through Fenton chemistry, producing
the highly reactive hydroxyl radical. Cancer cells are more susceptible to oxidative insults
compared to normal cells due to fast cell proliferation and metabolism so additional ROS stress
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induced by exogenous agents can overwhelm the relatively low antioxidant capacity and disrupt
the redox homeostasis inside cancer cells leading to selective tumor cell toxicity (Huang, Chen et
al. 2013).
This dissertation provides an investigation into applications of peptide-functionalized iron
oxide magnetic nanoparticles for cancer therapy. Peptides were chosen as the targeting ligands for
the studies completed as part of this dissertation, and chapter 2 reviews various targeting modalities
utilized to effectively target magnetic nanoparticles to tumor tissues. Chapter 3 then reviews
magnetic nanoparticles for remote controlled therapies such as thermal therapy, nanoscale energy
delivery, and combinational therapies.
1.1 Objectives
The overall objective of this dissertation was to develop peptide-functionalized iron oxide
magnetic nanoparticles for cancer therapy applications such as magnetically mediated
hyperthermia, magnetically mediated energy delivery, and reactive oxygen species generation in
order to enhance the efficacy of conventional cancer treatments. The overall objective was
accomplished through the following four projects:
1. Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for
hyperthermia treatment of cancer
2. Effect of synthesis method on the physical and chemical properties of dextran-coated iron oxide
nanoparticles
3. Peptide conjugated magnetic nanoparticles for magnetically mediated energy delivery to A549
lung carcinoma and H358 bronchi alveolar
4. Peptide conjugated iron oxide nanoparticles for the enhancement of radiation therapy
Chapter 4, entitled “Synthesis and characterization of CREKA-conjugated iron oxide
nanoparticles for hyperthermia treatment of cancer” presents a peptide-conjugated iron oxide
magnetic nanoparticle system for targeted magnetically mediated hyperthermia treatment in
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combination with chemotherapy. This chapter analyzes the physicochemical characteristics of the
nanoparticle system and provides a proof-of-concept study with magnetically mediated
hyperthermia and cisplatin, a common chemotherapeutic. Although iron oxide nanoparticle
synthesis has been extensively studied, researchers are continually searching for methods to
improve size, stability, and heating capabilities of the nanoparticles. The iron oxide nanoparticles
developed in chapter 4 had optimal size and stability but low heating capabilities compared to other
systems in literature. Chapter 5 entitled “Effect of synthesis method on the physical and chemical
properties of dextran-coated iron oxide nanoparticles” aimed to improve the properties of dextrancoated iron oxide nanoparticles synthesized by the co-precipitation method. This chapter also
solidified the process by which dextran-coated iron oxide nanoparticles are synthesized in our lab.
Chapter 6, “Peptide conjugated magnetic nanoparticles for magnetically mediated energy
delivery to A549 lung carcinoma and H358 bronchi alveolar”, utilizes iron oxide nanoparticles
conjugated to a cell penetrating peptide in the presence of an AMF to elicit intracellular changes
through MagMED. The physicochemical properties of the nanoparticle system are characterized
and a variety of assays are completed in hopes of improving our understanding of the intracellular
effects of this treatment.

Chapter 7, “Peptide conjugated iron oxide nanoparticles for the

enhancement of radiation therapy” utilizes the iron oxide nanoparticles developed in chapter 6 to
catalyze intracellular ROS generation and permeabilize lysosomal structures which sensitizes the
cancer cells to subsequent radiation treatment. Finally, chapter 8 reports the conclusions of this
dissertation and potential future directions for peptide-functionalized iron oxide nanoparticles.
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Chapter 2 Active targeting strategies of iron oxide magnetic nanoparticles
2.1 Introduction
Magnetic nanoparticles have been utilized in a variety of biological applications due to their
flexible design and low toxicity, including contrast agents in magnetic resonance imaging (MRI),
magnetic separation, magnetically mediated hyperthermia (MMH), and magnetically mediated
energy delivery (MagMED). Although a multitude of magnetic nanoparticles exist, iron oxide is a
class of magnetic nanoparticles that has received particular interest due to ease of preparation, ease
of modification, and superparamagnetic properties. Maghemite (Fe2O3) and magnetite (Fe3O4) iron
oxide crystals usually fall below the superparamagnetic size threshold of approximately 15 nm,
making them the most common form of iron oxide studied for biological applications (Tucek,
Zboril et al. 2006, Pankhurst, Thanh et al. 2009, Laurent, Dutz et al. 2011). In addition, iron oxide
nanoparticles are biocompatible at low doses and biodegradable, which increases their potential for
biological applications.
Coating of magnetic nanoparticles with a biocompatible compound is required prior to
biological use. The magnetic nanoparticle coating can serve to decrease nanoparticle aggregation
by suppressing particle-particle interactions, prevent degradation of the core iron oxide in
biological environments, and provide functional groups for conjugation of targeting agents, drugs,
or other biological compounds (Gupta and Gupta 2005). Coating the magnetic nanoparticles can
also mask the nanoparticles from recognition by the immune system, prolonging circulation time
and ultimately leading to increased uptake.
There are a wide variety of organic and inorganic coatings for magnetic nanoparticles that
protect and stabilize the nanoparticles for biological use. There are several recent reviews that
examine these coatings and their applications (Gupta, Naregalkar et al. 2007, Veiseh, Gunn et al.
2010, Xie, Liu et al. 2011, Jiang, Win et al. 2013, Jin, Lin et al. 2014, Chu, Yu et al. 2015, Wu, Wu
et al. 2015). Organic coating materials include small molecules, surfactants, polymers, and
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biomolecules. Magnetic nanoparticles coated with these materials are commonly used for MRI,
drug targeting, and magnetic separation. Citric acid and silanes are examples of small molecules
which can be used to synthesize water-soluble iron oxide nanoparticles directly (Wydra, Kruse et
al. 2013) and to functionalize compounds to bare iron oxide nanoparticles. Small molecules allow
the magnetic nanoparticles to retain their saturation magnetization values after coating due to the
low mass fraction of the total particle (Wu, Wu et al. 2015). Polymers are a class of organic coatings
that pose several advantages over small molecules such as multifunctional groups and ability to
provide more colloidal stability (Pierrat, Zins et al. 2007). Several polymers, both natural and
synthetic, have been studied for functionalizing magnetic nanoparticles. Dextran is widely used
due to its biocompatibility and stability following crosslinking, but other polymers commonly
studied include poly (ethylene glycol), chitosan, poly (D,L-lactide) (PLA), and poly (acrylic acid)
(Chu, Yu et al. 2015). Biomolecules have continued to gain interest as coating materials for
magnetic nanoparticles, and a variety of biomolecules have been successfully conjugated to the
surface of iron oxide nanoparticles including enzymes, antibodies, proteins, and polypeptides
(Glickson, Lund-Katz et al. 2009, Hajshafiei, Fatahian et al. 2014, Zaloga, Janko et al. 2014, Wu,
Wu et al. 2015, Xie and Zang 2016).
Inorganic coatings can also be used to coat magnetic nanoparticles for biological applications,
and these are also used for improving semiconductor efficiency and information storage. Silica is
by far the most explored inorganic coating for biological magnetic nanoparticles. Silica coatings
enhance nanoparticle dispersion by screening the magnetic dipolar attraction between the
nanoparticles while providing protection from acidic environments (Tarn, Ashley et al. 2013).
Other inorganic coatings include metals (gold, silver, copper, etc.), metal oxides, and sulfoxides.
Prolonging circulation time of magnetic nanoparticles by coating with a biocompatible agent
is often insufficient to accumulate the nanoparticles at a specific tissue site. For example,
researchers have taken advantage of the underdeveloped, leaky vasculature of cancer tissue to
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passively target cancer tissue by the enhanced permeation and retention (EPR) effect (Bertrand,
Wu et al. 2014). As nanoparticles circulate throughout the body, they passively accumulate within
cancerous tissue and are retained due to the inability of the tissue to properly remove waste. While
this method has been shown to increase magnetic nanoparticle concentrations within tumor tissues,
the concentration is often insufficient to induce a therapeutic effect or significantly influence MRI
contrast. Therefore, active targeting is regularly utilized to increase magnetic nanoparticle
concentration within the tissue of interest and more specifically target the tissue based on selective
recognition as shown in Figure 2.1.

Figure 2.1 Targeting methods for magnetic nanoparticles include A) passive targeting and B) active
targeting. Active targeting includes targeting the i) extracellular matrix, ii) cell surface receptors
and/or iii) utilizing cell penetrating peptides to target specific intracellular organelles.
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2.2 Active Targeting
Active targeting of magnetic nanoparticles involves functionalizing the nanoparticle surface
with a specific moiety in order to direct the magnetic nanoparticle towards a specific binding site
of interest. The targeting method can help detect, characterize, and treat diseases based on
accumulation and aims to avoid off-target toxicities. This targeting method is often more effective
than relying solely on passive accumulation. Targeting functionalities for magnetic nanoparticles
include peptides, antibodies, and small molecules lending to a variety of biological targets such as
cell surface receptors, enzymes, proteins, and integrins.
Although there are a variety of methods for conjugating ligands to the surface of magnetic
nanoparticles, amines or carboxylic acids on the nanoparticle surface are commonly used for further
functionalization. These primary functional groups are usually present on the nanoparticle surface
via adsorption of polymers or small molecules (Hola, Markova et al. 2015). Amine functionalized
nanoparticles are easily modified with ligands containing carboxylic acids through the use of 1ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxosuccinimide (NHS)
crosslinking. Ligands with sulfhydryl groups such as those present on peptides and antibodies can
be functionalized to the surface using heterobifunctional linkers such as N-Succinimidyl 3-[2pyridyldithio]-propionate

(SPDP)

or

N-α-maleimidoacet-oxysuccinimide

ester

(AMAS)

(McCarthy and Weissleder 2008). However, it has been suggested that ECD/NHS chemistry leads
to randomly oriented antibodies on the nanoparticle surface which could result in a loss of
bioactivity of the conjugated antibody. Therefore, a more sophisticated method is to react amine
groups on the nanoparticle surface with heterobifunctional linkers to introduce maleimide, pyridyl
disulfide or iodoacetyl groups (Gruettner, Mueller et al. 2013). A comparison of antibody binding
after magnetic nanoparticle conjugation using EDC/NHS chemistry or maleimide and SPDP based
reactions demonstrated advantages of the latter. The bioactivity of the antibody was 88% after
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maleimide and SPDP reactions, and 35% for the EDC/NHS chemistry (Gruettner, Mueller et al.
2007).
Nanoparticles with carboxylic acid functionalized surfaces can also be modified with targeting
ligands but through a more tedious reaction which requires activation of the carboxylic acids.
Amine and carboxylic acid groups on the surface of nanoparticles are also interchangeable as
reaction of amine groups with succinic anhydride or glutaric anhydride converts the surface to
carboxylates, whereas the activation of carboxylic acid functionalized particles with EDC and NHS
followed by reaction with diamine results in amine functionalized nanoparticles.
There are a wide variety of moieties used to functionalize magnetic nanoparticles for active
targeting. Determining the appropriate ligand for functionalization depends upon the biological
target and the ultimate goal. Smaller peptides and nucleic acid based aptamers can be engineered
to have only one active molecular handle per molecule which ensures consistent linking to the
nanoparticle surface and no loss of binding activity. Small organic molecules can also be
engineered to assemble at high densities but may require longer linker molecules to ensure that the
nanoparticle coating does not obscure the active region (Veiseh, Gunn et al. 2010). Peptides and
aptamers can also be chemically synthesized and have been shown to be non-immunogenic unlike
many antibodies and proteins. Relatively bulky proteins and antibodies can be difficult to assemble
onto a nanoparticle surface due to lack of consistent covalent bonding orientation due to these
ligands having multiple active functional groups per molecule and non-specific physical
interactions between the molecule and the nanoparticle. However, due to the ease of conjugation
and specificity of these molecules they continue to gain interest for nanoparticle targeting. This
section provides an overview of recent advances in active targeting of magnetic nanoparticles via
antibody, aptamer, peptide, and small molecule functionalization.
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2.2.1 Antibodies
Antibodies are one of the most used biomolecules to provide specificity and bioactivity to
nanoparticles due to their high specificity and large diversity. It is feasible to obtain or engineer
specific antibodies against virtually any substance in high amounts so it is possible to find
antibodies that recognize a large number of antigens ranging from large pathogens (viruses,
bacteria, etc.) to small molecules (drugs, hormones, bacterial toxins, allergenic peptides, etc.).
Antibodies have high binding affinities and retain their specificity for target molecules even in
complex environments or low target concentrations (Montenegro, Grazu et al. 2013). Antibodies
have continued to gain interest for their cancer targeting abilities due to cancer cells having different
surface expression than healthy cells however, other applications include cell separation (Bloemen,
Denis et al. 2015) and targeting of atherosclerotic plaques (Jacobin-Valat, Laroche-Traineau et al.
2015).
Anti-human epidermal growth factor receptor 2 (HER/neu) monoclonal antibodies are
commonly used for breast cancer targeting as about 25% of breast cancer patients show
overexpression of HER2/neu, making it a target of interest for enhancing drug delivery. There are
a variety of anti-HER2 moieties that have been studied for nanoparticle targeting. Kanazaki et al.
synthesized iron oxide nanoparticles conjugated to one of three anti-HER2 moieties: Trastuzumab,
anti-HER single chain fragment variabile (scFv) and anti-HER2 peptide (Kanazaki, Sano et al.
2015). Iron oxide nanoparticles conjugated with the anti-Her2 scFv showed higher tumor
accumulation and tumor-to-background ratios than the other targeting moieties. Recently, Mu et al.
functionalized PEG coated iron oxide magnetic nanoparticles with the anti-HER2/neu peptide and
carboxymethylated-B-cyclodextrin to allow hydrophobic loading of paclitaxel (PTX) (Mu, Kievit
et al. 2015). SK-BR-3 (HER2/neu positive) and MDA MB 231 (HER2/neu negative) cells were
used for uptake studies and uptake was significantly greater in the SK-BR-3 cells indicating that
uptake was dependent upon the presence of HER2/neu. Cytotoxicity results showed that the iron
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oxide nanoparticle system was non-cytotoxic, and PTX treatment was nearly the same for both cell
lines but the nanoparticle formulation loaded with PTX was more effective on SK-BR-3 cells. In
vivo targeting of the nanoparticles to a SK-BR-3 xenograft tumor mouse model showed enhanced
accumulation of the targeted nanoparticles compared to non-targeted. The radiant efficacy ratio
(tumor/whole body) was increased by 2.5 fold in the targeted system.
Another recent study which utilized the Herceptin monoclonal antidoby (Trastuzumab) was
completed by Choi et al. In this study, chitosan conjugated, pluronic-based nano-carriers loaded
with iron oxide nanoparticles and doxorubicin were developed (Choi, Lee et al. 2015). The Cy5.5
fluorophore was conjugated to the nanoparticle along with Herceptin monoclonal antibody.
Cytotoxicity of the multifunctional nanoparticles was greater than DOX alone when tested on SKBR-3 cells likely due to the Herceptin antibody. Tumor bearing mice were established by
subcutaneous inoculation of SK-BR-3 cells into the right rear flank. After injection of the targeted
or non-targeted nanoparticle systems, the fluorescence intensity was monitored over time.
Accumulation at the tumor site of the targeted multifunctional NPs increased up to 24 hours post
injection and although the non-targeted system still accumulated at the tumor site, there was
significantly greater fluorescence in the mice receiving the targeted system compared to the nontargeted. Tumor growth suppression was monitored, and as expected, the targeted multifunctional
nanoparticles (day 20: 885 mm3) showed a stronger tumor suppression than the non-targeted
nanoparticles (day 20: 1314 mm3), DOX alone (day 20: 2873 mm3), or saline (day 20: 3340 mm3).
Animal weight was monitored during the experiment to confirm the absence of additional toxicities
due to the nanoparticle treatment.
Another common target in breast cancer cells is MUC1. Shanehsazzadeh et al. developed
dextran crosslinked iron oxide nanoparticles that were conjugated with C595 monoclonal antibody
to target MUC1 (Shanehsazzadeh, Gruettner et al. 2015). Uptake of the targeted nanoparticles into
MUC1 positive cells was more than 9 times higher than the uptake into MUC1 negative cells. In
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vitro MRI signal enhancements in MDA MB 231 and MCF 7 were -75 and -70%, respectively,
indicating that nanoparticle systems is uptake was sufficient to enhance contrast in MR imaging in
both cell lines.
The varying expressions of protein, ligands, and receptors on cancer cell surfaces are what
allows for selective targeting of nanoparticles. Prostate specific membrane antigen (PSMA) is
expressed at high levels in prostate cancer cells but minimally in healthy tissue, allowing for
selective targeting. PSMA contains a unique sequence which mediates internalization and
endosomal recycling, leading to high intracellular retention. The J591 antibody has high specificity
for PSMA and was selected by Tse et al. for conjugation to iron oxide nanoparticles to enhance
MRI contrast of preclinical prostate cancer (Tse, Cowin et al. 2015). Conjugation of J591 to the
iron oxide nanoparticles did not affect its binding ability to PSMA but rather increased the iron
concentration in cells positive for PSMA compared to cells lacking PSMA expression. In an in vivo
study with orthotopic LNCaP-luc tumor bearing mice, intravenous injection of the J591-conjugated
iron oxide nanoparticles led to significant reduction in MRI intensity compared to non-targeted
nanoparticles. Prussian blue staining also indicated significant accumulation of iron within the
tumor when the mice were treated with the targeted nanoparticles.
Epidermal growth factor receptor (EGFR) is commonly expressed on gliobastoma (GBM) and
is the target for the recombinant monoclonal antibody cetuximab. Cetuximab is a 152 kDa chimeric
monoclonal antibody which binds to the extracellular domain of the human EGFR, and has been
used to treat GBM. Kaluzova et al. conjugated cetuximab to amphiphilic triblock copolymer coated
iron oxide nanoparticles in order to investigate the therapeutic targeting effect of the cetuximabiron oxide nanoparticles against EGFR and EGFRvIII expressing GBM stem-like cells, as these
cells are responsible for tumor initiation, progression, and re-growth after chemoradiation
(Kaluzova, Bouras et al. 2015). GBM neurospheres were utilized for testing the nanoparticle system
as neurospheres are pathologically relevant models that maintain genomic changes of the primary

12

tumor, exhibit stem-like properties, and display the invasive characteristics of GBM. Cetuximabiron oxide nanoparticles significantly decreased cell survival in all neurospheres tested, especially
after 72 hours of treatment. Cetuximab alone had a modest effect and due to non-specific uptake of
free iron oxide nanoparticles, viability of N08-74 neurospheres was also compromised, but less
effectively. Mice were implanted with GBM neurspheres and the mice which received the
cetuximab-iron oxide nanoparticles lived significantly longer (164 days) compared to the control
(146 days) or the cetuximab only (147 days) groups. In follow-up work, a similar cetuximab
conjugated iron oxide nanoparticle system was used in combination with fractional radiotherapy to
increase the radiosensitivity of glioblastoma in a rodent model (Bouras, Kaluzova et al. 2015).
Primary in vitro work found that exposure of human GBM cells to cetuximab-iron oxide
nanoparticles for 24 hours followed by fractionated radiation resulted in a significant decrease in
GBM survival compared to control cells with radiation, cetuximab with radiation, or iron oxide
nanoparticles with radiation. Elevated levels of cleaved caspase 3 and apoptosis were found in the
cetuximab-iron oxide nanoparticle and radiation combined treatment as well. In vivo studies were
completed with athymic mice inoculated with GBM cells. Mice were treated with cetuximab-iron
oxide nanoparticles, cetuximab or PBS followed by fractionated radiation and the median survival
for the three groups was 60, 24, and 15 days, respectively, indicating that the tumor cells were
sensitized to subsequent radiation treatment by the cetuximab-iron oxide nanoparticles.
Another growth factor which is of particular interest for targeting cancer is the vascular
endothelial growth factor (VEGF). Many tumor types have extensive areas of hypoxia and necrosis
leading to up-regulation of angiogenesis which includes secretion of pro-angiogenic factors such
as VEGF, making VEGF a promising target for tumor tissue. Abakumov et al. synthesized bovine
serum albumin (BSA) coated iron oxide nanoparticles that were further functionalized with the
monoclonal antibody against VEGF (mAb VEGF) (Abakumov, Nukolova et al. 2015). In vitro
targeting of the nanoparticles to their receptor was evaluated on C6 glioma cells expressing
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membrane bound VEGF. The immunofluorescence assay suggested that the targeted nanoparticles
bound to glioma C6 cells but negative control IgG conjugated nanoparticles did not. Confocal
imaging showed that the nanoparticles were located within lysosomes following cell uptake. In vivo
MRI was completed on rats bearing glioma C6 tumors but there was no difference between the MR
image contrast in rats receiving IgG functionalized or mAb VEGF functionalized nanoparticles five
minutes and two hours following IV injection. However, after 24 hours, there was significant
contrast in the targeted group compared to the control indicating that the residence time of the
nanoparticles at the tumor is increased by functionalizing with mAb VEGF.
2.2.2 Aptamers
Aptamers are single stranded oligonucleotides, DNA or RNA, with the ability to bind with high
affinity and specificity to a broad range of targets such as peptides, proteins, drugs, organic and
inorganic molecules, or even whole cells and viruses based on their specific binding pockets or the
target molecule (Delaviz, Gill et al. 2015). Aptamer-based nanoparticle formulations have merits
comparable to those of natural receptors such as antibodies and enzymes. Aptamers have the ability
to be amplified by polymerase chain reaction, they are flexible yet fold into well-defined 3D
structures upon binding to the target, and they can be easily modified or labeled with dyes or
functional groups (Kim, Raston et al. 2016). Although aptamer technology is still in its infancy
compared to that for antibodies, interest and applications continue to grow. While aptamers are
used for nanoparticle targeting to specific tissues for imaging or theranostic applications, recent
advances in aptamer targeting have focused on detection and separation of target molecules
(Ilkhani, Sarparast et al. 2015, Zhang, Ma et al. 2015, Sun, Lu et al. 2016, Wang, Qian et al. 2016).
The opportunity for magnetic separation of a target molecule is afforded by attaching aptamers to
magnetic nanoparticles. For example, Delaviz et al. developed a method for selectively capturing
hepatitis C virus (HCV) particles from human plasma samples using aptamer-conjugated magnetic
nanoparticles (Delaviz, Gill et al. 2015). The aptamer used was specific for binding to E1E2
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glycoprotein of HCV. In vitro results indicated that after exposure to the aptamer functionalized
magnetic nanoparticles, the viral load in a solution was significantly reduced. At the highest
concentration of aptamer-conjugated magnetic nanoparticles used, viral particle removal was more
than 91%. A similar concept was utilized by Xi et al. who tethered selected aptamers against the
hepatitis B surface antigen (HBsAg) to the surface of carboxylated magnetic nanoparticles (Xi,
Huang et al. 2015). After binding of HBsAg to the nanoparticles, they were magnetically decanted
and treated with a primary and secondary antibody system which catalyzed the chemiluminescence
of AMPPD, allowing for quantification of the HBsAg concentration. The nanoparticle system
resulted in a linear relationship between concentration of HBsAg and chemiluminescence intensity
in the range of 0.1-200 ng/mL using aptamer H01. The detection limit of 0.1 ng/mL was below the
detection limit of the ELISA assay used in the hospital and this technique is more time efficient
than ELISA assays.
Another unique detection method developed by Hu et al. utilized a simple optical aptasensor
based on gold nanoparticles and magnetic beads for the detection of AGR2 proteins (Hu, Li et al.
2015). The system is a sandwich-type, where the magnetic beads are functionalized with the antiAGR2 aptamer and the gold nanoparticles are functionalized with the partially complementary
DNA probe of the aptamer. As the concentration of AGR2 increased in solution, the sandwich
structure disassembled so the magnetic beads bound to the proteins and the gold nanoparticles
remained in suspension. After separation of the magnetic beads containing the AGR2, the gold
nanoparticles were detected by a spectrometer to determine the concentration. Analyses of spiked
human serum samples for AGR2 protein concentration revealed a recovery range of 93.5-103.8%.
An interesting proof of concept study was completed by Park et al. for the optical detection of
Salmonella Typhimurium (Park, Jeong et al. 2015). Magnetic nanoparticles were functionalized
with aptamers that specifically interact with outer membrane proteins on the surface of Salmonella
Typhimurium. The surface reactivity of the magnetic nanoparticles is reduced via DNA-mediated
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shielding of catalytic activity. In the presence of hydrogen peroxide, uncoated magnetic
nanoparticles promote the oxidation of 3,3’,5,5’-tretramethylbenzidine (TMB) (a colorimetric
substrate) by peroxidase-like activity. The blue-colored product can be detected by the naked eye.
In the presence of Salmonella Typhimurium the aptamers detach from the nanoparticle surface and
the nanoparticles can react with the hydrogen peroxide and TMB to generate a blue-colored
substrate. However, this reaction is limited when the aptamers remain attached to the nanoparticle
due to lack of Salmonella Typhimurium. This study showed a decrease in colorimetric absorbance
of TMB following DNA (aptamer) attachment to the nanoparticles and then an increase in
colorimetric absorbance when Salmonella Typhimurium was added, causing the aptamers to detach
and expose the nanoparticles.
As previously mentioned, aptamers have also been conjugated to magnetic nanoparticles for
imaging and targeted drug delivery applications as they are cheaper than antibodies yet have similar
binding affinities. Meng et al. developed a multifunctional nanoprobe for contrast enhanced
bimodal cellular imaging and targeted therapy (Meng, Lu et al. 2015). This mesoporous silica
nanoparticle based system was loaded with doxorubicin and chlorin e6 and coated with MnO2 sheets
and aptamer sgc8 for targeting PTK7 expressing cells. In the binding and cell uptake studies, there
was a significant increase in fluorescence of CEM (positive) cells compared to Ramos (negative)
cells after treatment with the nanoprobe. A control aptamer sequence was also tested as a targeting
modality and in both cell lines a weak signal was observed. A second recent study that utilized
aptamer targeted nanoparticles for drug delivery was completed by Roy et al. The anticancer biodrug bovine lactoferin (bLf) was conjugated to iron oxide nanoparticles encapsulated with chitosan
coated calcium phosphate (Roy, Kanwar et al. 2015). The nanoparticles were targeted with the
locked nucleic acid (LNA) modified aptamer against the epithelial cell adhesion molecule
(EpCAM) and nucleolin molecules. The nanoformulation was fed orally to mice injected with triple
positive (EpCAM, CD133, CD44) sorted colon cancer stem cells in a xenograft cancer stem cell
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mouse model. Complete regression of the tumor was observed in 70% of mice fed the non-targeted
nanocomposites, with 30% of the mice showing recurrence after 30 days. Only 10% of the mice
fed the targeted system showed tumor recurrence indicating a higher survival rate after treatment
with the targeted nanoparticles.
2.2.3 Peptides
Peptides are short, single strand amino acid sequences that target receptors on cell surfaces or
components of the extracellular matrix of tissues. Peptides can often rival the binding affinity of
much larger molecules such as antibodies, but due to their smaller size, multiple peptides can be
functionalized to the surface of a single nanoparticle resulting in nanoparticles that contain multiple
binding sites. A variety of peptides have been synthesized for specific biological targets, and this
section reviews the most recent advances in peptide conjugated magnetic nanoparticles.
2.2.3.1 Targeting the extracellular matrix
CREKA is a linear, five amino acid peptide, which was found to bind to fibrin(ogen) complexes
within the extracellular matrix of tumors. Fibrin(ogen) is upregulated within the ECM of tumor
tissue compared to healthy tissue, making it a potential target for nanoparticle accumulation. In
2010, Agemy et al. developed a self-amplifying nanoparticle delivery system by conjugating
CREKA to the surface of iron oxide nanoworms through a Michael addition reaction between the
thiol on the cysteine in the peptide sequence and the maleimide on the functionalized nanoparticles
(Agemy, Sugahara et al. 2010). CREKA nanoworms accumulated in the vessels of orthotopic
22Rv1 human prostate cancer xenograft tumors and caused clotting in them, as evidenced by the
presence of fibrin(ogen)-containing deposits in the vessel lumens. After methylation of the CREKA
peptide to increase stability, a 70% reduction in blood flow to the tumor was observed as well as a
strong reduction in tumor size and extended survival of the animals. Based upon this CREKAconjugated nanoworm system, Kruse et al. developed CREKA-conjugated iron oxide nanoparticles
for magnetically mediated hyperthermia treatment of lung cancer (see Chapter 4) (Kruse, Meenach
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et al. 2014). CREKA conjugated iron oxide nanoparticles bound to fibrin clots to a greater extent
than non-functionalized nanoparticles and had sufficient heating capabilities to induce
hyperthermia conditions upon exposure to an alternating magnetic field (AMF) (292 kHz, 56
kA/m). A combination proof of concept study was then completed to prove that magnetically
mediated hyperthermia can increase the efficacy of a common chemotherapeutic, cisplatin, in A549
lung carcinoma.
The CREKA peptide has also been used to target fibrin(ogen) complexes in adhered blood
clots, or thrombi. Song et al. developed a similar CREKA-conjugated iron oxide nanoparticle
system, which was also conjugated with fluorescein, as a multimodal imaging agent of
microthrombi (Song, Huang et al. 2014). The CREKA functionalized nanoparticles tested in vitro
were shown to bind to fibrin clots to a greater extent than non-targeted nanoparticles.
Microthrombus was induced in microcirculation of a rat model with acute myocardial ischemia
reperfusion. CREKA-conjugated iron oxide nanoparticles were found to preferentially accumulate
within microthrombi and generated a 1.95 fold greater fluorescence ratio as compared to the nontargeted nanoparticles. CREKA-conjugated iron oxide nanoparticles also resulted in signal loss on
MR T2 images in vivo whereas no significant change resulted after PBS or non-targeted
nanoparticle treatment.
2.2.3.2 Targeting cell surface ligands
Other peptides have been developed to target specific cell surface ligands that are
overexpressed on cancer cells but have low or no expression on healthy cells. Chlorotoxin (CTX)
is a tumor targeting peptide that has been shown to preferentially bind to a variety of cancer cells
such as prostate, intestinal, sarcomas, and glioblastoma by binding to metalloproteinase-2 (MMP2)
on the cell surface. Previous work by the Zhang group with chlorotoxin for magnetic nanoparticle
targeting for MRI (Sun, Du et al. 2010) and siRNA delivery (Veiseh, Kievit et al. 2010) led to the
development of their multifunctional nanocomposite system (Stephen, Kievit et al. 2014). This
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multifunctional nanocomposite was developed to deliver O6-benzylguanine (BG) glioblastoma
multiforme (GBM). BG, an inhibitor of DNA repair by serving as a pseudo-substrate for DNA
methyltransferase (MGMT), irreversibly inactivates the DNA repair protein. Therefore, when BG
is combined with a DNA methylating agent, temozolomide (TMZ), resistance of GBM to TMZ is
reduced. The nanocomposite was comprised of a redox responsive biopolymer shell of PEG and
chitosan that was conjugated to chlorotoxin and loaded with BG and iron oxide nanoparticles. BG
is known to induce bone marrow toxicity so while free BG and TMZ significantly reduce white
blood cell counts and platelet levels indicating toxicity, the BG nanoparticle formulation with TMZ
resulted in significantly reduced degree of WBC and platelet suppression. Animal survival
increased from 4 days to 9 days when treated with TMZ combined with the BG nanoparticle
formulation, compared to TMZ with the unloaded nanocomposite. The magnetic nanoparticles also
allowed for MR T2 imaging contrast enhancement. Overall, this nanocomposite is promising for
targeted combination treatment of GBM.
A peptide recently used for conjugation to magnetic nanoparticles is bombesin (BBN) or its
human counterpart gastrin releasing peptide (GRP). This peptide has been shown to play an
important role in cancer growth as gastrin releasing peptide receptors are overexpressed in many
cancers but have low expression levels in normal tissues. In this study, a bombesin analogue was
conjugated to dextran coated iron oxide nanoparticles as a new targeting MRI contrast agent for
breast cancer detection (Jafari, Salouti et al. 2015). There was no significant decrease in cell
viability of T47D cells after 24 hours of incubation with bombesin-conjugated iron oxide
nanoparticles up to a concentration of 30 µg/mL. In addition, no difference in cell viability between
bombesin targeted and non-targeted nanoparticles was obervered. T47D cell surfaces were highly
labeled with bombesin-conjugated iron oxide nanoparticles due to specific binding of bombesin to
the overexpressed GRP receptor on the surface. Non-targeted iron oxide nanoparticles were not
assoicated with T47D cell surfaces and Bombesin-conjugated iron oxide nanoparticles did not bind
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to 5637 cells, which do not express GRP. An in vivo proof of concept study for bombesinconjugated iron oxide nanoparticles for MR imaging contrast was also completed successfully.
A more common biological target is the αvβ3 integrin, an adhesion integrin overexpressed on
the surfaces of endothelial cells of neo-angiogenic vessels involved in the angiogenic process
(Schleich, Po et al. 2014). Angiogenesis, or the process by which new blood vessels are formed, is
the ultimate cause of tumor growth and metastasis. Therefore, researchers have continued to utilize
the αvβ3 integrin as a target for enhanced nanoparticle delivery. The arginine-glycine-aspartic acid
(RGD) peptide has been shown to preferentially bind to the αvβ3 integrin and has therefore been
functionalized to a variety of magnetic nanoparticles to improve accumulation at the tumor site and
enhance MR imaging or drug delivery.
Several recent studies have shown RGD-functionalized magnetic nanoparticles to enhance the
negative contrast of T2 MR imaging (Zhang, Jugold et al. 2007, Kumar, Yigit et al. 2010, Xie, Chen
et al. 2010, Xie, Liu et al. 2011, Yang, Zhuang et al. 2011, Chen, Tao et al. 2012, Jarzyna, Deddens
et al. 2012, Lin, Dayananda et al. 2012, Rosen, Chan et al. 2012, Zhao, Huang et al. 2012,
Menichetti, Manzoni et al. 2013, Passemard, Staedler et al. 2013). For example, Melemenidis et al.
utilized a cyclic variant of RGD (cRGD) conjugated to iron oxide nanoparticles and analyzed
binding to the αvβ3 integrin. HUVECs were stimulated with S-nitroso-N-acetylpenicillamine
(SNAP) to upregulate the αvβ3 integrin, and binding of the cRGD-targeted nanoparticles increased
by 14-fold compared to binding in non-stimulated cells (Melemenidis, Jefferson et al. 2015).
Additionally, under nanoparticle exposure via flow conditions of 1 dyne/cm2, SNAP stimulated
HUVECs retained cRGD-targeted nanoparticles 44 times more than non-stimulated cells.
Intravenous (IV) administration of cRGD iron oxide nanoparticles to mice bearing melanoma or
colorectal subcutaneous tumors resulted in enhanced negative contrast within the tumor on T 2
weighted images compared to pre-contrast images.
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Other groups have worked to develop RGD-targeted dual-modality imaging probes. Wang et
al. also used a cyclic form of RGD conjugated to liposomes encapsulating 2,3-dimercaptosuccinnic
acid (DMSA) coated iron oxide nanoparticles and CdSe quantum dots into the interior vesicle and
phospholipid bilayer, respectively (Wang, Li et al. 2015). The average fluorescence of RM-1 cells
after exposure to targeted liposomes was about 2.5 times stronger than after exposure to nontargeted liposomes due to interaction of cRGD with the avB3 integrins on the cell surface. An in
vivo bone metastasis model of prostate cancer was used to examine MR imaging capabilities. Four
hours after administration of the targeted liposomes there was a relative signal decrease in T2
indicating accumulation of the magnetic-fluorescent liposomes. Deng et al. developed dual
modality RGD-targeted magnetic nanoparticles radiolabeled with 125I for SPECT and MR
imaging (Deng, Zhang et al. 2015). Twenty-four hours post nanoparticle injection, the Bcap37
tumor-to-contralateral site ratio was 10.61 in SPECT imaging, and a significant signal reduction in
MR imaging was observed. Xue et al. also combined SPECT and MR imaging modalities into a
single RGD-targeted nanoparticle system using 99mTc radiolabeling and ultra-small iron oxide
nanoparticles for MRI contrast. Using free RGD as a competitive binding agent the authors proved
that accumulation of the nanoparticles at the tumor site was due to RGD binding to the a vB3
integrins, since a decrease in both SPECT and MRI contrast was observed under the competitive
conditions.
RGD-targeted magnetic nanoparticles are commonly used for negative contrast enhancement
in T2 MR imaging. However, recent studies have developed targeted magnetic nanoparticles for T1
MRI contrast (Luo, Yang et al. 2015) or both T1 and T2 contrast (Xue, Zhang et al. 2015). Luo et
al. developed RGD-targeted ultra-small iron oxide nanoparticles (<5 nm) for T1 MRI contrast since
the magnetic moment of the nanoparticles sharply decreases as their size decreases due to reduction
of their volume magnetic anisotropy and spin disorders on the surface (Luo, Yang et al. 2015). A
xenografted U87MG tumor model was used to show T1 enhancement via the targeted, ultra-small
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nanoparticle system. Both targeted and non-targeted nanoparticles increased the signal to noise
ratio of T1 MR images but the effect over three hours was significantly greater for the RGD targeted
nanoparticles.
RGD conjugation to magnetic nanoparticles also provides the opportunity for dual targeting
for drug delivery: magnetic and active targeting. Lin et al. recently developed RGD-functionalized
poly[(N-isopropylacrylamide-r-acrylamine)-b-L-lactic

acid]

(PNAL)

coated

iron

oxide

nanoparticles loaded with paclitaxel for the treatment of HeLa cells (Lin, Kang et al. 2015). In vitro
studies confirmed the cytotoxicity enhancement of the nanoparticle system in the presence of a
magnetic field, which was further enhanced by functionalization with RGD. In vivo studies
completed by Schleich et al. with paclitaxel and iron oxide nanoparticle-loaded PEGylated PLGA
nanoparticles showed that by combining RGD-functionalization to the nanoparticle surface with
magnetic targeting, survival of CT26 tumor bearing mice was significantly increased to 21.5 days
from 14.7 or 15 days for active or magnetic targeting, respectively (Schleich, Po et al. 2014).
Additionally, tumor growth was significantly reduced when the combination targeting modalities
were compared to either alone.
A variety of other peptides have been used as specific biological targets but they are not as
common as some of the previously discussed peptides. The EPPT (Glu-Pro-Pro-Thr) peptide,
which targets under-glycosilated MUC-1 tumor antigen found on more than 90% of breast cancers,
has not been used since 2010 for magnetic nanoparticle delivery (Medarova, Rashkovetsky et al.
2009, Kumar, Medarova et al. 2010). A different magnetic nanoparticle system developed by
Sungsuwan et al. induced the production of MUC-1 specific antibodies that recognized MUC-1positive tumor cells, killing them through complement-mediated cytotoxicity. Rather than being
functionalized with EPPT as in the previous example, the magnetic nanoparticles were
functionalized with amphiphilic lipo(glycol)peptides leading to antigen presentation to the immune
system. Another tumor targeting peptide is WSG (Try-Ser-Gly), which was used to coat iron oxide
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nanoparticles without the aid of another coating material. The WSG coated nanoparticles more
easily assembled into cancers compared to non-targeted nanoparticles, indicating the tumor
targeting properties of WSG (Wei, Yin et al. 2013).
2.2.3.3 Cell penetrating peptides
Another peptide category that has been of particular interest recently is that of cell penetrating
peptides (CPPs). Also known as membrane translocation sequences, Trojan peptides, or protein
transduction domains, these small, cationic and/or amphipathic peptides have the ability to enter
cells and mediate uptake of a wide range of macromolecular cargoes (Farkhani, Valizadeh et al.
2014). The cellular uptake mechanism depends upon the attached cargo as CPPs attached to small
cargoes can enter the cell via direct translocation whereas large molecules attached to CPPs tend to
be up taken via micropinocytosis in an energy dependent manner (Ma, Shi et al. 2011). A few
recent reviews give additional details on the uptake mechanisms of CPPs and their conjugation to
a wide array of nanoparticle systems (Chou, Ming et al. 2011, Cleal, He et al. 2013, Farkhani,
Valizadeh et al. 2014, Amin, Joo et al. 2015, Jafari, Dizaj et al. 2015). Thus, this section will focus
on very recent advances in CPP conjugation to magnetic nanoparticles.
The first CPP to be discovered was the HIV-1 encoded TAT peptide which mediates interaction
with anionic motifs on the cell surface in a non-receptor mediated manner (Bolhassani 2011, Koren
and Torchilin 2012). The TAT peptide carries both a transmembrane and nuclear localizing signal
within its sequence, making it an even more attractive targeting modality for nuclear delivery. In a
study by Wang et al., the TAT peptide and FITC fluorophore were functionalized to PEG600-bPGA, which was then self-assembled with iron oxide nanoparticles (Wang, Qiao et al. 2012). The
TAT functionalized nanoparticles quickly entered Caco-2 cells, and the fluorescence following 4
hours of incubation was much greater in cells exposed to the targeted nanoparticles compared to
non-targeted nanoparticles. The targeted magnetic nanoparticles were found to internalize into the
cells and penetrate the nuclear membrane while the non-targeted control nanoparticles were located
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at the cell membrane. Another study by Nair et al. focused on the intracellular location and
trafficking of TAT-conjugated iron oxide nanoparticles using 3D electron tomography (Nair,
Fukuda et al. 2012). TAT-conjugated PEG coated iron oxide nanoparticles were exposed to human
glioblastoma, and it was shown that some of the nanoparticles had accumulated in a vacuole then
moved out into the cytoplasm. In unpublished work by Hauser et al., TAT-conjugated dextran
coated iron oxide nanoparticles were developed to enhance radiation therapy in A549 lung
carcinoma (see Chapter 7). Radiation treatment increases mitochondrial formation of hydrogen
peroxide. The presence of excess iron ions catalyzes the formation of highly reactive hydroxyl
radicals. Therefore, the more intracellular iron oxide present, the greater the damage by the
hydroxyl radical.

TAT peptide functionalization to iron oxide nanoparticles increased the

intracellular iron concentration and increased reactive oxygen species (ROS) formation in the
presence of radiation compared to radiation alone. The TAT-conjugated nanoparticles were found
to destabilize lysosomal membranes and interact with the mitochondria, sensitizing the cells to
radiation treatment. In subsequent work by Hauser et al. the TAT-conjugated dextran coated
nanoparticles were utilized for magnetically mediated energy delivery (MagMED) (see Chapter 6).
The nanoparticles were internalized by A549 or H358 lung cancer cells and induced celluar damage
upon exposure to an AMF. An increase in ROS generation was observed upon exposure to an AMF,
and a slight increase in cell apoptosis was observed. Although the iron oxide nanoparticles were
too large to permeate the nuclear membrane, the TAT peptide promoted lysosomal destabilization
and escape of the nanoparticles into the cytosol, allowing for enhanced effects of the nanoparticles.
The TAT peptide has also been shown to be toxic due to destabilization of organelle membranes.
Cavalli et al. conjugated a γ-amino-proline derived peptide to dextran coated iron oxide
nanoparticles and compared their toxicity with TAT-functionalized nanoparticles (Cavalli, Carbajo
et al. 2012). While the γ-amino-proline derived peptide conjugated iron oxide nanoparticles
exhibited lower internalization than the TAT peptide, they were determined to be less toxic and
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stable towards protease degradation. These nanoparticles were also able to reduce T 2 intensity
without showing HeLa cell cytotoxicity.
Another magnetic nanoparticle system that utilizes CPPs was developed by Chen et al. They
utilized a peptide and a polymer to enhance nanoparticle penetration of the blood-brain barrier
(BBB). PF127, a pluronic polymer that enhances BBB penetration via inhibiting the P-glycoprotein
efflux pump, and angiopep-2 (ANG), a peptide with high capability for BBB penetration via
receptor mediated endocytosis, were both conjugated to polyacrylic acid coated iron oxide
nanoparticles (Chen, Su et al. 2014). The effects of PF127 and ANG were analyzed separately and
both were found to enhance intracellular concentrations of iron oxide in U87 cells. The combined
targeting system was analyzed in an ex vivo BBB model and found to increase the amount
permeated from 4.9 µg/mL for PF127 targeted only to 7.6 µg/mL. The dual targeted nanoparticles
also had increased transversal relaxation rates (167.54/mM/second) compared to conventional iron
oxide nanoparticle products.
2.2.4 Small Molecules
Small molecules, such as glucose and folic acid, have also gained interest as targeting agents
of magnetic nanoparticles due to the ability to functionalize the nanoparticle surface with an
increased number of targeting groups with limited steric constraints (McCarthy and Weissleder
2008). The more targeting ligands, the more likely there will be a multivalent effect between the
particle and its target.
Glucose functionalization to magnetic nanoparticles was recently investigated for targeting
colon cancer metastasis in the liver due to increased metabolic activity of cancer cells requiring
excess glucose, leading to a targeting method for glucose functionalized magnetic nanoparticles.
Wydra et al. functionalized glucose to the surface of citric acid stabilized iron oxide nanoparticles
via amine-carboxyl coupling of d-glucosamine and citric acid (Wydra, Rychahou et al. 2015).
Glucose functionalization to the nanoparticle surface increased internalization by CT26 cells
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compared to citric acid coated or uncoated nanoparticles. Cells with internalized magnetic
nanoparticles were exposed to an AMF for 30 minutes and the generation of reactive oxygen
species was analyzed. Although there was a slight increase in ROS generation due to the presence
of uncoated and glucose coated iron oxide nanoparticles, only the citric acid coated iron oxide
nanoparticles resulted in significant ROS generation. All the nanoparticle systems combined with
AMF exposure significantly increased apoptosis in CT26 cells compared to no AMF exposure
when the percent apoptosis was measured 24 hours post treatment. Therefore, it appears as though
the increase in ROS generation after exposure of CT26 cells containing internalized magnetic
nanoparticles to an AMF can trigger apoptotic pathways and result in increased apoptosis compared
to IONP exposure alone.
Glucose functionalization of the surface of magnetic nanoparticles to target cancer cells due to
their enhanced metabolic activity has been studied by other groups as well (Xiong, Zhu et al. 2012,
Herea, Chiriac et al. 2015). Maharramov et al. coated iron oxide nanoparticles with 2-deoxy-Dglucose, which is a glucose analogue in which the hydroxyl group bound to the second carbon is
replaced by a hydrogen atom (Maharramov, Ramazanov et al. 2014). The goal of using the glucose
analogue was to target the nanoparticles to the cancer cells due to metabolic needs, but block the
glycolytic pathway. A proof of concept study on the growth inhibitory effects of 2-deoxy-Dglucose functionalized magnetic nanoparticles was completed on HCT116, HT29, and RKO
colorectal cells. Although 2-deoxy-D-glucose was more toxic alone, the nanoparticle formulations
significantly reduced the viability compared to control cells. Future use for the nanoparticle system
would include MR imaging.
Other groups have developed glucose functionalized magnetic nanoparticles for cancer cell
targeting via the glucose transporter protein (Shan, Hu et al. 2012, Barbaro, Di Bari et al. 2015).
Barbaro et al. developed a small D-glucose coated iron oxide nanoparticle using metal vapor
synthesis to target pancreatic cancer cells that express glucose transporter (GLUT-1) in the cell
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membrane (Barbaro, Di Bari et al. 2015). Glucose coated iron oxide nanoparticles were taken up
at greater concentrations into BxPC3 cells expressing GLUT-1 compared to polyvinylpyrrolidone
(PVP) iron oxide nanoparticles. Additionally, pre-treatment with antiGLUT1 reduced cellular
accumulation of glucose functionalized nanoparticles by 41% but did not affect PVP functionalized
nanoparticles.
Folic acid is another small molecule that is of particular interest for tumor targeting of magnetic
nanoparticles due to its high binding affinity to the folate receptor (FR), low cost, ease of
conjugation, compatibility with both organic and aqueous solvents, and a lack of immunogenicity
(Low, Henne et al. 2008). The FR is overexpressed on the surface of several cancers including
breast, kidney, lung, brain and ovary (Parker, Turk et al. 2005) and due to the limited expression
of FR on normal tissues, folate may be an appropriate choice for targeting tumor cells in NP based
cancer therapies. Folate can bind to FR and facilitate the transfer of folate-targeted nanoparticles
through receptor mediated endocytosis. Folic acid is an essential nutrient needed by all cells for
biosynthesis of nucleotides and the normal action of some metabolic pathways that mediate uptake
via a non-destructive endosomal pathway (Parker, Turk et al. 2005, Murthy 2007, Mansoori,
Brandenburg et al. 2010).
Bahrami et al. in 2015 reviewed folate conjugated nanoparticles as a therapeutic approach for
cancer therapy with a section devoted to magnetic nanoparticles (Bahrami, Mohammadnia-Afrouzi
et al. 2015). For additional information or studies prior to 2015, readers are directed to this review.
Therefore, this section will summarize recent advances in folate-conjugated magnetic
nanoparticles. Several investigations have developed strategies to conjugate folate derivatives to
magnetic nanoparticles and characterize their physicochemical properties (Dolores, Raquel et al.
2015, Karamipour, Sadjadi et al. 2015, Socaci, Magerusan et al. 2015) while others have proven
the targeting ability and receptor-mediated endocytosis associated with folate functionalized
nanoparticles (Li, Yang et al. 2015, Razjouyan, Zolata et al. 2015). FR targeted core-shell magnetic
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nanoparticles have been of particular interest for thermal therapy (Sadhasivam, Savitha et al. 2015),
drug delivery (Li, Dong et al. 2015, Tudisco, Cambria et al. 2015) and imaging (Chen, Zheng et al.
2015, Ma, Liu et al. 2015, Yin, Hong et al. 2015) of cancer. Carbon encapsulated iron oxide
nanoparticles were surface engineered with PEG-folic acid by Sadhasivam et al. to induce selective
hyperthermia in FR overexpressed cancer cells (Sadhasivam, Savitha et al. 2015). The nanoparticle
system was non-toxic to human fibroblasts (low FR expression) both with and without AMF
exposure as determined by the LDH assay. However, in HeLa cells (high FR expression),
significant cytotoxicity was induced upon treatment with the targeted nanoparticles and AMF
compared to the targeted nanoparticles alone. This is a result of enhanced uptake by the HeLa cells
as non-targeted nanoparticles resulted in a relative iron uptake of 0.105 mg/mL while the targeted
nanoparticles resulted in a relative iron uptake of 0.316 mg/mL.
Li et al. encapsulated iron oxide nanoparticles and sorafenib (SRF) into folate-conjugated
PLGA nanoparticles (Li, Dong et al. 2015). Cell uptake potential of SFR, non-targeted magnetic
nanoparticles and targeted magnetic nanoparticles were investigated in FR over-expressing
BEL7402 hepatocellular carcinoma. Uptake was time dependent in all systems, but significantly
greater for targeted nanoparticles. The 24 hour IC50 values in BEL7402 cells for SRF, non-targeted
magnetic nanoparticles and targeted magnetic nanoparticles were 2.35 µg/mL, 2.48 µg/mL, and
0.84 µg/mL respectively, suggesting that folic acid-targeted nanoparticles were more effective at
inducing cell toxicity.
Another application of folic acid targeted nanoparticles to enhance the intracellular transport
of N-methylated drugs was evaluated by Tudisco et al. (Tudisco, Cambria et al. 2015). PEG, folic
acid, and carboxy-X-rhodamine were conjugated to magnetic nanoparticles along with
tetraphosphonate cavitand (Tiiii) that has molecular recognition properties towards N-methylated
guests. The most significant finding of this study was that the nanoparticles were able to facilitate
intracellular transport of PCZ, an N-methylated molecule, when PCZ and the nanoparticles were
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introduced to LoVo cells simultaneously. The decrease in cell viability following dual,
simultaneous treatment compared to PCZ alone indicated that the nanoparticles interact with PCZ,
and are then internalized via folate receptors.
As previously mentioned, folate receptor targeted magnetic nanoparticles are often used as
MRI contrast agents. Ma et al. developed magnetic-lanthanide-doped fluoride nanoparticles which
were targeted with folic acid to be used as bimodal probes for cellular fluorescence and magnetic
resonance imaging of HeLa cells overexpressing FR (Ma, Liu et al. 2015). In vitro fluorescence
imaging after exposure to targeted and non-targeted nanoparticles was evaluated using HeLa cells
overexpressing FR. HeLa cells treated with folic acid-conjugated nanoparticles displayed a strong
green fluorescence. In contrast, HeLa cells treated with non-targeted nanoparticles and MCF-7 cells
(lower FR expression) treated with targeted nanoparticles had a weak fluorescence signal. The
targeted nanoparticles were also used to increase T2 contrast in HeLa cells in vitro. Yin et al. were
also interested in magnetic nanoparticles for dual imaging modalities (Yin, Hong et al. 2015).
Amphiphiles were embedded with oligo(p-phenyleneethynylene) (OPE) via covalent linkages and
this OPE based structure was further functionalized with folic acid to serve as the targeting ligand.
These amphiphilic OPE molecules were used to encapsulate fluorescent magnetic nanoparticles so
the final magnetic nanoparticles could be used for fluorescence and magnetic resonance imaging.
HeLa cells were incubated with the targeted and non-targeted nanoparticle formulations at different
concentrations (with and without folic acid) for three hours. A decrease in MRI signal intensity was
observed as nanoparticle concentration increased. However, cells incubated with the targeted
nanoparticles exhibited a greater signal decrease than those incubated with non-targeted
nanoparticles at concentrations greater than 0.042 mg/mL. The dual imaging capability of this
nanoparticle system was analyzed in vivo as well. Tumor bearing mice were injected with the
targeted or non-targeted nanoparticle system. MR imaging four hours after injection indicated a T2
signal reduction within the tumor compared to pre-injection images for both nanoparticle systems.
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However, the signal reduction was greater in the targeted nanoparticle groups due to increased
intra-tumor iron concentration as confirmed by Prussian blue staining. Two-photon optical imaging
of tumor biopsies showed similar results to the MRI analyses. Tumor slices excised from mice
treated with targeted nanoparticles showed intense fluorescence with high resolution and
sensitivity. However, weak fluorescence was observed in tumors of mice that received the nontargeted nanoparticle formulation.
While the majority of FR targeted nanoparticles are used for cancer therapy or imaging
applications, Dai et al. coated superparamagnetic iron oxide nanoparticles with glucose and dextran
then functionalized the nanoparticles with folic acid due to its specific binding to the recruited and
activated macrophages of synovium in rheumatoid arthritis (RA) that overexpress folic acid
receptors. RA was induced in rat paws using Freund’s complete adjuvant injection, and 14 days
after the injection, degeneration or necrosis in the epithelium as well as infiltration of inflammatory
cells were observed. Functionalized nanoparticles were injected and the rat ankles were imaged via
MRI 24 hours later. The folic acid functionalized nanoparticles resulted in significant negative
contrast enhancement while non-targeted nanoparticles only marginally reduced the signal
intensity. Another non-cancer application of folate receptor targeted magnetic nanoparticles was
investigated by Li et al. who developed a small magnetite antiretroviral therapy (SMART)
nanoparticle platform to assess antiretroviral drug tissue biodistribution and PK using MRI scans
(Li, Gendelman et al. 2015). Alendronate (ALN), a bisphosphate drug that is clinically used to treat
osteoporosis, was conjugated to polymers for stable magnetite coating. Folic acid was then
conjugated to the polymers that were attached to the exterior of magnetite. The nanoparticles were
detected by MRI and rapid uptake by mononuclear phagocytes (MP) provided a noninvasive
method of detecting regions of disease-associated infection including virus induced inflammation.
This platform provided a means to rapidly evaluate the efficiency of targeting strategies for HIV
reservoirs.
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Additionally, a variety of studies have utilized folate-conjugated micelles (Li, Yan et al. 2015)
or liposomes loaded with magnetic nanoparticles for drug delivery and MR imaging contrast. For
example, Du et al. synthesized thermosensitive liposomes functionalized with PEG2000 and folic
acid containing C60-Fe3O4 nanocomposites and docetaxel (Du, Han et al. 2015). This
multifunctional liposome formulation allowed for combined magnetic and folate receptor targeting
as well as controlled docetaxel release and thermal ablation via the magnetic nanoparticles in the
presence of RF. In vitro studies indicated that these multifunctional liposomes resulted in higher
inhibition efficiency of MCF-7 (FR positive) cells than docetaxel alone suggesting that the delivery
system was able to deliver more drug into the cells. Cellular uptake was analyzed by adding FITC
to the multifunctional liposomes, and the uptake of the magnetic liposomes was greater than the
nanoparticles with docetaxel having no folate targeting or liposome structure. Upon radio frequency
exposure, the C60 component of the liposome generated heat, destabilizing the liposome structure
and releasing docetaxel. In vivo studies indicated that dual targeting (FR and magnetic) and RF
exposure significantly reduced tumor growth compared to control groups.
2.3 Conclusions and Future Perspectives
Active targeting of magnetic nanoparticles has significantly improved nanoparticle specificity
and accumulation compared to passive targeting and utilization of the enhanced permeation and
retention effect. Conjugation of ligands to the surface of magnetic nanoparticles has afforded the
opportunity to target specific entities within a tissue, whether it be a component of the extracellular
matrix, cell surface receptors, or organelles. Active targeting of magnetic nanoparticles has been
repeatedly shown to improve nanoparticle uptake into tissues and cells, making magnetically
mediated hyperthermia more effective and increasing MRI contrast. As discussed in this review, a
variety of targeting ligands can be conjugated to the surface of magnetic nanoparticles. Antibodies,
aptamers, peptides, and small molecules have all proven to be effective targeting agents for
magnetic nanoparticles, but choosing the appropriate targeting ligand is dependent upon the target
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and application of the nanoparticle system. Although antibodies are very specific targeting
moieties, they are expensive. Aptamers have increased in popularity as an alternative to antibodies
in that the specificity is retained, and their synthesis is less expensive than antibody production.
Peptides can be synthesized for a variety of targets with binding specificity rivaling that of larger
molecules such as antibodies. They are relatively inexpensive to synthesize and, due to their smaller
size, nanoparticles can be functionalized with multiple peptides per particle to increase the binding
opportunities. Small molecules have also gained interest as targeting agents as their size allows for
multiple molecules per particle and lower steric constraints than other targeting ligands.
Although significant improvements in active targeting of magnetic nanoparticles both in vitro
and in vivo have been realized, there are still shortcomings that should be addressed in order to
continue to advance. First, in attempt to translate targeted nanoparticle systems into the clinic and
receive FDA approval, a single nanoparticle formulation with the ability to be functionalized with
a variety of targeting ligands should be established. This would allow for a versatile system that
could be easily altered for different targets and applications. Secondly, subcellular targeting is a
relatively new focus in magnetic nanoparticle targeting but poses interesting opportunities.
Lysosome sequestration is the normal fate of magnetic nanoparticles taken up by cells through
endocytosis leading to degradation and low therapeutic effect. However, if the nanoparticles are
appropriately functionalized to target subcellular organelles, their potential for therapeutic efficacy
is drastically increased. Finally, in vivo testing of targeted magnetic nanoparticles should be scaled
to larger animals in order to improve understanding and translation of the targeted nanoparticles to
humans.
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Chapter 3 Magnetic nanoparticles and nanocomposites for remote controlled therapies
The chapter is taken directly or adapted from work published in Hauser, Wydra, et al. (2015)
Copyright 2015 Elsevier B.V. Used with permissions from Anastasia K. Hauser, Robert J. Wydra,
Nathanael A. Stocke, Kimberly W. Anderson and J. Zach Hilt, “Magnetic nanoparticles and
nanocomposites for remote controlled therapies”, Journal of Controlled Release and Elsevier B.V.
3.1 Introduction
Magnetic nanoparticles (MNPs) have been extensively studied for a variety of biological
applications such as FDA-approved MRI contrast agents (Reimer and Balzer 2003), FDA-approved
iron deficiency treatment (Auerbach 2008), thermal therapy, and drug delivery. MNPs are often
coated with or embedded in a polymer or organic matrix in order to: increase colloid stability and
extend circulation time in biological environments, provide a means for functionalization with
targeting agents or fluorescent markers, or afford the opportunity for drug loading and conjugation
(Berry and Curtis 2003, Gupta and Gupta 2005, Duguet, Vasseur et al. 2006, Berry 2009, Shubayev,
Pisanic et al. 2009, Frimpong and Hilt 2010, Amstad, Textor et al. 2011, Ho, Sun et al. 2011).
MNPs are able to convert energy from an alternating magnetic field (AMF) to heat primarily
through Neel and Brownian relaxations, with Neel relaxation being the internal dipole rotation and
Brownian referring to the physical rotation of the nanoparticle. The heat generated by the MNPs in
the presence of an AMF can be utilized for a variety of therapies, including controlled release of a
drug, local thermal therapy, magnetically mediated energy delivery (MagMED), and combinational
treatments. Additionally, MNPs respond to static magnetic field gradients and low frequency
AMFs where the heating effect is negligible or non-existent, allowing for other controlled drug
delivery strategies, including external guiding/targeting of magnetic nanoparticles and mechanical
deformations/disruptions for triggered release.
The unique capability of MNPs and their composites to be remotely controlled has been utilized
for various applications (Brazel 2009, Liu, Hu et al. 2009, Satarkar, Biswal et al. 2010, Kumar and
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Mohammad 2011, Bonini, Berti et al. 2013, Li, Huang et al. 2013, Thevenot, Oliveira et al. 2013,
Jhaveri, Deshpande et al. 2014, Ridi, Bonini et al. 2014, Schleich, Danhier et al. 2015). When
applied in drug delivery, the remote control of the MNPs enables for controlled drug delivery
(temporal and/or spatial). For temporal control, the remote actuation is often based on the AMF
heating of MNPs to cause a temperature-responsive change in the delivery system release
properties. In other cases of temporal control, the remote actuation is based on static or low
frequency magnetic fields where the mechanical forces induced by the magnetic field result in
modulation of the release behavior. For spatial control, the applied magnetic field can remotely
control the accumulation of a delivery system within the body. In many cases, enhanced therapeutic
delivery and associated outcomes have been reported as a result of the remote control over the
temporal and/or spatial release of a drug.
Magnetically mediated hyperthermia (MMH) treatment, also referred to as magnetic fluid
hyperthermia (MFH), is another important application of MNPs. MMH is the heating of tissue to
hyperthermia temperatures of approximately 41-45°C by activation of the MNPs in the presence of
an AMF. This inherently localized heating therapy has been studied extensively for cancer therapy
both in isolation or combination with a conventional cancer therapy such as chemotherapy or
radiation (Pankhurst, Connolly et al. 2003, Tartaj, Morales et al. 2003, Mornet, Vasseur et al. 2004,
Goya, Grazu et al. 2008, Corchero and Villaverde 2009, Pankhurst, Thanh et al. 2009, Kumar and
Mohammad 2011). Localized thermal therapy via MMH has been shown to be more effective than
other forms of hyperthermia delivery.
MMH has also been shown to enhance the efficacy of traditional cancer therapies such as
chemotherapy, radiation, surgical resection, and gene therapy. A variety of chemotherapeutics are
more effective when administered in the hyperthermia range due to increased rate constants of
alkylation, increased drug uptake, and inhibition of repair of drug-induced lethal or sub-lethal
damage (Issels 2008). Chemotherapeutics have also been chemically or physically bound to
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magnetic nanoparticles for controlled drug release upon exposure to an external stimuli such as an
AMF or change in pH, and upon further exposure to AMF, simultaneous thermal therapy can be
administered (Gautier, Allard-Vannier et al. , Jhaveri, Deshpande et al. 2014, Rejinold, Jayakumar
et al. 2015). Additionally, hyperthermia has been shown to increase blood supply to the tumor,
which increases local oxygen levels. Since the efficacy of radiation therapy is tied to the formation
of free radicals more than direct DNA damage, MMH can enhance the effectiveness of radiation
by increasing free radical formation. Overall, thermal therapy via MNPs is a promising treatment
method when combined with traditional therapies due to localized tumor heating and sensitization
of the tumor tissue to additional modalities.
One of the major translational hurdles of MMH is that a large concentration of nanoparticles is
required to achieve the necessary increase in temperature in vitro and especially in vivo, and this
limitation, to date, has limited the application of MMH to direct injection into solid tumors for in
vivo application (Johannsen, Jordan et al. 2004, Jordan, Scholz et al. 2006). Therefore, researchers
have recently focused more on MagMED for nanoscale energy therapy (Kozissnik, Bohorquez et
al. 2013). This form of therapy utilizing AMF-activated MNPs relies on intracellular effects of
MNPs and results in a therapeutic effect without a measurable temperature rise, with the exact
mechanism of toxicity still under investigation. Intracellular concentrations of MNPs can be
increased by cellular targeting with ligands and antibodies, which has been shown to further
enhance the effectiveness of MagMED as a treatment modality (Berry and Curtis 2003, Gupta and
Gupta 2005, Shubayev, Pisanic et al. 2009, Creixell, Bohorquez et al. 2011, Kievit, Stephen et al.
2012). Therapeutic approaches based on MagMED have led many researchers to focus on
determining intracellular targets and understanding intracellular mechanisms.
This chapter summarizes recent advances in applications of MNPs and magnetic
nanocomposites for remote controlled thermal therapy, nano-scale energy delivery, and
combinational therapy (Figure 3.1).
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Figure 3.1 This section highlights the uses of MNPs for controlled release therapies. A) Thermal
therapy can be remotely controlled for i) local applications or ii) nanoscale heating applications. B)
Thermal therapy is often administered in combination with a secondary treatment such as i) a
therapeutic or ii) radiation.
3.2 Remote controlled energy release
3.2.1 Thermal therapy
Magnetic nanoparticles have been extensively studied for thermal therapy applications due to
their ability to convert energy from an AMF into thermal energy. This controlled release of thermal
energy from MNPs can be used for hyperthermia treatment, which is defined as the heating of tissue
to 41-45°C (Hildebrandt, Wust et al. 2002) and has been shown to be an effective treatment of
various types of cancer. Some have suggested that the efficacy of hyperthermia is likely due to
tumor tissue being more susceptible to heat insults than healthy tissue (Jordan, Scholz et al. 1999,
Moroz, Jones et al. 2002). Magnetically mediated hyperthermia (MMH), which is also known as
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magnetic fluid hyperthermia (MFH), is where MNPs or larger magnetic particles are localized
within the tumor environment and then exposed to an AMF, resulting in heat generation. For cancer
therapy, MMH has several advantages over other delivery routes of thermal therapy in that it is
localized to only the tumor tissue through selectively targeting (e.g., active or passive targeting,
direct injection, etc.) and provides even temperature distribution throughout the tumor tissue. By
comparison, regional and whole body hyperthermia are used to heat larger regions such as a limb
or cavity, or to treat metastatic disease, but often lead to undesirable damage of healthy tissue.
Beyond delivering thermal energy, MNPs have additional physical properties that make them
advantageous for thermal delivery such as physical rotation of the nanoparticle in the presence of
an AMF (Zhang, Kircher et al. 2014), elevated nanoparticle surface temperatures (Polo-Corrales
and Rinaldi 2012) and nanoscale heating effects (Xu, Karmakar et al. 2010, Creixell, Bohorquez et
al. 2011). These are all potential explanations to the improvement of MMH over other hyperthermia
treatments.
This improvement was demonstrated by Rodriguez-Luccioni et al. when they addressed the
effects of MMH using MNPs functionalized with carboxymethyl dextran compared to hot water
hyperthermia (HWH) on MCF-7 and Caco-2 cells (Rodriguez-Luccioni, Latorre-Esteves et al.
2011). MMH resulted in a greater decrease in cell viability for both cell lines compared to HWH.
A thorough review of MMH using iron oxide nanoparticles and the mechanisms of heat dissipation
was written by Laurent et al. in 2011 (Laurent, Dutz et al. 2011), and others have addressed the
advances, challenges, promises, and perils of MNPs for hyperthermia applications (Kozissnik,
Bohorquez et al. 2013, Singh, McMillan et al. 2014). Therefore, this section focuses on recent
studies that utilize controlled delivery of thermal energy from MNPs and the therapeutic and
immunotherapeutic effects of the treatment.
Several research groups have studied the efficacy of magnetically mediated thermal therapy as
a treatment modality for cancer both in vitro and in vivo (Le, Shinkai et al. 2001, Johannsen, Jordan
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et al. 2004, Ivkov, DeNardo et al. 2005, Johannsen, Thiesen et al. 2005, Kettering, Winter et al.
2007, Kallumadil, Tada et al. 2009, Suto, Hirota et al. 2009, Lee, Jang et al. 2011, Bae, Park et al.
2012, Kut, Zhang et al. 2012, Lartigue, Hugounenq et al. 2012, Mustafa, Zhang et al. 2013, Rivet,
Yuan et al. 2014, Soni, Tyagi et al. 2014). Thermoablation is another form of thermal therapy
induced by raising the bulk solution temperature above 45°C. A recent review highlights the use of
various nanomaterials, including MNPs, for thermoablative treatment, imaging, and diagnostics
(Sawdon, Weydemeyer et al. 2014). The temperature at which the thermal therapy is performed
dictates cellular response, with apoptosis being linked to hyperthermia temperatures and necrosis
being associated with thermoablation. Both of these thermal therapy treatments can be administered
via MNPs in the presence of an AMF, but it is important to understand the properties of magnetic
nanoparticles in cellular environments in order to synthesize magnetic nanoparticle systems with
the potential for maximum energy delivery. Di Corato et al. analyzed energy delivery by magnetic
nanoparticles in a cellular environment and compared it to nanoparticles in suspension (Di Corato,
Espinosa et al. 2014). In all systems, there was a systematic decrease in the heating efficiency for
nanomaterials associated with tumor cells, which was likely due to inhibition of the Brownian
relaxation in cellular conditions. The magnitude of this decrease was associated with the type of
nanoparticle, but in general, it was determined that nanoparticles in the superparamagnetic domain
are minimally affected by the cellular environment.
Various superparamagnetic nanoparticle systems have been developed to improve the efficacy
of thermal therapy as a treatment of cancer. Wydra et al. developed an iron oxide nanoparticle
system coated with citric acid or poly(ethylene glycol) (400) dimethacrylate (PEG400DMA) via
atomic transfer radical polymerization (ATRP) (Wydra, Kruse et al. 2013). A549 lung carcinoma
were exposed to 10 mg/mL Fe3O4 and exposed to an AMF (301 kHz, 27.9 kA/m) for 10 minutes
resulting in a bulk solution temperature of 55°C in the center of the dish where the magnetic field
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amplitude was greatest. Minimal cell death occurred in the periphery indicating that temperatures
in the thermal ablation range were sufficient at inducing cell death, most likely through necrosis.
Other studies have looked to address the differences between thermal therapies in the
hyperthermia and thermoablation temperature ranges (Hu, Ma et al. 2011, Wang, Dong et al. 2012).
In a study completed by Wang et al., the efficacy of high end hyperthermia treatment (47°C) was
compared to thermoablation treatment at 51°C on subcutaneous MPC-83 tumors in female mice
(Wang, Dong et al. 2012). Thermal therapy was administered at temperatures of 47 or 51°C for 30
minutes (300 kHz, 100 G) after the tumors had grown to 10 mm in diameter. After hyperthermia
treatment at either temperature, the tumors in the 20 mice disappeared within 14 days. However,
subcutaneous nodules of 3 mice in the 47°C group and 2 mice in the 51°C group began to relapse
within 2 months after hyperthermia. Additionally, 7/10 mice in the 47°C group and 8/10 in the
51°C group were alive 140 days after hyperthermia treatment. This is a significant increase in
survival of the hyperthermia groups compared to the control. In another study by Hu et al., A549
xenograft mice were injected with three different doses of iron oxide MNPs, which resulted in
varying tumor temperatures of 41.3, 44.5, and 46.8°C (Hu, Ma et al. 2011). Tumor temperatures
from 42-46°C resulted in disruption of the enzymatic system and structure of the tumor, therefore
inducing apoptosis. Above 46°C, numerous large necrotic areas were observed within the tumors,
and the nanoparticles were either distributed in the interstitial matrix of tumors or phagocytized by
tumor cells.
In addition to cellular death, thermal therapy has a variety of consequences on the tumor
microenvironment (Kolosnjaj-Tabi, Di Corato et al. 2014) and tumor growth factor expression
(Wang, Xu et al. 2014). In a study completed by Kolosnjaj-Tabi et al. in 2014, PEG-coated iron
oxide nanocubes were injected intratumorally into epidermoid carcinoma xenograft mice and
treated for three days with 30 minutes of AMF exposure (111 kHz, 23.8 kA/m), which resulted in
a temperature rise of 7.8 ± 2.2°C (Kolosnjaj-Tabi, Di Corato et al. 2014). This hyperthermia
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treatment resulted in the slackening of generally compact collagen fibers, which in turn increased
nanocube penetration into the cell-rich tumor core. After MMH treatment, the intra-fibrillar space
of the collagen matrix was shown to increase from 101 ± 17 nm to 133 ± 32 nm due to a phase
transition of the collagen network. Thermal therapy via magnetic nanoparticles has also been shown
to down regulate vascular endothelial growth factor (VEGF) in rats with Walker 265 breast
carcinoma (Wang, Xu et al. 2014). Thermal treatment in the range of 50-55°C was administered 1,
2 or 3 times for 30 minutes via AMF exposure (180 kHz, 55 G) resulting in tumor growth inhibition
and promoting the survival of tumor bearing rats. Gene expression of VEGF and its receptors in
the tumor were decreased, thereby inhibiting tumor angiogenesis.
Thermal therapy using MNPs in an AMF has also been utilized as an immunotherapeutic
treatment with promising results (Yanase, Shinkai et al. 1998, Shinkai, Yanase et al. 1999, Suzuki,
Shinkai et al. 2003, Toraya-Brown, Sheen et al. 2014). Magnetic cationic liposomes (MCLs) were
used for hyperthermia treatment in three of these studies due to their higher affinity for tumor cells
than neutrally charged magnetoliposomes. In one of the first immunotherapy treatment studies via
thermal therapy, T-9 rat glioma tumors were formed in the left flank of female rats, and MCLs were
injected into half the tumors followed by exposure to an AMF (118 kHz, 384 Oe) for 30 minutes
(3 times at 24 hour intervals) (Yanase, Shinkai et al. 1998). 89% of the rats treated with
hyperthermia had complete regression. Three months later, cured rats or naïve rats were challenged
with T-9 or malignant fibrous histiocytoma cells in the right flank. All right flank tumors (T-9 or
malignant fibrous histiocytoma) formed in the mice not initially treated with hyperthermia.
Conversely, T-9 right flank tumors did not form in mice treated with hyperthermia in the T-9 left
flank tumors. However, malignant fibrous histiocytoma cell injection into the right flank resulted
in tumor formation. Therefore, the immune response was found to be specific for the original T9
cells. Additionally, CD3+, CD4+, CD8+, and NK immunocytes were detected in the left and right
tumors of mice treated with hyperthermia, but no immunocytes were found in the control group.
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A subsequent study was completed on B16 melanoma subcutaneous tumors (Suzuki, Shinkai
et al. 2003) and showed that 9 out of the 10 mice had complete tumor disappearance 120 days after
two 30 minute hyperthermia treatments with MCLs in an AMF (118 kHz). Spleen cells were
obtained from the cured mice, and in an in vitro study, these cells were shown to have increased
cytotoxic activity against B16 cells compared to spleen cells from naïve mice. An in vivo
immunotherapy study was also completed wherein mice were challenged with B16 melanoma cells
120 days after treatment. In the naïve mice, tumors formed 6 days post inoculation. However, 66%
of the cured mice rejected the melanoma cells resulting in no nodule formation. The extended time
between hyperthermia treatment and secondary inoculation suggests that MMH has the potential
to decrease metastatic potential of B16 melanoma cells.
A more recent study on the immunotherapeutic effects of MMH was completed by TorayaBrown et al. in 2014 and showed that local hyperthermia treatment induced CD8+ T cell-mediated
resistance against distal and secondary tumors (Toraya-Brown, Sheen et al. 2014). B16 tumors
were established in both the left and right flanks simultaneously, but only the left flank tumor was
treated with MMH (43°C) for 30 minutes. Right flank tumors of the left flank heated group were
found to grow significantly slower than the non-heated group. Another experiment examined
secondary tumor formation in the right and left flanks after a right flank tumor was treated with
hyperthermia and then excised three days post treatment. Secondary tumor growth was inhibited
on both the primary tumor side and the contralateral side in the heated group compared to the nonheated group. This study also revealed that the timing of secondary tumor inoculation plays a role
in tumor formation. One day after hyperthermia treatment resulted in no resistance to secondary
tumor formation while inoculation 30 days after treatment inhibited tumor growth on the primary
side but not the contralateral side. Additionally, it was found that local hyperthermia increases
CD8+ T cells – required for inducing resistance against secondary tumors – as the effects of heating
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the primary tumor were completely abrogated by treating with CD8+ antibiotics to deplete CD8+
formation.
In addition to the in vitro and in vivo studies completed using magnetically mediated thermal
therapy, there have also been a few clinical trials investigating quality of life and feasibility of
thermotherapy using magnetic nanoparticles (Johannsen, Gneueckow et al. 2007, Johannsen,
Gneveckow et al. 2007). Maximum temperatures of 55°C were obtained in the prostate using only
25% of the available magnetic field amplitude, and mean intra tumor temperatures were kept
between 42 and 46°C for 60 minutes (once per week for 6 weeks). It was determined that this
treatment was not enough to kill the cancerous cells but is applicable as a combination treatment
(Johannsen, Gneueckow et al. 2007). A quality of life assessment was also completed on this
clinical trial, and it was found that quality of life was only temporarily impaired by MNP
thermotherapy with urinary symptoms which appeared almost exclusively during the first three
weeks of treatment (Johannsen, Gneveckow et al. 2007).
3.2.2 Nanoscale Energy Delivery
As discussed above, thermal therapy has been studied for decades, with various successes in
MMH and related treatments, but this approach has yet to gain widespread clinical recognition
either as an independent treatment or in conjunction with traditional therapies. This section
explores the most recent advances in the promising area of MagMED therapy, wherein MNPs are
engineered for the selective destruction of cells and/or intracellular structures without a
macroscopic temperature rise (Kozissnik, Bohorquez et al. 2013).
Instead of relying on a bulk temperature rise to induce hyperthermia conditions, it was
suggested by Gordon, et al. in 1979 that intracellular hyperthermia would be more advantageous
due to insulation by the cell membrane and lack of convection from blood flow which dissipates
heat away from the tumor tissue which is especially problematic in small metastatic tumors
(Gordon, Hines et al. 1979). Although there was a growing body of evidence suggesting that local
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heating and energy delivery could be used to kill cancer cells, theoretical calculations by Rabin et
al. indicated that the heat dissipation from the nanoparticle surface through conduction is greater
than the heat being generated by the nanoparticles (Rabin 2002). At the single nanoparticle level,
Rabin’s calculations suggest the nanoparticle temperature difference at steady state to be no greater
than 10-5 °C, indicating that a single nanoparticle cannot cause any thermal damage. On the macroscale, Rabin’s most conservative calculation indicated that the region occupied by a cluster of
magnetic nanoparticles within a cell must be at least 1.1 mm in diameter (two orders of magnetude
larger than the typical cancer cell) in order to induce a temperature rise of 6 °C, suggesting that a
larger target region is required in order to achieve hyperthermia temperatures. These calculations
were completed without taking into account the effects of blood perfusion and potentially higher
thermal conductivity values that would both require an even larger heated region in order to reach
the same hyperthermia levels.
Dispite the theoretical calculations by Rabin in 2002, nanoscale heating effects of MNPs were
continually studied, and in 2011, an especially interesting study by Creixell et al. showed the ability
of internalized iron oxide MNPs in the presence of an AMF to induce significant cellular toxicities
without a measureable temperature rise. Iron oxide MNPs were targeted to the epidermal growth
factor receptor (EGFR) overexpressed on MDA MB 468 cells by conjugation of epidermal growth
facotr (EGF) (Creixell, Bohorquez et al. 2011). The targeted MNPs were internalized by MDA
MB 468 breast cancer cells and in the presence of an AMF induced a significant decrease in cell
viability without a measureable temperature rise. Additionally, the cell survival fraction
significantly decreased with increasing field amplitude. After these ground-breaking results, the
phrase magnetically mediated energy delivery (MagMED) was coined to describe the conversion
of magnetic field energy to other forms such as heat or rotational work but without significantly
increasing the bulk temperature (Kozissnik, Bohorquez et al. 2013).

43

The theoretical calculations were further disputed when Huang, et al. utilized iron oxide
nanoparticles targeted to proteins on the membrane of cells expressing TRPV1 to locally deliver
heat and open cation channels (Huang, Delikanli et al. 2010). Within 15 seconds of applying the
AMF, the cytosolic calcium concentration increased from 100 nM to 1.6 µM due to increased
calcium influx through the thermally activated TRPV1 channel. Nanoparticle heating at the surface
was confirmed using a tethered thermoresponsive fluorophore (DyLight549) which decreased in
fluorescence almost immediately upon AMF exposure, indicating heating of more than 15 °C
within 15 seconds. Golgi-targeted green fluorescence protein was used to monitor bulk cell
temperatures, and remained virtually unchanged during AMF exposure. In a similar study by PoloCorrales and Rinaldi in 2012, surface temperature of magnetic nanoparticles in the presence of an
AMF was monitored using thermoresponsive fluorescent polymers (Polo-Corrales and Rinaldi
2012). Iron oxide MNPs were functionalized with a polymer consisting of poly(Nisopropylacrylamide) copolymerized with a fluorescent modified acrylamide. As temperature
increased above 35 °C, the polymer coating changed from hydrophilic to hydrophobic, resulting in
an increase in fluorescence intensity. In the presence of an AMF, fluorescence intensity of the
polymer coating increased although there was negligible bulk temperature rise, suggesting that the
nanoparticle surface temperature was above 35 °C and further contradicting the theoretical
calculations provided by Rabin in 2002.
Localized MNP heating has also been studied as a mechanism for timed drug release from
liposomes. Amstad et al. fabricated liposomes containing iron oxide MNPs within their lipid bilayer
with a Tm well above body temperature (Amstad, Kohlbrecher et al. 2011). Upon actuation of the
MNPs by an AMF, the liposome permeability increased due to local temperature increases above
Tm. However, the liposomal structure remained intact suggesting that the bulk temperature did not
rise above Tm and allowed for repeated release from the liposomes.

44

In addition to the effects of surface heating of magnetic nanoparticles in an AMF, rotational
work has also been studied as an explanation to the experimental effects of MagMED. For example,
mechanical forces have been used to induce lysosomal permeabilization, leading to the release of
proteolytic enzymes such as cathepsins which initiate apoptotic pathways (Linder, Erdal et al. 2005,
Kirkegaard and Jaattela 2009, Johansson, Appelqvist et al. 2010). This technique has also been
shown to stimulate apoptosis in apoptosis-resistant cell lines (Jaattela 2004). For example, Sanchez
et al. functionalized a ligand of a G-protein coupled receptor which is over expressed in several
malignant cancers to iron oxide MNPs and showed that the internalized nanoparticles decreased
cell survival through a lysosomal pathway upon nanoparticle activation by a low power AMF (275
kHz, 40/52 mT) (Sanchez, Diab et al. 2014). Similarly, Domenech et al. induced lysosomal
permeabilization using EGFR-targeted MNPs in the presence of an AMF (233 kHz, 42 kA/m)
(Domenech, Marrero-Berrios et al. 2013). In EGFR positive cells (MDA MB 231), lysosomal
disruption was linked to increased cytoplasmic cathepsin B concentrations and increased ROS
generation, which led to a significant decrease in viability compared to cells treated with the
nanoparticles and no AMF. Connord et al. developed a miniaturized electromagnet to fit under a
confocal microscope allowing for real-time analysis of MMP and AMF (53 mT) treatment
(Connord, Clerc et al. 2015). Iron oxide MNPs coated with PEG-Amine and functionalized with
gastrin, which specifically binds to cholecystokinin-2 receptor, were used in this study. Confocal
images taken prior to AMF exposure indicate co-localization of Lysotracker and the MNPs.
However, after 30 minutes of AMF treatment, the lysosomes had been permeabilized and colocalization decreased. Another interesting but not fully understood observation was lysosomal
alignment with the magnetic field. These results indicate the importance of real-time imaging in
order to better understand the intracellular effects of MagMED.
Zhang et al. developed a dynamic magnetic field generator to induce nanoparticle rotations
about their axis to confirm whether physical nanoparticle rotations can disrupt lysosomal
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membranes and induce apoptosis (Zhang, Kircher et al. 2014). By functionalizing the nanoparticles
with lysosomal-associated membrane protein-1 (LAMP1), it was found that the shear forces
generated by oscillating torques were enough to damage the lysosomal membranes, proving that
Brownian rotation of magnetic nanoparticles also plays an important role in MagMED treatment.
In addition to the thermal and mechanical effects described above, the production of reactive
oxygen species (ROS) via iron oxide nanoparticles is a potential chemical effect of MagMED.
Several studies have correlated the production of ROS to the inherent cytotoxicity of iron oxide
MNPs (Mahmoudi, Simchi et al. 2009, Khan, Mohammad et al. 2012, Ahamed, Alhadlaq et al.
2013, Ahamed, Alhadlaq et al. 2013, Koenczoel, Weiss et al. 2013, Luo, Li et al. 2015). Iron oxide
MNPs catalyze the Haber-Weiss reaction which makes use of Fenton chemistry (Kehrer 2000). The
Fenton chemistry reaction set is shown as Equation 1 and the Haber-Weiss reaction (net reaction)
is shown as Equation 2.
Fe3+ + O2· - → Fe2+ + O2
Fe2+ +H2O2 → Fe3+ + OH- + OH·
O2· - + H2O2 → O2 + OH- + OH·

[1]
[2]

When iron oxide nanoparticles enter a cell, they can stimulate the generation of ROS via one of
two pathways: (1) the release of ions into the cytosol resulting in the iron ions participating in the
Haber-Weiss cycle or (2) the surface of the nanoparticle may act as a catalyst (Klein, Sommer et
al. 2012). Although this reaction can proceed without the addition of an AMF, recent work by
Wydra et al. demonstrated that the reaction is further catalyzed by iron oxide nanoparticles in the
presence of an AMF (Wydra, Oliver et al. 2015). This study used the degradation of methylene
blue by magnetite nanoparticles, and hydrogen peroxide was used to measure the reactivity of
uncoated iron oxide MNPs in an AMF. Temperature is a driving factor of the Fenton reaction up
to 40 °C, so by increasing the surface temperature of the MNPs, hydroxyl radical formation was
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catalyzed, degrading methylene blue. At low nanoparticle concentrations, where the bulk
temperature remained constant upon exposure to an AMF, local nanoscale heating effects were
more pronounced, leading to an enhancement in methylene blue degradation compared to the
Arrhenius prediction.
3.3 Combination therapy
Thermal therapy is often used in combination with conventional cancer therapies such as
chemotherapy, radiation, surgical resection, and gene therapy to enhance the efficacy of these
treatments. A variety of chemotherapeutics are more effective when administered in the
hyperthermia range due to increased rate constants of alkylation, enhanced drug uptake, and
inhibition of repair of drug-induced lethal or sub-lethal damage (Issels 2008, Hervault and Thanh
2014). When selecting a chemotherapeutic combination therapy, an important consideration is the
mechanism of action to make sure that it will complement the hyperthermia modality. When
utilizing MMH, chemotherapeutics can either be administered in bulk or bound to the MNPs and
released upon exposure to an AMF. Cisplatin (CDDP) (Lee, Rodriguez-Luccioni et al. 2011,
Alvarez-Berrios, Castillo et al. 2013, Petryk, Giustini et al. 2013, Kruse, Meenach et al. 2014),
bortezomib (BZ) (Alvarez-Berrios, Castillo et al. 2014, Alvarez-Berrios, Castillo et al. 2015), and
melphalan (Brusentsov, Brusentsova et al. 2007) are common chemotherapeutics that have been
studied for bulk combination treatments with MMH.
Cisplatin binds to DNA, resulting, ultimately, in inter- or intra-strand crosslinking that prevents
DNA transcription, blocks cell replication, and finally results in apoptosis. Cisplatin has been
previously shown to be more effective when administered in the hyperthermia temperature range
(Halamikova, Vrana et al. 2007, Issels 2008, Itoh, Yamada et al. 2010). Lee et al. reported the
effects of treatment sequence and heating technique (MMH or HWH) on Caco-2 cells (Lee,
Rodriguez-Luccioni et al. 2011). The highest cytotoxicity was observed when CDDP and MMH
were applied at the same time with an additional drug exposure period, but MMH was more
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effective than HWH independent of treatment sequence. The mechanism of cell death after
combined treatment is likely to be a form of programmed cell death, such as apoptosis rather than
necrosis. In a subsequent study (Alvarez-Berríos, Castillo et al. 2013), the enhancement of cisplatin
in Caco-2 cells by MMH was correlated with an increase in cell membrane fluidity. The presence
of copper inhibited CDDP uptake in control cells by hindering copper transporter-mediated active
transport, but this same inhibition was not seen in HWH or MMH. Platinum concentration inside
cells after MMH was significantly greater than after HWH, which corresponded to the increase in
membrane fluidity observed after MMH. Another study by Kruse et al. used crosslinked dextran
coated iron oxide MNPs in the presence of an AMF to administer hyperthermia treatment to A549
lung carcinoma in combination with CDDP (Kruse, Meenach et al. 2014) (see Chapter 4).
Hyperthermia treatment was administered for 30 minutes simultaneously with CDDP and resulted
in an additive effect of the combined treatment when analyzed 72 hours post treatment.
An in vivo study of MMH (60 minutes at 43°C) combined with CDDP on murine mammary
adenocarcinoma model showed that MMH combined with CDDP was 1.7 times more effective
than MMH alone and 1.4 times more effective than CDDP alone (Petryk, Giustini et al. 2013).
Tumor growth was monitored over time and the control took 14 days to grow three times its original
size whereas MMH alone resulted in a delay to 21 days, CDDP alone took 25 days and the
combined treatment took 36 days.
Bortezomib (BZ), an inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells, is another chemotherapeutic that has been studied in combination with MMH
(Alvarez-Berrios, Castillo et al. 2014, Alvarez-Berrios, Castillo et al. 2015). Alvarez-Berrios et al.
showed that MMH enhances the cytotoxicity of BZ in both BZ sensitive (MDA MB 468 and caco2) and resistant (A2780) cancer cell lines (Alvarez-Berrios, Castillo et al. 2014). Carboxymethyl
coated iron oxide MNPs (3.8 mg/mL) in the presence of an AMF (233 kHz) at 29.39 or 34.73 kA/m
resulted in hyperthermia treatment at 43°C or 45°C, respectively. A different concentration of BZ
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for each cell line was used in order to produce approximately the same level of proteasome
inhibition after a pre-exposure time of 3 hours. Although BZ sensitive cells and BZ resistant cells
showed similar levels of proteasome inhibition, thermal sensitization induced by MMH in
combination with BZ in cells resistant to BZ resulted in significant cell death potentially due to an
increase in cell membrane fluidity.
BZ is a drug that increases the toxicity of proteotoxic stress in cancer cells because such cells
produce significant amounts of misfolded and non-functional proteins, such that alternative
mechanisms of cell protection against proteomic stress can be overwhelmed (Alvarez-Berrios,
Castillo et al. 2015). Additionally, it has been shown that the combination of cellular effects
induced by MMH, such as microtubule disruption and protein damage, results in progressive
enhanced proteotoxic stress, which can lead to programmed cell death. MCF-7 cells treated with
MMH or MMH and BZ at 43 °C (30 minute recovery time) showed more protein aggregation
surrounding the nucleus compared to HWH or BZ with HWH, respectively. After 2.5 hours of
recovery time, MMH had induced significant microtubule damage (43°C). It was speculated that
the combination of microtubule damage and increased protein aggregation caused by MMH
induces progressive enhanced proteotoxic stress, which produces significant cell death.
As previously mentioned, chemotherapeutics can be combined with MMH by functionalizing
the magnetic nanoparticle with a chemotherapeutic of interest – by tethering with a responsive
linker or encapsulation within a coating matrix – resulting in controlled drug release upon exposure
to an external stimuli such as an AMF (as discussed in greater detail in section 2.1 above) or change
in pH. Huang et al. recently synthesized pH sensitive cisplatin-loaded magnetite hydroxyapatite
nanoparticles (Huang, Chen et al. 2015). In a low pH environment, 20% of the CDDP was released
compared to 5% at a pH of 7. After treatment with the nanoparticles at 300 µg/mL for 48 hours,
A549 viability was significantly decreased, and further decreased in the presence of an AMF for
30 minutes resulting in a temperature increase to 43°C. Additionally, in an in vivo subcutaneous rat
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model, tumor growth was completely inhibited in the group treated with the nanoparticle system
combined with AMF treatment. In another study by Babincova et al., iron oxide nanoparticles were
coated with a hydrophilic starch polymer coupled with phosphate functional groups (Babincova,
Altanerova et al. 2008). The negative coating charge allowed for ionic binding of positively charged
species such as cisplatin. A 20 minute hyperthermia treatment was induced using an AMF (3 MHz,
1.5 mT), and during this time, almost all of the drug was released from the nanoparticle. The
combined MMH and CDDP treatment from the drug loaded iron oxide nanoparticle resulted in a
relative viability of 23.6 ± 8.6%. This is significantly less than either the hyperthermia treatment
(85.2 ± 7.5%) or the equivalent CDDP treatment (73.8 ± 5.6%) alone, indicating a synergistic
toxicity of CDDP and MMH.
5-fluorouracil (5-FU) has also been conjugated to iron oxide nanoparticles for combination
therapy. Li et al. functionalized a magnetite core with PMSA followed by covalent modification
with poly-A15 (Li, Huang et al. 2013). The nanoparticles were then functionalized with 5-FU and
tagged with a HER2 antibody. A subcutaneous model with a bladder cancer cell line (MBT-2) was
used to evaluate the efficacy of combined 5-FU and 15 minute thermal therapy treatment. For small
tumors, hyperthermia treatment alone was able to significantly reduce the tumor volume. However,
for larger tumors, only the combined treatment of using 5-FU functionalized nanoparticles for
MMH resulted in a decrease in tumor volume. A complementary result was seen when the targeted,
drug functionalized nanoparticles were injected through the tail vain followed by AMF exposure.
The nanoparticles without AMF treatment did not inhibit tumor growth (likely due to no 5-FU
release) nor did treatment with an equivalent dose of 5-FU. The drug loaded nanoparticles with
AMF exposure led to complete tumor regression two days after the last treatment. In another study,
5-FU and curcumin were functionalized to magnetic nanoparticles, and when exposed to an AMF,
the dual drug release combined with thermal therapy led to an enhanced efficacy compared to either
drug treatment alone (Balasubramanian, Girija et al. 2014). This is thought to be due to increased
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efficiency of drug diffusion from the nanoparticles or to the fact that injured cells could not
recuperate from the impairment induced by thermal treatment owing to the combined treatment of
5-FU and curcumin.
Heat shock protein (HSP) inhibitors are of particular interest due to up regulation of heat shock
proteins during hyperthermia treatment. Geldanamycin, a HSP 90 inhibitor, was conjugated to iron
oxide nanoparticles via a thermally cleavable linker for controlled release upon exposure to an
AMF (Yoo, Jeong et al. 2013). An in vitro study on MDA MB 231 cells showed geldanamycin
functionalized iron oxide MNPs negated the increased HSP 90 expression seen with MMH alone,
and an in vivo study resulted in complete tumor regression 8 days after treatment when the
geldanamycin functionalized MNPs were used for MMH.
Additional studies have been completed using methotrexate (Gao, Yan et al. 2012),
doxorubicin (Xu, Karmakar et al. 2012), and erlotinib (Xu, Karmakar et al. 2012) functionalized
magnetic nanoparticles for combination therapy. These studies also indicate that drug combined
with hyperthermia via MNPs in an AMF is more effective than either treatment alone. Methotrexate
combined with MMH resulted in a synergistic treatment of MCF-7 cells in vitro (Gao, Yan et al.
2012) while doxorubicin efficacy was significantly increased when combined with MMH (Xu,
Karmakar et al. 2012).
MMH can also be combined with radiation and gene therapy for enhanced efficacy. There are
several studies that address hyperthermia combined with radiation (Horsman and Overgaard 2007,
Hurwitz, Hansen et al. 2011, Neshasteh-Riz, Rahdani et al. 2014), but minimal studies that utilize
MMH with radiation therapy. Hyperthermia has been shown to increase blood supply to the tumor,
which increases the local oxygen levels and the efficacy of radiation therapy is tied to the formation
of free radicals more so than DNA damage. In an orthotopic tumor model of R3327 Dunning tumor
cell line, MNPs with an aminosilane shell were used for two rounds of MMH for 30 minutes each
combined with 20 Gy, 40 Gy or 60 Gy total radiation therapy (Johannsen, Thiesen et al. 2006).
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Thermal therapy viability inhibition alone was 44.1-51.7% whereas the combined treatment (20 Gy
radiation total with hyperthermia) had an inhibition of 87.5-89.2% compared to the control. A
clinical trial was also completed in which 59 patients with recurrent glioblastoma received a direct
injection of iron oxide MNPs followed by 30 minutes of heating (43°C) in an AMF (100 kHz, 215 kA/m) (Maier-Hauff, Ulrich et al. 2011). A median radiation dose of 30 Gy was given to the
patients immediately before or following hyperthermia treatment. The combined therapy resulted
in an extension of the median overall survival after primary tumor diagnosis from 14.6 to 23.2
months. There was also a gain of 7.2 months for survival following tumor recurrence. Although
there are differences between the treatments of the patients, the increase in survival time can be
attributed to the combination of thermo-radiotherapy.
Thermal therapy via magnetic nanoparticles combined with gene therapy is a recently
developed area in this field. A review of heat responsive gene expression utilizing thermal therapy
via other methods than MNPs was published in 2009 (Walther and Stein 2009). More recently in
2014, Shah et al. evaluated the efficacy of pro-apoptotic amphipathic tail-anchoring peptide
(ATAP) delivery by MNPs. MMH was used to increase pro-apoptotic proteins in glioblastoma
multiforme cells and metastatic breast cancer cells, while the ATAP peptide selectively targeted
mitochondria and induced cytochrome c release through disruption of the mitochondrial membrane.
The result of gene therapy treatment combined with MMH resulted in enhanced toxicity compared
to ATAP therapy alone, which is likely due to an increase in peptide solubility upon conjugation
to the nanoparticles. In another study completed by Yin et al. in the same group, lethal-7a miRNA
was conjugated to MNPs, as lethal-7a is a known tumor suppressor that inhibits malignant growth
by targeting factors such as the BRCA family, RAS, IGF1R and c-Myc, which all overlap with
downstream regulation of heat shock proteins (Yin, Shah et al. 2014). Combined thermal therapy
via MMH and gene therapy with lethal-7a showed an additive effect, resulting in significantly more
apoptosis in brain cancer cells than either treatment alone. Overall, gene therapy combined with
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MMH is a promising avenue for combination therapy and can potentially result in more
personalized treatment of cancer.
3.4 Conclusions
Thermal therapy using MNPs has been shown to decrease cancer cell growth both in vivo and
in vitro to a greater extent than thermal therapy administered by external methods such as HWH.
In addition, immunotherapeutic effects of thermal therapy have been observed and show promise
for future development. However, due to the bulk concentration of nanoparticles required to heat
tissue into the hyperthermia range, translation to clinical trials has been minimal. Additionally,
applications of MMH as a viable treatment modality is limited by tumor size due to heat transfer
from small tumors (i.e. metastases) to the surrounding tissue. In order to improve thermal therapy
via MNPs, in vivo heating properties need to be improved and specific strategies for targeting to
tumor tissue to decrease non-specific accumulation need to be developed.
Energy delivery on the nanoscale provides another avenue of thermal therapy where only
intracellular nanoparticles are actuated by an AMF, resulting in subcellular heating effects without
a macroscopic temperature rise. Energy delivery on the nanoscale has been shown to result in
destabilization of lysosomal membranes and toxic effects to other organelles. Previously, the focus
of MNP development was improving the heating capabilities to overcome the thermal delivery
limitations, but in addition to this need for other therapy strategies, many researchers are now
exploring intracellular targets for nanoscale thermal therapy applications. Further studies need to
be performed to gain a better fundamental understanding of the mechanisms at play. However, an
exciting prospectus is to combine the knowledge gained through combined chemotherapy with this
new therapy strategy.

Novel nanoparticle architectures should be synthesized to deliver

therapeutics intracellularly, relying on nanoscale thermal effects to improve efficacy.
Thermal therapy as a single treatment is often insufficient to induce irreparable cellular
damage, but when combined with a secondary treatment, the combination therapy is often found to
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be more effective than either treatment alone. A variety of chemotherapeutics are more effective
when administered at elevated temperatures due to increased rate constants of alkylation, increased
drug uptake, and repair inhibition of drug-induced lethal or sub-lethal damage. Thermal therapy
also increases oxygen content within tissue, making radiation more effective. Therefore, as a
combination treatment, thermal therapy via MNP activation in an AMF has greater application.
However, the same limitations such as concentration dependence, heating properties, and AMF
parameters still remain. As the field progresses, it will be important to develop targeted MNPs with
excellent heating properties in order to overcome some of these limitations and, as previously
mentioned, explore nanoscale thermal therapy in combination with conventional treatments.
In the last several years, there have been many exciting developments in the use of MNPs and
their composites for remote controlled therapies. These include novel remote controlled drug
delivery systems at various scales for modulated release and magnetic field guidance, controlled
energy release for thermal therapy and nanoscale energy therapy, and thermal therapy in
combination with other treatments such as chemotherapy or radiation. With numerous in vivo
demonstrations of efficacy, these remote controlled therapies are starting to progress to the clinic,
and they are expected to greatly impact the treatment of various diseases in the future.

Copyright © Anastasia Kruse Hauser 2016
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Chapter 4 Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles
for hyperthermia applications

The dextran-coated iron oxide nanoparticle system were synthesized via a one-step co-precipitation
reaction. The dextran surface was then crosslinked and functionalized with the CREKA peptide.
The physicochemical properties of the nanoparticles were characterized at each step of the synthesis
process. The goal of this work was to analyze the physicochemical properties of the nanoparticle
system and to complete a proof-of-concept magnetically mediated hyperthermia study. The chapter
is taken directly or adapted from work published in Kruse, Meenach, et al. (2014) Copyright 2014
Elsevier B.V. Used with permissions from Anastasia M. Kruse, Samantha A. Meenach, Kimberly
W. Anderson and J. Zach Hilt, “Synthesis and characterization of CREKA-conjugated iron oxide
nanoparticles for hyperthermia applications”, Acta Biomaterialia and Elsevier B.V.
4.0 Abstract
One of the current challenges in the systemic delivery of nanoparticles in cancer therapy
applications is the lack of effective tumor localization. Iron oxide nanoparticles coated with
crosslinked dextran were functionalized with the tumor homing peptide CREKA, which binds to
fibrinogen complexes in the extracellular matrix of tumors. This allows for the homing of these
nanoparticles to tumor tissue. The iron oxide nanoparticle core allows for particle heating upon
exposure to an alternating magnetic field (AMF) while the dextran coating stabilizes the particles
in suspension and decreases the cytotoxicity of the system. Magnetically mediated hyperthermia
(MMH) allows for the heating of tumor tissue to increase the efficacy of traditional cancer
treatments using the iron oxide nanoparticles. While MMH provides the opportunity for localized
heating, this method is currently limited by the lack of particle penetration into tumor tissue, even
after effective targeted delivery to the tumor site. The CREKA-conjugated nanoparticles presented
were characterized for their size, stability, heating capabilities and biocompatibility. The particles
had a hydrated diameter of 52 nm, were stable in PBS and media with 10% v/v FBS over at least
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twelve hours, and generated enough heat to raise solution temperatures well into the hyperthermia
range (41 – 45 °C) when exposed to an AMF due to an average specific absorption rate (SAR) of
83.5 W/g. Cytotoxicity studies demonstrated that the particles have low cytotoxicity over long
exposure times at low concentrations. A fibrinogen clotting assay was used to determine the binding
affinity of CREKA-conjugated particles, which was significantly greater than the binding affinity
of dextran, only coated iron oxide nanoparticles demonstrating the potential for this particle system
to effectively home to a variety of tumor locations. Finally, it was shown that in vitro MMH
increased the effects of cisplatin compared to cisplatin or MMH treatments alone.
4.1 Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United
States each year (ACS 2013). Survival without treatment for stage IV NSCLC is 6 months if left
untreated and only 9 to 12 months with treatment. Hyperthermia, the heating of tissue to 41-45 °C,
has been shown to be effective in treating lung cancer when used in conjunction with radiation or
chemotherapy (Vertrees, Das et al. 2005, Itoh, Yamada et al. 2010, Lee, Rodriguez-Luccioni et al.
2011). Current hyperthermia treatments (e.g., whole body and regional hyperthermia) have several
disadvantages, including damaging healthy tissue, limited penetration of heat into the body, underdosage of heat, and complications such as increased heart rate and increased cardiac output
(Zwischenberger, Vertrees et al. 2004, Issels 2008, Kumar and Mohammad 2011). Hyperthermia
treatments are further challenged by deep seated tumors and lack the ability to penetrate
surrounding tissues to raise the tumor tissue into the hyperthermia range (Dennis, Jackson et al.
2009). Although various limitations exist, treatment of cancer via hyperthermia in conjunction with
cisplatin was shown to have synergistic effects (Babincova, Altanerova et al. 2008) and
sensitization of cisplatin-resistant cell lines (Hettinga, Lemstra et al. 1995). Cisplatin (20 µg/mL or
200 µg/mL) combined with mild incubator-induced hyperthermia at 41 °C was shown to
significantly decrease the surviving fraction of T24 bladder cancer cells in vitro (Itoh, Yamada et
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al. 2010). In another study completed by Hettinga and coworkers, murine tumor cells were mutated
in vitro for cisplatin resistance (Hettinga, Lemstra et al. 1995). The cisplatin-resistant cell line was
exposed to cisplatin (0 - 10 µg/mL) for 45 minutes at either 37 °C or 44 °C. Hyperthermia with
cisplatin exposure resulted in a significant decrease in the percentage of cell survival of the
cisplatin-resistant cells. A second experiment demonstrated that the cisplatin-resistant cells were
sensitized by hyperthermia by pre-heating the cells at 44 °C for 10 minutes prior to 45 minutes of
cisplatin exposure at 37 °C. This treatment sequence further decreased the cell survival of the
cisplatin-resistant cells (Hettinga, Lemstra et al. 1995).
In the presence of an alternating magnetic field (AMF), iron oxide magnetic nanoparticles
generate heat and can induce hyperthermia. Magnetically-mediated hyperthermia, which is the
heating of tissue using heat generated by magnetic nanoparticles in the presence of an AMF, shows
great promise in overcoming the limitations of current hyperthermia treatments due to the ability
of nanoparticles to deliver heat directly to the tumor site, therefore limiting the heat exposure to
surrounding tissues. Iron oxide nanoparticles (IONPs) have the ability to passively or actively target
tumors, and in the presence of an external AMF, can generate heat via multiple possible loss
mechanisms including Néel paramagnetic switching, friction losses from Brownian rotation, and
hysteresis (Dennis, Jackson et al. 2009). IONPs have been studied as imaging agents, drug delivery
systems, and therapeutic enhancers due to their inherent biocompatibility, magnetic properties, and
lack of protein adsorption after proper coating (Laurent, Dutz et al. 2011). In cancer therapy
applications of IONPs, the main limitation to treating solid tumors is the limitations of particle
localization. Vascularization and the enhanced permeation and retention (EPR) effect allow for
passive targeted delivery of nanoparticles to the periphery of solid tumors. However, active
targeting through peptides or ligands can result in higher local concentrations of nanoparticles and
lower systemic concentrations, which is required for more effective treatment (Ruoslahti, Bhatia et
al. 2010).
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CREKA, a tumor homing peptide, recognizes fibrin-associated plasma proteins, which are
overexpressed in cancerous tissue but not in normal, healthy tissue. The walls of tumor vessels and
the interstitial space within tumors contain these fibrin-fibronectin complexes due to protein
seepage from the leaky vasculature of the tumor (Ruoslahti, Bhatia et al. 2010). It was shown that
CREKA can specifically target fibrin-fibronectin complexes as demonstrated by the lack of the
peptide targeting to syngeneic B16F1 melanoma tumors grown in mice null of fibrinogen or lacking
plasma fibronectin but significant homing to syngeneic B16F1 melanoma tumors in wild-type mice
of the same litter (Simberg, Duza et al. 2007). CREKA is a small, linear peptide of five amino
acids, which makes it attractive to use for conjugation with nanoparticles since multiple peptides
can be conjugated to a single nanoparticle (Simberg, Duza et al. 2007). IONPs do not require
internalization into cancer cells to be effective at heating the tumor tissue. Internalization of IONPs
has been shown to enhance the anti-cancer effects of thermal energy dissipation compared to bulk
hyperthermia methods (Creixell, Bohorquez et al. 2011). Intracellular hyperthermia does not result
in a bulk temperature rise but rather relies on the ability of individual nanoparticles to raise the
temperature of their immediate surroundings (Krpetic, Nativo et al. 2010). Although targeting
promoted uptake of IONPs can enhance their intracellular concentration, the targeting peptides,
such as EGFR, are still cell line specific. Therefore, CREKA conjugation to IONPs is advantageous
over other peptides in that it binds to complexes within the tumor vasculature rather than specific
integrins on the surface of cells (Ruoslahti, Bhatia et al. 2010).
In this study, peptide-conjugated dextran-coated IONPs for enhanced tumor homing have been
developed and characterized. Physicochemical characterization and in vitro biocompatibility
studies are imperative for rationally developing and understanding a nanoparticle system. Prior to
in vivo studies, the properties of this nanoparticle system such as size, stability, heating profiles,
toxicity, and fibrinogen binding affinity need to be optimized. The desired size range for our
nanoparticles is around 50 nm, which is expected to allow for tumor penetration and initial
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accumulation to tumor tissue via the EPR effect. Stability in media is an important property for
systemically delivered nanoparticles, and the heating properties must be sufficient to induce
hyperthermia conditions upon exposure to an AMF with substantial SAR values. Nanoparticle
systems used for biological applications such as these must be screened for toxicity at low
concentrations over long time frames, and for this specific peptide-conjugated IONP system, the
binding affinity of the particles to fibrinogen complexes was important to verify since fibrinogen
complexes within the tumor vasculature are the target of this system. A proof-of-concept study was
then completed to show that this nanoparticle system could be used to enhance the effectiveness of
cisplatin through magnetically mediated hyperthermia. This peptide-conjugated IONP has optimal
physical characteristics, such as size (Fox, Szoka et al. 2009, Phillips, Gran et al. 2010) and
stability, for tumor homing via fibrin-fibronectin complexes and heating capabilities, which can be
utilized for the hyperthermia treatment of lung cancer, in combination with chemotherapy.
Although this study focuses on CREKA-conjugated IONPs for the treatment of lung cancer, this
nanoparticle system has the ability to treat a multitude of cancerous tumors since it recognizes
fibrinogen complexes rather than specific surface integrins, which are often cell line dependent.
4.2 Materials and Methods
4.2.1 Materials
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran,
epichlorohydrin (ECH), cisplatin (CDDP), fibrinogen, di-methyl sulfoxide (DMSO), and thrombin
were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide (NH4OH) was
purchased from EMD Chemicals (Gibbstown, NJ). N-α-maleimidoacet-oxysuccinimide ester
(AMAS) linker was obtained from Thermo Scientific (Rochester, NY). CREKA peptide conjugated
with 5-fluorescein isothiocyanate-aminohexanoic acid (FITC-CREKA) was custom ordered
through Biomatik (Cambridge, Ontario). Fetal bovine serum (FBS) was purchased from Fisher
Scientific (Florence, KY). Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine,
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Fungizone®, and sodium pyruvate were all purchased from Invitrogen (Grand Island, NY), and
trypsin was purchased from American Type Culture Collection (ATCC, Manassas, VA). 190 proof
ethanol was purchased from Pharmco-Aaper (Shelbyville, KY) and phosphate buffered saline
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). All materials were used
as received.
4.2.2 Crosslinked dextran coated iron oxide nanoparticle synthesis
A modified one-pot co-precipitation method (Frimpong, Dou et al. 2010) was used to prepare
dextran coated IONPs. FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams
and 0.8 grams, respectively) and dissolved in 25 mL deionized (DI) water and sealed in a threeneck flask under vigorous stirring and an inert nitrogen environment. 11 grams of dextran was
solubilized in 50 mL of DI water and added to the three-neck flask. The solution was heated to 85
°C at which 5 ml of NH4OH was injected into the vessel. The reaction was carried out for 1 hour
at 85 °C. The particles were centrifuged at 1000 rpm for 10 minutes to remove large agglomerates.
The remaining particles were then dialyzed against DI water for 24 hours. Dextran coated IONPs
were crosslinked using ECH for increased stability (Stephen Palmacci 1993). The particle colloid
(9 mL, 1 mmol Fe) was added to 9 mL 5M NaOH and 2 mL ECH. The reaction was carried out for
24 hours at room temperature under continuous agitation. The particles were then dialyzed against
DI water for 24 hours to remove excess ECH. Crosslinked IONPs were then aminated to allow for
peptide conjugation. This was accomplished by reacting 0.2 mL of 30% ammonium hydroxide with
the particles (5 mL, 0.2 mmol Fe) for 24 hours at room temperature under continuous agitation.
The particles were then dialyzed against DI water for 24 hours.
4.2.3 CREKA conjugation of iron oxide nanoparticles
Amine conjugated IONPs were further conjugated with AMAS linker. The primary amines on the
nanoparticles react with the N-hydroxysuccinimide of the linker, and CREKA can then be
conjugated to the particle surface by reacting the sulfhydryl group on the cysteine with the
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maleimide group of the linker. Particles were re-suspended at a concentration of 1 mg Fe/mL in
PBS, and 2.5 mg AMAS per 2 mg Fe were dissolved in DMSO prior to addition to the nanoparticle
suspension (Simberg, Duza et al. 2007). After the AMAS addition under vortexing, the reaction
was carried out for 40 minutes at room temperature. Particles were then washed three times with
PBS on 100,000 MWCO cellulose Millipore filtration columns. FAM-CREKA was then added to
the particle suspension at 25 mg per 4 mg Fe (Simberg, Duza et al. 2007). Particles were incubated
overnight at 4°C and then washed again with PBS. To serve as a control for the CREKA-conjugated
IONPs, fluorescein isothiocyanate (FITC) was conjugated to amine groups on crosslinked dextran
IONPs. FITC was added in a 1:10 molar ratio to iron oxide (0.434 mmol Fe3O4 and 0.0434 mmol
FITC) and dissolved in 5 mL ethanol. The reaction was carried out for six hours at room
temperature. The particles were then washed with DI water and concentrated using ultrafiltration
columns. A summary of the systems investigated is included in Table 4.1, and a schematic of the
systems synthesized is included in Figure 4.1.
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Figure 4.1 Iron oxide nanoparticle synthesis process for the (a) dextran coating, (b) epichlorohydrin
crosslinking, (c) amine conjugation, and (d) conjugation with an AMAS linker, connecting the
FAM-labeled CREKA to the primary amine.
4.2.4 Particle characterization
Transmission electron microscopy (TEM). TEM was completed using a JEOL 2010F system
operating at 200 KeV. Iron oxide nanoparticles were diluted to 200 µg/mL Fe in DI water and then
dried on carbon TEM grids prior to analysis.
Ultraviolet (UV)-Visible spectroscopy. The stability of the nanoparticles was analyzed using a
CaryWin 50 probe UV-visible spectrophotometer. IONPs were diluted to 200 µg/mL Fe in PBS or
DMEM with 10% FBS. Sample absorbance was read at 540 nm over 12 hours.
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Thermogravimetric analysis (TGA). TGA was used to quantify the mass percent of the iron oxide
core in the particle systems using a Netzsch Instruments STA 449A system. Approximately 5 mg
of particle sample was heated at a rate of 5 °/minute. At 100 °C, the sample was held isothermally
for 20 minutes to vaporize residual water. The samples were heated at 5 °/minute until reaching
500 °C where they were held isothermally for an additional 20 minutes. The reported mass loss
reported was the actual mass loss normalized to the initial sample mass after isothermal heating at
100 °C.
Dynamic light scattering (DLS). DLS measurements were obtained using a Beckman Coulter Delsa
Nano C particle analyzer. Nanoparticle solutions were diluted to 200 µg/mL and were sonicated
in a water bath prior to size analysis.
Alternating magnetic field (AMF) heating. The nanoparticle heating profiles were obtained using
a custom made Taylor Winfield magnetic induction source, and the temperature was measured with
a fiber optic temperature sensor (Luxtron FOT Lab Kit from LumaSense).

Nanoparticle

suspensions were diluted in DI water to a concentration of 5 mg/ml iron oxide. One milliliter of
suspension in a 2 ml microcentrifuge tube was placed in the center of the AMF induction coil. The
suspension was heated at a field amplitude of 58 kA/m and frequency of 292 kHz until the
temperature of the suspension reached steady-state. The specific absorption rate (SAR) values of
the nanoparticle suspensions were then calculated using the following equation:

𝑆𝐴𝑅 =

𝐶𝑝,𝐹𝑒 𝑚𝐹𝑒 + 𝐶𝑝,𝐻2𝑂 𝑚𝐻2𝑂 𝑑𝑇
𝑚𝐹𝑒
𝑑𝑡

[4.1]

where Cp,Fe is the heat capacity of iron, mFe the mass of iron, Cp,H2O the heat capacity of water, mH2O
the mass of water, and dT/dt the initial slope of the heating profile.
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4.2.5 Cytotoxicity analysis of particle systems
A549 lung carcinoma cells obtained from ATCC were cultured from passages 5 - 10 in DMEM
supplemented with 10% FBS, 10 μg/ml Fungizone®, 2 μg/ml penicillin-streptomycin, and 4mM
L-glutamine. Cells were seeded into 96-well plates at 4,000 cells/well and incubated for 24 hours.
The cells were then exposed to nanoparticles in complete cell media at concentrations of 50, 100,
350, and 500 µg Fe/ml. Cytotoxicity was determined using a calcein red fluorescent stain (1 µM,
λex=540nm and λem=590nm) after 24 and 48 hours. Cell viability was analyzed using a Biotek
SynergyMx microplate reader and the fluorescence of the cells exposed to the nanoparticle
solutions was normalized to the fluorescence of the control cells.
4.2.6 CREKA and CREKA IONP binding affinity to fibrinogen clots
To synthesize fibrinogen clots, 75 µL of fibrinogen solution (2 mg/mL) in 0.9% NaCl was added
to a 96-well plate. 30 µL of a 2.5 U/mL thrombin solution in 0.9% NaCl was subsequently added
to the same 96-well plates. The plates were placed in an incubator shaker at 37°C for 5 minutes,
and then gels were formed after four hours incubation at 37°C. Binding affinity of fluorescently
labeled CREKA conjugated IONPs (CREKA-IONP) was compared to the binding affinity of
unconjugated CREKA (CREKA only) and FITC conjugated iron oxide nanoparticles without
CREKA (FITC-IONP). CREKA-IONP and FITC-IONP systems were diluted by taking 5, 10, 25,
and 50 µL of nanoparticle solution and diluting to a total volume of 50 µL with DI water. The exact
nanoparticle concentration was not necessary as taking the fluorescence ratio of the bound to free
particles was determined at the same concentration. CREKA was diluted to 50, 100, 250 and 500
µM. 50 µL of solution (particle or CREKA only) was added to each clot. After one hour, half of
the samples were washed twice with 120 µL of DI water to remove any CREKA or IONPs not
bound to the fibrinogen clots, and the fluorescence of the plate was read on the microplate reader
(λex=488 nm and λem=520 nm). The bound CREKA or FITC fluorescence (washed gels) was
normalized to the corresponding free (unwashed gels) solution for each sample.
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4.2.7 In vitro magnetically mediated hyperthermia and cisplatin combined treatment
One mL of A549 lung carcinoma cells (passage 15) was suspended in complete cell culture media
in a 1.5 ml microcentrifuge tube at a concentration of 300,000 cells. The vials were then centrifuged
at 800 x g for 5 minutes to pellet the cells. The media supernatant was removed and the cells were
resuspended in 1 mL of the respective treatment solutions. The six treatments are outlined in Table
4.3. Cisplatin treatments were administered at 100 µM, IONP were administered at a concentration
of 3 mg/mL, and hyperthermia was induced by the presence of an alternating magnetic field (5158 kA/m). Treatments lasted 30 minutes, and all controls were also exposed to experimental
conditions (i.e. room temperature) for 30 minutes. After treatment, the vials were centrifuged at
800 x g for 5 minutes, the treatment solution was removed, and replaced with fresh media. A second
centrifugation cycle was completed to further wash the cells of the treatment solutions. The treated
cells were then seeded into 48-well plates at 30,000 cells/mL (250 µL/well). The viability of the
cells was analyzed 48 and 72 hours post-treatment using a calcein AM assay (2 µM, λex=494 nm
and λem=517 nm) analyzed by a microplate reader. The fluorescence of the cells exposed to the
various treatments was normalized to the fluorescence of the control cells at each time point.
Additional analyses were completed to determine the type of effect MMH and cisplatin had on
A549 cells after 72 hours using the following equations (Babincova, Altanerova et al. 2008):
synergistic, [MMH + CDDP] < [MMH] x [CDDP]/100; additive, [MMH + CDDP] = [MMH] x
[CDDP]/100; sub-additive, [MMH] x [CDDP]/100 < [MMH + CDDP] < [MMH]; if [MMH] <
[CDDP]; interference, [MMH] < [MMH + CDDP] < [CDDP], if [MMH] < [CDDP]; and
antagonistic, [CDDP] < [MMH + CDDP], if [MMH] < [CDDP], where [MMH] represents the cell
viability percentage exposed to magnetically mediated hyperthermia alone, [CDDP] represents the
cell viability percentage exposed to cisplatin alone, and [MMH+CDDP] represents the cell viability
percentage exposed to combined magnetically mediated hyperthermia and cisplatin.
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4.2.8 Statistical analysis
Statistical analysis was completed using Daniel’s XL Toolbox in Microsoft Excel. A 1-way
ANOVA test was used to determine the statistical differences of the cytotoxicity analysis and
magnetically mediated hyperthermia study. A Student’s t-test was used to determine the statistical
differences of the fibrinogen binding study.
4.3 Results and Discussion
4.3.1 Particle characterization
The iron oxide nanoparticles exhibited diameters of 5 – 13 nm as shown by the TEM images
in Figure 4.2. The clustering of the iron oxide suggests that multiple cores are encapsulated by the
dextran coating for each nanoparticle. Due to the low density (i.e., low contrast) of the dextran
coating, no differences were observed between the TEM images of the Fe3O4+Dx and Fe3O4+DxECH nanoparticles. As seen in Table 4.1, size analysis indicated that the number average hydrated
diameters of the nanoparticle systems were approximately 52 nm. All polydispersity indexes were
below 0.2 indicating uniform nanoparticle sizes.

Figure 4.2 TEM images of (a) dextran coated iron oxide nanoparticles (Fe3O4+Dx) and (b) dextranepichlorohydrin crosslinked iron oxide nanoparticles (Fe3O4+Dx-ECH).
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Table 4.1 Nanoparticle systems synthesized and characterized, their size as analyzed via DLS, and
SAR values from AMF heating. Size of Fe3O4+Dx-ECH-Amine-CREKA via DLS could not be
completed due to the fluorescent tag but minimal difference from the other systems is expected.
Nanoparticle System
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx-ECH-Amine
Fe3O4+Dx-ECH-Amine-CREKA

Size (nm)
52 ± 16
56 ± 11
52 ± 8
---

SAR (W/g)
81 ± 19
98 ± 16
89 ± 9
66 ± 18

Particles of this size have been shown to extravasate into tumor tissue and have been used in
passive tumor targeting by taking advantage of the leaky vasculature of the tumor and the enhanced
permeation and retention effect (Fox, Szoka et al. 2009, Phillips, Gran et al. 2010).
Ensuring the stability of nanoparticles in various types of solutions over time is very important,
especially for the systemic delivery of therapeutics. Particle-particle interactions can induce
aggregation and particle settling which can adversely affect the properties of the nanoparticles, such
as heating capabilities and tumor targeting. Particle aggregates greater than 200 nm not only settle
out of solution, but also attract opsonin proteins in vivo which label the particles for removal
through the mononuclear phagocyte system (MPS)/reticuloendothelial system (RES) (Fox, Szoka
et al. 2009). Using UV-visible spectroscopy, it was shown that the nanoparticles were stable in
both PBS and DMEM supplemented with 10% v/v FBS for each stage of particle synthesis over a
time period of 12 hours (Figure 4.3), with the normalized absorbance indicating minimal to no
particle settling in solution. Overall, these results indicate the high stability of the evaluated particle
systems in multiple solutions.
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Figure 4.3 Normalized absorbance (at 540 nm) of the iron oxide nanoparticle systems in (a) PBS
and (b) DMEM with 10% v/v FBS over 12 hours using UV-visible spectroscopy.
Thermogravimetric analysis was used to confirm the presence of the dextran coating on the
iron oxide nanoparticles. This showed that the coating accounted for 59 - 64% of the nanoparticle
mass prior to CREKA conjugation. The coating weight percentage was calculated by subtracting
the final mass fraction from the initial normalized mass. As depicted in Figure 4.4, crosslinking of
the dextran coating with ECH was confirmed by the shift of the mass loss profile to the right where
an increase in the temperature at which the greatest mass loss occurred shifted from 285 °C
(Fe3O4+Dx) to 306 °C, (Fe3O4+Dx-ECH and Fe3O4+Dx-ECH-Amine), indicating a greater thermal
stability of the coating. The observed single drop in particle mass with increasing temperature
confirms a single dextran layer on the surface of the particles, as this abrupt change in weight has
been previously associated with a monolayer of dextran (Bautista, Bomati-Miguel et al. 2005) .
The dextran coating of the final CREKA-IONP only accounted for 30% of the nanoparticle mass
due to the dissolution of free dextran and AMAS linker in DMSO during the final CREKA
conjugation process. Dextran has a very high affinity for DMSO resulting in any free or weakly
bound dextran solubilizing in the DMSO and being washed from the nanoparticle system during
the washing process. As indicated by UV-visible spectroscopy, the CREKA-IONP remained stable
in PBS and DMEM indicating that dextran was still present on the surface of the particles.
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Figure 4.4 Normalized mass loss of each nanoparticle system in the synthesis process via TGA.
4.3.2 Remote controlled heating of iron oxide magnetic nanoparticles via AMF
In the presence of an AMF (58 kA/m, 292 kHz), the iron oxide nanoparticle systems (5 mg/mL
Fe3O4) heated the bulk solution into or above the hyperthermia range (41 - 45 °C) as seen in Figure
4.5. Fe3O4+Dx, Fe3O4+Dx-ECH, and Fe3O4+Dx-ECH-Amine particles heated to 41 °C within 300
seconds. The final CREKA-IONP system took longer to reach the hyperthermia range and heated
to a lower final temperature than the other systems. The iron concentration of the nanoparticles was
determined using an iron assay prior to dilution for heating in the AMF except for the CREKAIONP system. The exact iron concentration of the CREKA-IONP could not be determined due to
low volume of particles so the initial iron concentration used in the synthesis of the CREKA-IONP
was used. Therefore, if any iron oxide nanoparticles were lost in the ultracentrifugation washing
steps post CREKA conjugation, the actual iron concentration of the AMF heating samples would
be lower than calculated, accounting for the lower final temperature and decreased initial slope of
the heating profile. The SAR values are reported in Table 4.1 and indicate the energy being
produced per gram of iron oxide. The lower SAR value for the CREKA-IONP is rationalized by
the previous explanation of the concentration discrepancy. The AMF amplitude and frequency
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correspond to a field frequency product of 1.7 x 1010A/(m·s) which is significantly greater than the
often quoted limit for use in humans (Atkinson, Brezovich et al. 1984). The high field frequency
product may be an issue for future use in humans, but, the cited value is only an estimation. There
is a need for further studies to determine the effects of alternating magnetic fields on healthy tissues
in order to more accurately determine the limitations of AMF exposure (Kozissnik, Bohorquez et
al. 2013).

Figure 4.5 Heating profiles of each nanoparticle system in the synthesis process (5 mg/mL Fe3O4)
in the presence of an alternating magnetic field at 58 kA/m and 292 kHz (n = 3). The gray box
indicates the target hyperthermia range.
4.3.3 Cytotoxicity analysis of particles
The cytotoxicity of the particles produced in each step in the particle synthesis was evaluated
using A549 lung carcinoma cells. A549 cells were exposed to low doses of iron oxide nanoparticles
for 24 and 48 hours, and the viability of the cells was analyzed using a calcein AM stain. As
depicted in Figure 4.6, the particles exhibited no toxicity (at least 100% viability) after 24 hours.
Dextran is a hydrophilic, water-soluble polymer which is inert in biological systems, therefore
decreasing protein adsorption to the nanoparticle surface which would lead to toxicity (Imren,
Gumusderelioglu et al. 2006). After 48 hours, the particles were still mostly non-toxic at these
concentrations, but there was a significant difference between the control and the CREKA-IONP
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at 100, 350, and 500 µg Fe/mL as determined via a 1-way ANOVA test. However, the viability of
the A549 cells after exposure to these concentrations for 48 hours is still above 80%, indicating
that the particles are minimally toxic even though the difference from the control is significant.

Figure 4.6 Normalized viability of each nanoparticle system in the synthesis process on A549 lung
cancer cells after (a) 24 hours of exposure and (b) 48 hours of exposure. Error bars represent
standard error (n = 4) and * indicates a significant difference (p < 0.05) using a 1-way ANOVA
test.
4.3.4 Fibrinogen binding affinity
CREKA-IONPs were shown to bind to fibrin clots with a significantly greater bound-to-free
fluorescence ratio than fluorescently tagged iron oxide nanoparticles (FITC-IONP) (Table 4.2). The
bound-to-free fluorescence ratios of free CREKA and CREKA-IONPs were not significantly
different, indicating that conjugation to the nanoparticle surface does not inhibit the binding
properties of CREKA. The sulfhydryl group on the cysteine of CREKA is not required for binding
to fibrinogen clots. Therefore, conjugation to the nanoparticle surface through a Michael addition
reaction with an AMAS linker does not influence the fibrinogen binding properties of CREKA.
These results indicate that CREKA can be functionalized to the IONP in order to localize the
nanoparticles at the tumor site through binding with fibrinogen complexes in the extracellular
matrix. CREKA-IONPs do not bind to specific integrins on the cell surface providing the
opportunity to target a wider range of cancers. Additionally, CREKA-IONPs have resulted in
amplified homing by inducing localized tumor clotting in vivo (Simberg, Duza et al. 2007). These
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clots then attract more CREKA-IONPs, and the cycle continues. This amplified homing of CREKA
to the fibrin complexes within the tumor make it attractive for localizing high concentrations of
IONPs at the tumor site for magnetically mediated hyperthermia.
Table 4.2 Bound-to-free fluorescence for each system to fibrin clots represented by average ±
standard error (n = 4). The * indicates a significant difference from the FITC-IONP bound-to-free
fluorescence ratio (p<0.05).
System
CREKA only
CREKA-IONP
FITC-IONP

Bound-to-free fluorescence
0.69* ± 0.03
0.62* ± 0.03
0.42 ± 0.04

4.3.5 Magnetically-mediated hyperthermia
The heating properties of the magnetic iron oxide nanoparticles were utilized to induce in vitro
hyperthermia conditions on A549 lung carcinoma, and the effects of combined MMH and cisplatin
treatments were evaluated since MMH is known to increase cisplatin efficacy at elevated
temperatures (Lee, Rodriguez-Luccioni et al. 2011, Alvarez-Berrios, Castillo et al. 2013). Five
treatments plus a control were evaluated as seen in Table 4.3 and cell viability 48 and 72 hours
post-treatment was determined to allow time for cellular response to the treatments. After 48 hours
(Figure 4.7), there was no significant difference between MMH treatment alone and combined
cisplatin and MMH treatment (CDDP+MMH). However, at this time point there was also no
difference between the viability of cells exposed to cisplatin and the control, indicating that the
cells had not responded to the cisplatin treatment. As seen in Figure 4.8, after 72 hours there was a
significant difference (p < 0.01) between the viability of cells exposed to MMH treatment alone
and combined cisplatin and MMH treatment (CDDP+MMH). At this time point, the cells had
responded to the cisplatin treatment, as shown by the significantly decreased viability of cells
exposed to cisplatin compared to the control. Additionally, cell morphology dramatically changed
when the cells were treated with cisplatin combined with MMH compared to either treatment alone.
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Images in Figures 4.7 and 4.8, show the cell with blebs, or localized decoupling of the cytoskeleton
from the cell membrane, which is an indicator of apoptosis, or programmed cell death (Charras,
Coughlin et al. 2008). Therefore, cisplatin combined with MMH had a significantly greater effect
on cell viability than either treatment alone.
Table 4.3 Magnetically mediated hyperthermia treatments and controls.
Treatment

Description

Control

Media only

IONP

3 mg/mL Fe3O4 (Fe3O4+Dx-ECH)

MMH

3 mg/mL Fe3O4 plus 30 minutes AMF exposure

CDDP

100 µM cisplatin

CDDP+IONP

100 µM cisplatin plus 3 mg/mL Fe3O4

CDDP+MMH

100 µM cisplatin plus 3 mg/mL Fe3O4 and 30 minutes AMF exposure

The type of effect induced by the combined MMH and CDDP treatment was analyzed using
the equations outlined in section 4.2.7. Seventy-two hours after treatment, the percent viability of
the combined treatment was 23.7 ± 2.9 and [MMH] x [CDDP]/100 equaled 26.2 ± 2.1, where the
error represents standard error (n = 12). Therefore, the combined treatment of hyperthermia and
cisplatin was determined to be additive since these values are not significantly different, as
indicated by a Student’s t-test. This analysis was not completed on the 48 hour post-treatment data
due to the cell viability of cisplatin only treatment not being different from the control.
There are several theories as to how the effects of cisplatin are enhanced by hyperthermia.
Cisplatin operates by binding to DNA forming inter- or intra-strand crosslinks and interfering with
the transcription DNA for protein synthesis, therefore preventing cell division and ultimately
leading to cell death (Butour, Alvinerie et al. 1991). In vitro studies have shown that hyperthermia
increases the intracellular concentration of cisplatin (Ohno, Siddik et al. 1994, Takahashi, Emi et
al. 2002) due to increased permeability of the cell membrane (Alvarez-Berrios, Castillo et al. 2013).
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Therefore, the number of DNA-cisplatin crosslinks is also increased (Meyn, Corry et al. 1980).
Additionally, inhibition of cellular resistance to cisplatin has been observed when combined with
hyperthermia (Hettinga, Lemstra et al. 1997). In vivo, hyperthermia results in increased blood flow
and vascular permeability allowing for greater drug uptake and improved oxygenation of the tumor
tissue (Issels 2008). Hyperthermia has been shown to promote cell death by increasing the fluidity
of membranes causing adverse intracellular and surface events, inactivating microtubule processes
and by enhancing cellular antigen expression or antigen antibody complexation (Hetzel and Dunn
1984). The efficacy of hyperthermia alone is not enough to replace any of the current chemotherapy
standards, but its effects are sufficient to enhance the toxic effects of many chemotherapeutics.
Therefore, by combining magnetically mediated hyperthermia and cisplatin, the effective dosage
of cisplatin can be decreased, and thereby potentially decreasing the toxic side effects of the
chemotherapeutic.
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Figure 4.7 Relative viability of A549 lung cancer cells 48 hours post magnetically mediated
hyperthermia treatment. Error bars represent standard error (n = 12) and ** indicates a significant
difference (p < 0.01). Representative images of A549 cells stained with calcein AM after 48 hours
for: (a) Control, (b) IONP, (c)MMH, (d) CDDP, (e) CDDP+IONP, and (f) CDDP+MMH.
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Figure 4.8 Relative viability of A549 lung cancer cells 72 hours post magnetically mediated
hyperthermia treatment. Error bars represent standard error with n = 12 and ** indicates a
significant difference (p < 0.01). Representative images of A549 cells stained with calcein AM
after 72 hours for: (a) Control, (b) IONP, (c) MMH, (d) CDDP, (e) CDDP+IONP, and (f)
CDDP+MMH.
4.4 Conclusion
CREKA-conjugated dextran coated iron oxide nanoparticles were successfully developed and
characterized for their use in targeted hyperthermia applications. The nanoparticles have properties
suitable for systemic tumor targeting through the enhanced permeation and retention effect such as
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stability in cell culture media and a size of approximately 50 nm (Fox, Szoka et al. 2009, Phillips,
Gran et al. 2010). In the presence of an alternating magnetic field, the particles generated sufficient
heat to increase the bulk solution temperature into the hyperthermia range. CREKA-conjugated
nanoparticles were shown to bind to fibrinogen clots with a higher affinity than FITC-conjugated
iron oxide nanoparticles, suggesting that the nanoparticles can be effective at targeting fibrinogen
overexpressed in tumor tissues. The binding affinity of CREKA was not inhibited by conjugation
to the iron oxide nanoparticles as shown by similar bound-to-free ratios of fluorescence. Low
concentrations of the nanoparticle systems were non-toxic over long periods of time, indicating that
the particles can be used for biological applications. When magnetically mediated hyperthermia
was administered in conjunction with cisplatin, an enhanced cytotoxic effect was observed
compared to cisplatin or hyperthermia alone. This peptide-conjugated nanoparticle system can be
further studied to assess its ability to localize at tumor sites at sufficient concentrations to induce
hyperthermia conditions upon exposure to an external alternating magnetic field.

Copyright © Anastasia Kruse Hauser 2016
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Chapter 5 The effects of synthesis method on the physical and chemical properties of
dextran coated iron oxide nanoparticles
The heating properties of the dextran-coated iron oxide nanoparticles synthesized in Chapter 4 were
inferior compared to other nanoparticle systems synthesized by the co-precipitation method. This
was thought to be due to dextran increasing the solution viscosity and preventing crystal growth
after nucleation. Therefore, the goal of this chapter was to analyze how the timing of dextran
addition into the co-precipitation reaction affected the physicochemical properties of the
nanoparticles. The chapter is taken directly or adapted from work published in Hauser, Mathias,
et al. (2015) Copyright 2015 Elsevier B.V. Used with permissions from Anastasia K. Hauser,
Ronita Mathias, Kimberly W. Anderson and J. Zach Hilt, “The effects of synthesis method on the
physical and chemical properties of dextran coated iron oxide nanoparticles”, Materials Chemistry
and Physics and Elsevier B.V.
5.0 Abstract
Iron oxide nanoparticles coated with dextran were synthesized via four variations on the coprecipitation method. The methods ranged from in situ formation of the nanoparticles within the
dextran solution to the adsorption of dextran to the nanoparticle surface following nucleation and
extensive washing. The timing of the addition of dextran into the reaction mixture was found to
greatly influence the physical and chemical properties of the magnetic nanoparticles. Batches of
dextran coated iron oxide nanoparticles were synthesized by each method in triplicate, and the
nanoparticles were further crosslinked with epichlorohydrin. The properties of the nanoparticles
such as size, percentage of dextran coating, stability in solution, crystallinity, and magnetic
properties were evaluated. The simultaneous semi-two-step method injected the reducing agent and
the dextran solution into the reaction vessel at the same time. This method resulted in the greatest
batch-to-batch reproducibility of nanoparticle properties and the least variation in nanoparticles
synthesized in the same batch. The two-step method resulted in the greatest variation of the
characteristics examined between batches. The one-step method was used with both five grams and
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one gram of dextran to investigate the effects of solution viscosity on the resulting nanoparticle
characteristics. The one-step method with five grams of dextran resulted in nanoparticles with
significantly smaller crystal sizes (5.4 ± 1.9 nm) and lower specific adsorption rate (SAR) values
(138.4 ± 13.6 W/g) in an alternating magnetic field (58 kA/m, 292 kHz). However, this method
resulted in nanoparticles that were very stable in PBS over 12 hours, which is most likely due to
the greater dextran coating (60.0 ± 2.7 weight percent). For comparison, the simultaneous semitwo-step method generated nanoparticles 179.2 ± 18.3 nm in diameter (crystal size 12.1 ± 0.2 nm)
containing 18.3 ± 1.2 weight percent dextran with a SAR value of 321.1 ± 137.3 W/g.
5.1 Introduction
Nanoparticle research has been driven by the need for new technological applications in data
storage, biomedical sciences, drug delivery, and therapeutics. Iron oxide nanoparticles represent a
class of materials with such applications and are very promising due to their potential
biocompatibility and magnetic properties which can be used for magnetic resonance imaging,
magnetically mediated hyperthermia, etc. (Andrade, Souza et al. 2010, Frimpong and Hilt 2010).
The magnetic differences of iron oxide nanoparticles compared to the bulk material are a
consequence of inter and intra particle interactions. Additionally, when the iron oxide nanoparticles
are of a single domain, they exhibit superparamagnetism by which they do not retain magnetization
in the absence of an externally applied magnetic field (Yoffe, Leshuk et al. 2013).
While the increased surface-to-volume ratio is an attractive property of superparamagnetic iron
oxide nanoparticles, it also leads to considerable difficulty as a result of the

tendency of

nanoparticles to aggregate to reduce their surface energy by forming strong magnetic dipole
interactions between the particles (Easo and Mohanan 2013). Monodispersed particles with high
magnetic saturation are required for many biological applications, so it is often of interest to
functionalize the nanoparticles with a coating layer to prevent agglomeration (Mahmoudi, Simchi
et al. 2009). The coating layer can also be designed to increase the circulation time and the
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biocompatibility of the nanoparticles for use as MRI contrast agents and magnetically mediated
hyperthermia (Laurent, Dutz et al. 2011, Saraswathy, Nazeer et al. 2014). Dextran is a
biocompatible long chain hydrophilic polymer composed of glucose with mostly α-1, 6 glycoside
linkages (Sreeja and Joy 2011) that strongly physisorb to magnetite nanoparticles in alkaline
solutions via non-covalent interactions of the abundant hydroxyl groups resulting in enmeshed
nanoparticle cores (Yoffe, Leshuk et al. 2013). The hydroxyl groups of dextran can then be easily
crosslinked and functionalized with primary amines to attach various targeting ligands, peptides,
or probes (Simberg, Duza et al. 2007, Park, Von Malzahn et al. 2008, Ayala, Herrera et al. 2013,
Kruse, Meenach et al. 2014). Functionalization with primary amines throughout the nanosctructure
allows for increased loading capacity and the potential for attachment of multiple targeting ligands,
imaging agents or therapeutics into one system (Tassa, Shaw et al. 2011).
Iron oxide nanoparticles can be synthesized by various methods including co-precipitation
(Massart 1981, Kang, Risbud et al. 1996, Frimpong, Dou et al. 2010), microemulsion (Lee, Lee et
al. 2005), thermal decomposition (Park, An et al. 2004, Sun, Zeng et al. 2004, Lee, Woo et al. 2008,
Buyukhatipoglu and Clyne 2010, Sharapova, Uimin et al. 2010, Ayala, Herrera et al. 2013), and
mechanical synthesis (Janot and Guerard 2002, Arbain, Othman et al. 2011). The co-precipitation
method has traditionally been the most common method and is the primary method by which
clinically approved iron oxide nanoparticles are synthesized (Qiao, Yang et al. 2009). Coprecipitation requires the reaction to be performed in an inert atmosphere to prevent oxidation of
the Fe2+ ions and oxidation of magnetite nanoparticles to maghemite. The surface of magnetite
nanoparticles will oxidize to maghemite in the presence of oxygen which reduces the magnetic
saturation of the material (Gupta and Gupta 2005). The process of co-precipitation involves initial
nucleation followed by slow growth as the solutes diffuse to the surface of the crystal (Easo and
Mohanan 2013). Within the co-precipitation method, there are various procedures that alter
parameters of the reaction in order to tune the properties of the iron oxide nanoparticles produced.
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Variables such as pH, temperature, reaction time, and iron ion ratios have been examined to
determine their effects on the size, stability, and heating properties of the nanoparticles. Vayssieres
et al. (Vayssieres, Chaneac et al. 1998) varied the pH of the reaction solution between 8.5 and 12
and found that the resulting iron oxide nanoparticles became smaller as the solution increased in
alkalinity. It was also determined that a minimum pH of 10-11 is required for the nanoparticle size
to remain stable over time. Murbe et al. (Murbe, Rechtenbach et al. 2008) addressed the effect of
reaction temperature on the physical and chemical properties of iron oxide nanoparticles showing
that as the temperature at which initial nucleation occurred increased from 25 to 70°C, the
nanoparticle size also increased from 16 to 39 nm. Additionally, the magnetic saturation of the
nanoparticles increased from 76 to 88 emu/g. Frimpong et al. (Frimpong, Dou et al. 2010)
addressed the effects of reaction temperature and staged reactions on the magnetic properties of
citrate capped iron oxide nanoparticles, and they also found that as temperature increased, the
nanoparticle crystal size also increased. The saturation magnetization was also influenced by the
reaction temperature and method as the one-step method resulted in nanoparticles with a lower
magnetic saturation value and decreased heating capabilities than the two-step reactions. A
significant amount of research has been completed on dextran coated iron oxide nanoparticles,
specifically on varying the molecular weight of the dextran. Xu et al. (Xu, Shen et al. 2005) formed
iron oxide nanoparticles in the presence of dextran with a molecular weight of 20 or 40 kDa. The
40 kDa dextran resulted in a viscous reaction solution, so the 20 kDa dextran coated nanoparticles
were preferred. However, the magnetic saturation of the nanoparticles was lower than expected due
to significant agglomeration of the nanoparticles and a wide range of hydrodynamic radii. Although
the effects of reaction temperature, time, pH, and dextran molecular weight have been analyzed,
the time and method of dextran addition into the reaction solution have not yet been evaluated.
Therefore, this chapter sought to determine the effects of the timely addition of dextran to the
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reaction mixture on the physical and chemical properties of the dextran coated iron oxide
nanoparticles.
It is important to understand the effects of dextran on the properties of iron oxide nanoparticles
in order to develop a synthesis protocol that results in consistent and desirable physicochemical
properties. As depicted in Figure 5.1, four co-precipitation methods were developed to synthesize
dextran coated iron oxide nanoparticles that were further crosslinked with epichlorohydrin to
increase the thermodynamic stability of the dextran on the surface of the nanoparticles (Palmacci
and Josephson 1993). The methods varied by the time of dextran addition to the reaction mixture:
from in situ formation of the iron oxide nanoparticles to formation followed by extensive washing
prior to dextran adsorption. Three batches of nanoparticles were synthesized via each method in
order to address the variability within a single method as well as the differences between the
methods. All other parameters such as pH, reaction temperature, and dextran molecular weight
were kept constant among the methods. After synthesis, both the dextran coated and
epichlorohydrin crosslinked nanoparticles were characterized for size, dextran weight percent,
stability, crystallinity, and heating ability in the presence of an alternating magnetic field. Each of
these properties is important to evaluate prior to in vivo studies should the nanoparticles be used
for biological applications. It is also important to develop protocols for iron oxide nanoparticle
synthesis that result in consistent properties of the nanoparticles such as desired size, stability in
solution, crystallinity to allow for heating in an AMF as well as image contrast, and dextran coating
to increase circulation and biocompatibility. This article addresses the development of a synthesis
method that results in consistent and desirable properties of iron oxide nanoparticles.
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Figure 5.1 Schematic of iron oxide nanoparticle synthesis methods. The co-precipitation reaction
for each of the methods is completed at 85 °C for one hour after the addition of the reducing agent
(ammonium hydroxide).
5.2 Materials and Methods
5.2.1 Materials
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran,
epichlorohydrin (ECH) were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). Phosphate buffered saline
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). All materials were used
as received.
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5.2.2 Dextran coated iron oxide nanoparticle synthesis via two-step method
A modified one-pot co-precipitation method (Frimpong, Dou et al. 2010) was used to prepare
dextran coated IONPs. FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams
and 0.8 grams, respectively) and dissolved in 40 mL deionized (DI) water and sealed in a threeneck flask under vigorous stirring and an inert nitrogen environment. 5 grams of dextran was
solubilized in 20 mL of DI water. The solution was heated to 85 °C at which 5 mL of NH4OH was
added dropwise to the reaction vessel. The reaction was carried out for 1 hour at 85 °C. The
particles were magnetically decanted and washed three times with DI water. The nanoparticles were
then re-suspended in 45 mL DI water and added to a three next flask. The dextran solution was
added to the reaction vessel and the vessel was purged with nitrogen. The nanoparticles and dextran
solution were stirred vigorously at room temperature for 24 hours. After 24 hours, the nanoparticles
were magnetically decanted and washed three times with DI water. Finally, the nanoparticles were
dialyzed against DI water for 24 hours (100 kDa molecular weight cutoff) then probe sonicated for
10 minutes and centrifuged at 1000 rpm for 5 minutes to remove large agglomerates.
5.2.3 Dextran coated iron oxide nanoparticle synthesis via semi-two-step method
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL
of DI water. The solution was heated to 85 °C at which 5 ml of NH4OH was added dropwise to the
reaction vessel. The dextran solution was then injected dropwise into the vessel. The reaction was
carried out for 1 hour at 85 °C. The particles were magnetically decanted and washed three times
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large
agglomerates.
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5.2.4 Dextran coated iron oxide nanoparticle synthesis via simultaneous semi-two-step method
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL
of DI water. The reaction solution was heated to 85 °C at which 5 ml of NH4OH was added to the
dextran solution and the combined solution was injected dropwise into the vessel. The reaction was
carried out for 1 hour at 85 °C. The particles were magnetically decanted and washed three times
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large
agglomerates.
5.2.5 Dextran coated iron oxide nanoparticle synthesis via one-step method
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. Five grams of dextran or one gram of dextran
was solubilized in 20 mL of DI water and added to the three-neck flask. The solution was heated
to 85 °C at which 5 ml of NH4OH was injected dropwise into the vessel. The reaction was carried
out for 1 hour at 85 °C. The particles were magnetically decanted and washed three times with DI
water and then dialyzed against DI water for 24 hours (100 kDa molecular weight cutoff). After
dialysis, the nanoparticles were probe sonicated for 10 minutes and then centrifuged at 1000 rpm
for 5 minutes to remove large agglomerates.
5.2.6 Epichlorohydrin crosslinking of dextran coated iron oxide nanoparticles
Dextran coated IONPs were crosslinked using ECH for increased stability (Palmacci and Josephson
1993). The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M NaOH and 1.5 mL ECH.
The reaction was carried out for 24 hours at room temperature under continuous agitation. The
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particles were then magnetically decanted and dialyzed against DI water (100 kDa molecular
weight cutoff) for 24 hours to remove excess ECH.
5.2.7 Particle characterization
Dynamic light scattering (DLS). DLS measurements were obtained using a Beckman Coulter Delsa
Nano C particle analyzer. Nanoparticle solutions were diluted to 200 µg/mL and were sonicated
in a water bath prior to size analysis.
Ultraviolet (UV)-Visible spectroscopy. The stability of the nanoparticles was analyzed using a
CaryWin 50 probe UV-visible spectrophotometer. IONPs were diluted to 200 µg/mL Fe in PBS.
Sample absorbance was read at 540 nm over 12 hours.
Fourier transform infrared (FTIR) spectra. Attenuated total reflectance FTIR (ATR-FTIR) was
used to determine surface functionalization with a Varian Inc. 7000e spectrometer. Dried samples
were placed on the diamond ATR crystal and the spectrum was obtained between 700 and 4000
cm−1 for 32 scans.
Thermogravimetric analysis (TGA). TGA was used to quantify the mass percent of the iron oxide
core in the particle systems using a Netzsch Instruments STA 449A system. Approximately 5 mg
of particle sample was heated at a rate of 5 °/minute. At 100 °C, the sample was held isothermally
for 20 minutes to vaporize residual water. The samples were heated at 5 °/minute until reaching
500 °C where they were held isothermally for an additional 20 minutes. The reported mass loss
was the actual mass loss normalized to the initial sample mass after isothermal heating at 100 °C.
Transmission electron microscopy (TEM). TEM was completed using a JEOL 2010F system
operating at 200 keV. IONPs were diluted to 1 mg/ml Fe in DI water and then dried on carbon
TEM grids prior to analysis.
X-ray diffraction (XRD). XRD patters were obtained by a Siemens D-500 X-ray spectrometer with
a CuKα radiation source (λ = 1.54 Ǻ) at 40 kV and 30 mA scanning from 5° to 65° at a scan rate
of 1° per minute. The XRD patterns were used to confirm the magnetite crystal structure of the iron
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oxide nanoparticles. The XRD patterns are in coherence with JCPDS card (19-0629). The crystal
domain size was estimated using the Scherrer equation [5.1]
𝐾𝜆

𝜏 = 𝛽𝑐𝑜𝑠𝛩

[5.1]

where τ is the mean size of the ordered (crystalline) domains K is a dimensionless shape factor with
a value close to unity(0.8396 for iron oxide) λ is the X-ray wavelength, β is the line broadening at
half the maximum intensity (FWHM) after subtracting the instrumental line broadening, in radians
and θ is the Bragg angle (17.72 °).
Alternating magnetic field (AMF) heating. The nanoparticle heating profiles were obtained using
a custom made Taylor Winfield magnetic induction source, and the temperature was measured with
a fiber optic temperature sensor (Luxtron FOT Lab Kit from LumaSense).

Nanoparticle

suspensions were diluted in DI water to a concentration of 3 mg/ml iron oxide. One milliliter of
suspension in a 2 ml microcentrifuge tube was placed in the center of the AMF induction coil. The
suspension was heated at a field amplitude of 58 kA/m and frequency of 292 kHz until the
temperature of the suspension reached steady-state. The specific absorption rate (SAR) values of
the nanoparticle suspensions were then calculated using the following equation:
𝑆𝐴𝑅 =

𝐶𝑝,𝐹𝑒 𝑚𝐹𝑒 + 𝐶𝑝,𝐻2𝑂 𝑚𝐻2𝑂 𝑑𝑇
𝑚𝐹𝑒
𝑑𝑡

[5.2]

where Cp,Fe is the heat capacity of iron, mFe is the mass of iron, Cp,H2O is the heat capacity of water,
mH2O is the mass of water, and dT/dt is the initial slope of the heating profile. The intrinsic loss
power (ILP) of the nanoparticle systems was calculated using the following equation:
𝐼𝐿𝑃 =

𝑆𝐴𝑅
𝐻2𝑓

[5.3]

where H is the magnetic field strength and f is the field frequency. This value will allow for the
heating properties of these systems to be compared more accurately to other systems in literature.
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5.3 Results and Discussion
The hydrodynamic diameter of the nanoparticles was analyzed via dynamic light scattering and
reported as the z-average while the variability of particle size within the batches was quantified by
the polydispersity index (PDI) in Table 5.1. The two-step method resulted in particles with the
largest hydrodynamic diameter along with the greatest deviation between batches. The PDI of the
nanoparticles synthesized by the two-step method was also the largest of the methods tested. After
crosslinking with epichlorohydrin, the hydrodynamic diameter of the nanoparticles decreased
significantly. This is likely due to the extra processing during crosslinking resulting in the loss of
larger nanoparticle agglomerates. The one-step method with five grams of dextran resulted in the
smallest nanoparticles most likely due to the high viscosity of the solution during nucleation
inhibiting the transport of the iron ions to the nanoparticle surface. The high viscosity solution helps
to prevent agglomeration of the nanoparticles but their formation is hindered due to transport
limitations during the nucleation process. Although the one-step nanoparticles were smaller in
hydrodynamic diameter which is advantageous for tumor targeting, their other properties such as
heating abilities suffered from the high viscosity solution. The one-step method with one gram of
dextran resulted in larger nanoparticles than the one-step method with five grams of dextran.
Additionally, there was greater variability in the nanoparticle sizes between the batches. The
simultaneous semi-two-step method resulted in nanoparticles with the most consistent sizes within
a single batch as indicated by the low PDI after crosslinking, as well as the greatest batch to batch
reproducibility as indicated by the lowest standard deviation. The batch-to-batch reproducibility is
thought to be due to the simultaneous semi-two-step method being the easiest method to control
since it involves a single injection of the ammonium hydroxide in a solution of dextran. The
viscosity of the solution is also that of water when initial nucleation occurs allowing for iron ions
to transport to the nucleation sites more effectively. Previous studies by Xu, et al. (Xu, Shen et al.
2005) found that lower molecular weight dextran (20kDa vs. 40kDa) was advantageous due to
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lower solution viscosity leading to more optimal nanoparticle characteristics. It is also important to
note that low molecular weight dextran can precipitate acute renal failure so it is important to coat
the nanoparticles with enough dextran to increase cytocompatibility and stability but not so much
that excess dextran is administered (Feest 1976). In another study by Saraswathy et al. 70kDa
dextran was used to coat iron oxide nanoparticles resulting in a 50 nm diameter and 12 nm core
size. The high molecular weight dextran was offset by a using a low weight percentage dextran
(3%) in water (Saraswathy, Nazeer et al. 2014). By using a high molecular weight dextran, the
potential to cause osmotic nephropathy is decreased, but the amount of dextran coating the
nanoparticle surface decreases, which could impact nanoparticle stability.

Table 5.1 Size analysis via dynamic light scattering of iron oxide nanoparticles synthesized by the
various methods represented by average ± standard deviation (three independent batches and three
samples from each batch).
Method
two-step
semi-two-step
simultaneous semi-two-step
one-step (5 grams Dx)
one-step (1 gram Dx)

Nanoparticle
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH

Size (nm)
382.4 ± 163.2
237.8 ± 28.8
233.9 ± 25.2
244.1 ± 54.7
179.2 ± 18.3
185.6 ± 23.8
171.4 ± 30.9
121.7 ± 24.7
248.0 ± 69.0
244.2 ± 34.4

PDI
0.35 ± 0.14
0.16 ± 0.02
0.19 ± 0.03
0.20 ± 0.08
0.18 ± 0.02
0.02 ± 0.03
0.22 ± 0.09
0.14 ± 0.02
0.20 ± 0.05
0.16 ± 0.05

Different synthesis methods also have an effect on dextran adsorbed to the surface of the iron
oxide nanoparticles. The presence of dextran on the surface of the iron oxide nanoparticles was
confirmed via FTIR spectroscopy (Figure 5.2). The synthesis methods resulted in similar spectra
with all spectra containing a broad peak between 3500-3200 cm-1 indicating the structural O-H in
the dextran chains. The peak associated with the asymmetrical stretching vibration of C-H in CH2
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is found at 2918 cm-1. Peaks at 1450, 1350, and 1273 cm-1 can be assigned to the deformation
vibration of H-C-OH of the dextran chains. Finally, the asymmetrical and symmetrical vibrations
of C-O-C can be found at 1157 and 849 cm-1, respectively.
Quantification of the dextran coating was completed using thermogravimetric analysis (TGA)
as shown in Table 5.2. The one-step method with 5 grams of dextran resulted in the greatest dextran
adsorption to the nanoparticle surface with approximately 60% of the nanoparticle weight being
composed of dextran. On the contrary, the one-step method with one gram of dextran resulted in
the least dextran adsorption and no significant change after crosslinking with epichlorohydrin as
depicted in Figure 5.3e. The two-step method and the semi-two-step method resulted in the most
variability between batches in the amount of dextran coating. In the semi-two-step method, this is
most likely due to the multiple injections of ammonium hydroxide and dextran and slight variability
in timing. Again, the simultaneous semi-two-step resulted in the most consistent dextran
adsorption. All of the weight loss profiles displayed a single drop in mass as temperature increased
indicating a single layer of dextran or crosslinked dextran on the nanoparticle surface (Figure 5.3).
Additionally, after crosslinking, the mass due to the coating decreased or remained the same most
likely due to further dialysis after crosslinking. The right shift in the temperature at which the
greatest mass loss occurs confirmed that dextran had been crosslinked as more energy was required
to break the covalent bonds prior to degrading the coating.
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Figure 5.2 FTIR spectra of dextran coated iron oxide nanoparticles synthesized by the various
methods.

Table 5.2 Dextran weight percentage via thermogravimetric analysis of iron oxide nanoparticles
synthesized by the various methods (n=3).

Synthesis Method
two-step
semi-two-step
simultaneous semi-two-step
one-step (5 grams Dx)
one-step (1 gram Dx)

Nanoparticle
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
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Coating Weight%
23.7 ± 7.8
19.0 ± 11.3
29.3 ± 6.1
16.7 ± 9.8
18.3 ± 1.2
15.7 ± 5.0
60.0 ± 2.7
58.0 ± 7.2
12.7 ± 1.7
13.0 ± 1.7

Figure 5.3 Mass loss and d%/dT with increasing temperature of dextran coated and epichlorohydrin
crosslinked iron oxide nanoparticles synthesized via the (a) two-step method, (b) semi-two-step
method, (c) simultaneous semi-two-step method, (d) one-step method with 5 grams dextran, and
(e) one-step method with 1 gram dextran.

Stability of the nanoparticles in solution is very important if the nanoparticles are to be used
for biological applications as agglomeration could lead to blockage of the circulatory system or
lack of targeting ability to the tissue of interest. Therefore, the stability of the nanoparticles in
phosphate buffered saline was analyzed over a 12 hour time period for both the dextran coated and
crosslinked systems synthesized by each of the methods (Figure 5.4). Dextran coated iron oxide
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nanoparticles synthesized by the one-step method with 5 grams of dextran were the most stable
both before and after epichlorohydrin crosslinking. This is due to the steric interactions of dextran
with the surrounding medium. Since nanoparticles produced by the one-step with 5 grams of
dextran had the greatest amount of dextran on the surface, it is expected that these nanoparticles
would also be the most stable. However, the two-step, semi-two-step, and the simultaneous semitwo-step methods, resulted in relatively stable nanoparticles in PBS after crosslinking.

Figure 5.4 Stability of dextran coated and epichlorohydrin crosslinked iron oxide nanoparticles
synthesized via the (a) two-step method, (b) semi-two-step method, (c) simultaneous semi-two-step
method, (d) one-step method with 5 grams dextran, and (e) one-step method with 1 gram dextran
in PBS over 12 hours analyzed by UV-visible spectroscopy (λ=540).
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The XRD patterns (Figure 5.5) of the iron oxide nanoparticles synthesized by each method are
in coherence with JCPDS card (19-0629) associated with magnetite. The sharp peaks indicate a
highly crystalline structure has been formed by each method. The broad peak at approximately 2Θ
equal to 17° is due to the presence of dextran which is confirmed by the XRD pattern of dextran
only (Figure 5.5f). This peak has the greatest intensity in the one-step method with five grams of
dextran which also has the greatest weight percent of dextran. Slight shoulders are seen in the XRD
patters of the other synthesis methods confirming the presence of dextran, but the lower intensity
matches the data obtained via thermogravimetric analysis. The highest intensity peak at 2Θ equal
to 35.44° corresponds to the (3 1 1) plane of the iron oxide crystal structure. This peak was used to
calculate the crystal size of the nanoparticles using the Scherrer equation and these crystal sizes
correspond well with the crystal sizes shown in TEM (Figure 5.6). Table 5.3 displays the calculated
crystal sizes from XRD spectra and the Scherrer equation along with the crystal sizes from TEM
while Figure 5.5 depicts the XRD patterns. All the crystal sizes of the iron oxide nanoparticles
synthesized were much smaller than the reported hydrodynamic diameter. This is due to multiple
crystals being encapsulated within the dextran coating. The crystal size of the nanoparticles
synthesized via the one-step method with 5 grams of dextran was significantly smaller than the
crystal sizes of the nanoparticles synthesized by the other methods as shown by both XRD (Figure
5.5d) and TEM (Figure 5.6d). This is thought to be due to the concentrated dextran during
nucleation. TEM images show the crystal size of nanoparticles synthesized via the two-step and
semi-two step were larger than the other methods, which is due to dextran addition taking place
post nucleation. Previous work has shown that crystal growth is retarded by the chemisorption of
poly(vinyl alcohol) to the surface of the particles when synthesized by a one-step method
(Mahmoudi, Simchi et al. 2009). Work completed by Pardoe et al. (Pardoe, Chua-anusorn et al.
2001) has shown that iron oxide nanoparticles coated with dextran are significantly smaller than
the control uncoated nanoparticles. Additionally, the polymer chosen to coat the nanoparticles
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influences the crystal size of the particles. For example, nanoparticles coated with PVA resulted in
larger crystals than dextran coated particles but both were smaller than uncoated nanoparticles
(Pardoe, Chua-anusorn et al. 2001). A similar effect was observed by Bee et al. (Bee, Massart et
al. 1995) in which iron oxide nanoparticle formation was prevented by either chelation of citrate
ions with metal ions and therefore preventing nucleation or by adsorption of the citrate ions on the
nuclei inhibiting growth of the nuclei. Without a high dextran concentration and therefore a lower
viscosity reaction solution, the iron oxide crystals had diameters closer to the other synthesis
methods. Once again, the two step method resulted in the most variability in crystal size while the
simultaneous semi-two-step was the most consistent.
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Figure 5.5 XRD patters of dextran coated iron oxide nanoparticles synthesized via the (a) two-step
method, (b) semi-two-step method, (c) simultaneous semi-two-step method, (d) one-step method
with 5 grams dextran, (e) one-step method with 1 gram dextran and (f) dextran only.
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Table 5.3 Iron oxide crystal size estimated using XRD spectra and the Scherrer equation and TEM
images of iron oxide nanoparticles synthesized by the various methods (mean ± st. dev. n=3 for
XRD and n=150 for TEM).
Synthesis Method
two-step
semi-two-step
simultaneous semi-two-step
one-step (5 grams Dx)
one-step (1 gram Dx)

XRD Size (nm)
10.0 ± 2.1
11.2 ± 1.0
12.1 ± 0.2
5.4 ± 1.9
12.4 ± 1.3

TEM Size (nm)
14.5 ± 4.2
14.7 ± 4.6
8.9 ± 2.2
6.8 ± 1.4
10.1 ± 3.1

Figure 5.6 TEM images of dextran coated iron oxide nanoparticles synthesized via the (a) two-step
method, (b) semi-two-step method, (c) simultaneous semi-two-step method, (d) one-step method
with 5 grams dextran, and (e) one-step method with 1 gram dextran.
The crystalline structure of iron oxide nanoparticles enables heating in the presence of an
alternating magnetic field via multiple possible loss mechanisms including Néel paramagnetic
switching, friction losses from Brownian rotation, and hysteresis (Dennis, Jackson et al. 2009).
Table 5.4 summarizes the specific absorption rates of the nanoparticles in the presence of an AMF
(58 kA/m, 292 kHz) and the corresponding intrinsic loss power (ILP). The one-step method with
five grams of dextran resulted in nanoparticles with the lowest SAR values which are again due to
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dextran chemisorption to the surface of the nanoparticles after nucleation (Sreeja and Joy 2011).
Nanoparticles produced by other methods had greater SAR values as well as increased variability.
The increased SAR value is thought to be due to nanoparticle agglomeration which would allow
for ferromagnetic contributions resulting in increased heating. The excess dextran coating on the
one-step method with 5 grams of dextran could also form a “dead layer” which would reduce the
total effective moment of the nanoparticles (Kodama 1999, Pardoe, Chua-anusorn et al. 2001).
Daou et al. (Daou, Greneche et al. 2008) established a similar effect by synthesizing magnetite
nanoparticles and showing that carboxylate coupling to the nanoparticle surface could induce spin
canting at the surface and reduce the saturation magnetization of the nanoparticles. Additionally,
this effect has been observed with citrate capped magnetite nanoparticles synthesized via the coprecipitation method in a one or two-step procedure (Frimpong, Dou et al. 2010). The decrease in
SAR value after crosslinking with epichlorohydrin is most likely an artifact of the nanoparticles
becoming more stable in solution and the additional probe sonication after dialysis. The
nanoparticles are not significantly agglomerating and therefore heating via ferromagnetic
contributions in addition to Neel paramagnetic switching and Brownian rotation. The ILP of these
systems ranged from 0.16 to 0.39 nHm2/kg with the one-step (5 grams Dx) being the lowest and
the semi-two-step being the highest, but with the most variability. Kallamadil et al. compared the
ILP of commercial ferrofluids of various hydrodynamic sizes and found that for hydrodynamic
diameters ranging from 100 to 170 nm and crystal sizes of approximately 7 nm, the ILP varied
between 0.15 and 0.35 nHm2/kg (Kallumadil, Tada et al. 2009). Therefore, these systems have
heating properties comparable to those commercially available even though the alternating
magnetic field strength may be slightly higher than others have used (Hergt, Hiergeist et al. 2004,
Fortin, Wilhelm et al. 2007).
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Table 5.4 Specific absorption rates (W/g) of iron oxide nanoparticles (3 mg/mL Fe3O4) heating in
an alternating magnetic field (58 kA/m, 292 kHz) of iron oxide nanoparticles synthesized by the
various methods (n=3).

Method
two-step
semi-two-step
simultaneous semi-two-step
one-step (5 grams Dx)
one-step (1 gram Dx)

Nanoparticle
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH
Fe3O4+Dx
Fe3O4+Dx-ECH

SAR (W/g)
323.6 ± 134.1
297.6 ± 102.5
384.3 ± 37.6
313.4 ± 50.9
321.1 ± 137.3
211.0 ± 46.6
138.4 ± 13.6
158.2 ± 51.1
313.9 ± 42.1
228.3 ± 32.4

ILP (nHm2/kg)
0.33 ± 0.14
0.30 ± 0.10
0.39 ± 0.04
0.21 ± 0.05
0.33 ± 0.14
0.21 ± 0.05
0.14 ± 0.01
0.16 ± 0.05
0.32 ± 0.04
0.23 ± 0.03

5.4 Conclusions
Overall, the simultaneous semi-two-step method of synthesizing dextran coated iron oxide
nanoparticles was the most consistent method and had the greatest batch-to-batch reproducibility.
The nanoparticles synthesized by this method were stable in PBS for 12 hours, had hydrodynamic
diameters less than 200 nm, generated sufficient heat in the presence of an AMF, and exhibited
crystallinity consistent with magnetite. All of these properties can be tuned to varying degrees by
simply altering the timing of dextran addition to the reaction. The amount of dextran also alters the
properties of the nanoparticles. The one-step reaction was completed with both one and five grams
of dextran to evaluate these effects. It was found that the nanoparticles synthesized with five grams
of dextran are more stable, adsorb a greater amount of dextran on their surfaces, and have smaller
hydrated diameters than the nanoparticles synthesized with one gram of dextran. However, the poor
heating properties and small crystal sizes suggested that the one-step method with 5 grams of
dextran may not be the preferred method for synthesizing the nanoparticles.
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The one-step method with 1 gram of dextran yielded nanoparticles with improved heating
properties and larger crystal sizes but larger and more inconsistent hydrolyzed diameters and
decreased stability. The semi-two step and two-step methods resulted in nanoparticles with
inconsistent physicochemical properties batch-to-batch. The heating properties were improved
compared to the one-step with 5 grams dextran, but the size was larger with greater polydispersity
indices. Also, the stability in PBS was decreased. Therefore, the method by which the dextran
coated iron oxide nanoparticles are synthesized greatly affects the physical and chemical properties
of the nanoparticles and thus, it is critical that the co-precipitation method for the preparation of
magnetic nanoparticles is carefully developed and controlled to get desired properties for specific
applications.

Copyright © Anastasia Kruse Hauser 2016
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Chapter 6 Peptide conjugated magnetic nanoparticles for magnetically mediated energy
delivery
Limitations of magnetically mediated hyperthermia have led to increased interest in magnetically
mediated energy delivery which does not rely on a bulk temperature increase for therapy, but rather
on magnetic nanoparticles internalized within cells exerting nanoscale heating or rotational forces
intracellularly. The goal of this chapter was to synthesize magnetic nanoparticles functionalized
with a cell penetrating peptide and analyze the cellular effects upon internalization and activation
via an alternating magnetic field. The chapter is taken directly or adapted from work recently
submitted to Future Nanomedicine. Used with permissions from Anastasia K. Hauser, Kimberly
W. Anderson and J. Zach Hilt, “Peptide conjugated magnetic nanoparticles for magnetically
mediated energy delivery.”
6.0 Abstract
Iron oxide nanoparticles have been extensively studied for magnetically mediated
hyperthermia applications, although one of the main limitations of this therapy is the high
nanoparticle concentration required to increase the tumor tissue temperature into the hyperthermia
range (42-45 °C). Therefore, it has been suggested that magnetically mediated energy delivery
(MagMED), or the use of magnetic nanoparticles to locally convert alternating magnetic field
(AMF) energy into other forms of energy (e.g., heat and rotational work) is a potential alternative
strategy. MagMED relies on internalized magnetic nanoparticles and does not require a bulk
temperature rise to induce cellular effects. Here, dextran-coated iron oxide nanoparticles
functionalized with a cell penetrating peptide (TAT peptide) were synthesized. Uptake of the
nanoparticle systems into A549 and H358 lung carcinoma was evaluated along with the
intracellular effects of MagMED on the two cell lines such as reactive oxygen species (ROS)
generation, lysosomal permeability, mitochondrial membrane depolarization, and initiation of
Caspase 3/7 apoptotic pathways. Long term cell viability was also analyzed following MagMED
treatment. In both A549 and H358 cells, the novel TAT functionalized nanoparticles and AMF
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exposure increased ROS generation compared to the nanoparticle system alone. The TAT
functionalized nanoparticles also induced lysosomal membrane permeability and mitochondrial
membrane depolarization, but these effects were cell line dependent and were not further enhanced
by AMF treatment. Although not statistically significant, there are trends suggesting an increase in
apoptosis via the Caspase 3/7 pathways when cells are exposed to TAT functionalized nanoparticles
combined with AMF, and although intracellular effects of MagMED treatment were observed,
there was no statistical decrease in cell viability 48 hours following treatment.
6.1 Introduction
Iron oxide nanoparticles have been studied for a wide variety of biological applications
including magnetic resonance imaging (MRI), cell separation techniques, drug delivery,
mangetically mediated hyperthermia (MMH), and in the treatment of anemia (Dennis, Jackson et
al. 2009, Hu, Ma et al. 2011, Laurent, Dutz et al. 2011, McCormack 2012, Plouffe, Murthy et al.
2015). In magnetically mediated hyperthermia, iron oxide nanoparticles convert energy from an
alternating magnetic field (AMF) to heat via Neél relaxation and Brownian rotation (Dennis,
Jackson et al. 2009). MMH targets a bulk temperature rise between 42-45 °C which can lead to
adverse cellular effects, and although MMH has been extensively studied, its translation into the
clinic has been limited. MMH studies completed in vitro utilize high nanoparticle concentrations
to achieve hyperthermia conditions in monolayer cells or cell suspensions (Laurent, Dutz et al.
2011, Rodriguez-Luccioni, Latorre-Esteves et al. 2011, Wydra, Kruse et al. 2013, Kruse, Meenach
et al. 2014) and most in vivo experiments directly inject nanoparticles into tumors (usually
subcutaneous) due to the need for high local concentrations to generate a bulk temperature rise (Hu,
Ma et al. 2011, Wang, Dong et al. 2012). Since direct injection is not suitable for many tumors and
metastases, there is a gap between bench scale MMH studies and clinical relevance.
Instead of relying on a bulk temperature rise to induce hyperthermia conditions, it was
suggested by Gordon, et al. in 1979 that intracellular hyperthermia would be more advantageous
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due to insulation by the cell membrane and lack of convection from blood flow which dissipates
heat away from the tumor tissue. This is especially problematic in small metastatic tumors (Gordon,
Hines et al. 1979). Nanoscale heating effects of the nanoparticles have the ability to induce cellular
toxicities as shown by Creixell et al. in 2011, where internalized iron oxide nanoparticles in the
presence of an AMF induced a significant decrease in cell viability without a measureable
temperature rise (Creixell, Bohorquez et al. 2011). Therefore, the phrase magnetically mediated
energy delivery (MagMED) was coined to describe the conversion of magnetic field energy to other
forms such as heat or rotation work but without significantly increasing the bulk temperature
(Kozissnik, Bohorquez et al. 2013).
Although there is a growing body of evidence suggesting that local heating and energy delivery
can be used to kill cancer cells, theoretical calculations by Rabin et al. indicate that the heat
dissipation from the nanoparticle surface through conduction is greater than the heat being
generated by the nanoparticles (Rabin 2002). These theoretical calculations were disputed when
Huang, et al. utilized iron oxide nanoparticles targeted to proteins on the membrane of cells
expressing TRPV1 to locally deliver heat and open cation channels (Huang, Delikanli et al. 2010).
Nanoparticle heating at the surface was confirmed using a tethered thermoresponsive fluorophore
which fluoresced almost immediately upon AMF exposure.
In addition to the effects of surface heating of magnetic nanoparticles in an AMF, rotational
work has also been studied as an explanation to the experimental effects of MagMED. For example,
mechanical forces have been used to induce lysosomal permeabilization (Sanchez, Diab et al. 2014,
Connord, Clerc et al. 2015), leading to the release of proteolytic enzymes such as cathepsins which
initiate apoptotic pathways (Linder, Erdal et al. 2005, Kirkegaard and Jaattela 2009, Johansson,
Appelqvist et al. 2010). This technique has also been shown to stimulate apoptosis in apoptosisresistant cell lines (Jaattela 2004). Zhang, et al. developed a dynamic magnetic field generator to
induce nanoparticle rotations about their axis to examine whether physical nanoparticle rotations
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can disrupt lysosomal membranes and induce apoptosis (Zhang, Kircher et al. 2014). By
functionalizing the nanoparticles with antibodies for the lysosomal protein marker, it was found
that the shear forces generated by oscillating torques were enough to damage the lysosomal
membranes, proving that Brownian rotation of magnetic nanoparticles also plays an important role
in MagMED treatment.
In addition to the thermal and mechanical effects described above, the production of reactive
oxygen species (ROS) via iron oxide nanoparticles is a potential chemical effect of MagMED. Iron
oxide nanoparticles catalyze the Haber-Weiss reaction which makes use of Fenton chemistry, and
this reaction is considered a major mechanism by which the highly reactive hydroxyl radical is
generated in biological systems (Kehrer 2000). The Fenton chemistry reaction set is shown as
Equation 6.1 and the Haber-Weiss reaction (net reaction) is shown as Equation 6.2.
Fe3+ + O2· - → Fe2+ + O2
Fe2+ +H2O2 → Fe3+ + OH- + OH·

[6.1]

O2· - + H2O2 → O2 + OH- + OH·

[6.2]

When iron oxide nanoparticles enter a cell, they can stimulate the generation of ROS via one of
two pathways: (1) the release of ions into the cytosol resulting in the iron ions participating in the
Haber-Weiss cycle or (2) the surface of the nanoparticle may act as a catalyst for the Haber-Weiss
cycle and the Fenton Reaction (Klein, Sommer et al. 2012). Although this reaction can proceed
without the addition of an AMF, recent work by Wydra, et al. demonstrated that the reaction is
further catalyzed by iron oxide nanoparticles in the presence of an AMF (Wydra, Oliver et al. 2015).
In order to increase intracellular concentrations of iron oxide nanoparticles and therefore
increase the efficacy of MagMED, magnetic nanoparticles can be functionalized with ligands,
peptides, or antibodies, in order to target and penetrate into the cells. Here, the TAT peptide
(sequence: YGRKKRRQRRR) was of particular interest due to its cell penetrating properties and
associated ability to avoid receptor mediated endocytosis, as well as its nuclear localizing signal.
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The TAT peptide contains a characteristic lysine-arginine sequence, and biomolecules with this tag
are known to bind to importin α and β in the cytoplasm which facilitate active transportation to the
nuclear pore complex (NPC) and, if attached to a small enough molecule or particle, through the
NPC into the nucleus (Austin, Kang et al. 2011). The positive charge of the NLS peptide also
destabilizes the endosome/lysosome membrane leading to nanoparticle and proteolytic enzyme
escape from the vesicles, which plays a role in apoptosis initiation. Previous work by Pan et al. in
2012 showed that functionalization of doxorubicin (DOX) loaded silica nanoparticles with the TAT
peptide facilitated DOX accumulation within the nuclear membrane (Pan, He et al. 2012). Another
study by Austin et al. proved that TAT-functionalized silver nanospheres were up taken in to HSC3 cancer cells at significantly greater concentrations than PEG functionalized nanospheres (Austin,
Kang et al. 2011). Several studies have utilized the TAT peptide as a cell internalization mechanism
(Josephson, Tung et al. 1999, Lewin, Carlesso et al. 2000, Rao, Reddy et al. 2008, Torchilin 2008,
Wang, Qiao et al. 2012) as well as a nuclear targeting moiety (Vives, Brodin et al. 1997, de la
Fuente and Berry 2005, Oyelere, Chen et al. 2007, Xu, Xie et al. 2008, Yang, Neshatian et al. 2014).
Due to the size of the iron oxide nanoparticles being larger than the upper limit of the nuclear pore
complex (20―70 nm), it was of interest to use the TAT peptide to escape endosome/lysosomes
and facilitate interaction with other organelles such as the mitochondria (Pan, He et al. 2012).
In this study, dextran coated iron oxide nanoparticles were functionalized with a cell penerating
peptide, TAT, and characterized for their physical and chemical properties. Uptake studies into
A549 and H358 non-small cell lung carcinoma cells indicated that attachment of the TAT peptide
to iron oxide nanoparticles significanly increased cell internalization of the nanoparticles. The
effects of internalized iron oxide nanoparticles in combination with AMF exposure on A549 and
H358 cells were evaluated. Although A549 and H358 are both non-small cell lung carcinoma cells,
this treatment is applicable to a wide variety of cancers, and these cells lines were chosen to assess
cell line variability of the treatment. Intracellular generation of ROS, lysosomal membrane

105

permeability, mitochondrial membrane depolarization, and apoptosis via the Caspase 3/7 pathway
were all evaluated. Finally, cell viability was analyzed to determine the toxicity effects of the
treatment. Figure 6.1 depicts the three main mechanisms by which MagMED can affect cells. After
internalization of the TAT conjugated iron oxide nanoparticles, the lysosomal/endosomal
membranes are permeabilized and facilitate nanoparticle escape into the cytosol. Upon actuation
by an AMF, nanoparticles dissipate energy through Neel relaxations, frictional energy via
Brownian rotation, and catalyze ROS generation. All three of these mechanisms can play a role in
the efficacy of MagMED.

Figure 6.1 TAT-conjugated iron oxide nanoparticles are internalized by cancer cells and
permeabilize endosomal/lysosomal membranes due to the positive charge of the peptide. Upon
exposure to an AMF, the nanoparticles generate the hydroxyl radical via Fenton chemistry, friction
from Brownian rotaion and nanoscale heat effects by Neél relaxation.
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6.2 Materials and Methods
6.2.1 Materials
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran,
epichlorohydrin (ECH) were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). Phosphate buffered saline
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). The activation buffer
2-[N-morpholino] ethane sulfonic acid (MES), N-hydroxysulfosuccinimide (sulfo-NHS) and 1ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) were purchased from
Thermo scientific (Rockford, IL). The TAT peptide was purchased from Biomatik. Phosphate
buffered saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine,
Fungizone®, sodium pyruvate, CellEvent Caspase 3/7 Assay, JC-1, and calcein AM were obtained
from Invitrogen (Frederick, MD). Acridine orange was purchased from Nexcelom Bioscience
(Lawrence, MA) and A549 lung carcinoma and trypsin were purchased from American Type
Culture Collection (ATCC, Manassas, VA). All materials were used as received.
6.2.2 Synthesis of uncoated iron oxide nanoparticles
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 60 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. The reaction solution was heated to 85 °C at
which 5 ml of NH4OH was diluted to 40 mL with DI water and the combined solution was injected
dropwise into the vessel. The reaction was carried out for 1 hour at 85 °C. The particles were
magnetically decanted and washed three times with DI water. The nanoparticles were then resuspended in DI water and dialyzed against DI water for 24 hours (100 kDa molecular weight
cutoff). After dialysis, the nanoparticles were probe sonicated for 10 minutes and then centrifuged
at 1000 rpm for 5 minutes to remove large agglomerates.
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6.2.3 Synthesis of dextran coated iron oxide nanoparticles (Fe3O4 + Dx)
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL
of DI water. The reaction solution was heated to 85 °C at which 5 ml of NH4OH was added to the
dextran solution and the combined solution was injected dropwise into the vessel. The reaction was
carried out for 1 hour at 85 °C. The particles were magnetically decanted and washed three times
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large
agglomerates.
6.2.4 Epichlorohydrin (ECH) crosslinking of dextran coated iron oxide nanoparticles (Fe3O4 +
Dx-ECH)
Dextran coated iron oxide nanoparticles were crosslinked using ECH for increased stability
(Palmacci and Josephson 1993). The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M
NaOH and 1.5 mL ECH. The reaction was carried out for 24 hours at room temperature under
continuous agitation. The particles were then magnetically decanted and dialyzed against DI water
(100 kDa molecular weight cutoff) for 24 hours to remove excess ECH.
6.2.5 Amine functionalization of crosslinked dextran coated iron oxide nanoparticles (Fe3O4 +
Dx-ECH-Amine)
An equal volume of ammonium hydroxide to mmol iron from Fe3O4 + Dx-ECH were combined
and placed on the shaker table for 24 hours. After 24 hours, the nanoparticles were dialyzed against
DI H2O for an additional 24 hours, with their water changed 3 times during this time period.
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6.2.6 TAT peptide conjugation to iron oxide nanoparticles (Fe3O4 + TAT)
10 mg of the TAT-peptide was dissolved in 10 mL MES buffer (2-[N-morpholino] ethane sulfonic
acid) and 4 mg EDC and 11 mg sulfo-NHS were also added to the solution. After 15 minutes of
continuous agitation, 14 µL of 2- mercaptoethanol was added to the reaction in order to quench
excess EDC. Amine-functionalized iron oxide nanoparticles were diluted to 1 mg Fe3O4/mL with
PBS. The iron oxide suspension was added to the TAT-peptide solution and reacted over night
under continuous agitation. After the TAT-iron oxide nanoparticles reaction was complete, the
particles were washed with PBS via magnetic decanting until the washing solution was clear. This
protocol was adapted from Pan, et al. (Pan, He et al. 2012).
6.2.7 Iron concentration assay
Between each step of synthesizing a new system of iron oxide nanoparticles, an iron assay was
used to determine the iron concentration of the nanoparticles. 20x, 50x, and 100x dilutions of the
iron oxide nanoparticles were made in DI water and 10 µL of each dilution was added to 10 µL 6M
HCl and allowed to sit for 3 hours. After this time, 500 µL of 1M acetic acid, 100 µL of
hydroxylamine hydrochloride, 100 µL of 1, 10 phenanthroline, and 280 µL of DI water were added
to each dilution. Solutions were left overnight. After 24 hours, the absorbance of each solution (λ
= 511 nm) was used to calculate the iron concentration based on a standard curve.
6.2.8 Iron oxide nanoparticle characterization
Dynamic light scattering (DLS). DLS measurements were obtained using a Beckman Coulter Delsa
Nano C particle analyzer Nanoparticle solutions were diluted to 200 µg/mL in DI water or cell
culture media and were sonicated in a water bath for five minutes prior to size analysis. The reported
nanoparticle sizes in cell culture media were recorded 10 minutes after bath sonication.
Zeta Potential. Zeta potential measurements were obtained using a Beckman Coulter Delsa Nano
C particle analyzer. Nanoparticle solutions were diluted to 200 µg/mL in 2mM NaCl and were
sonicated in a water bath prior to analysis.
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X-ray Diffraction (XRD). XRD patters were obtained by a Siemens D-500 X-ray spectrometer with
a CuKα radiation source (λ = 1.54 Ǻ) at 40 kV and 30 mA scanning from 5° to 65° at a scan rate
of 1° per minute. The XRD patterns were used to confirm the magnetite crystal structure of the iron
oxide nanoparticles. The XRD patterns are in coherence with JDPCS card (19-0629). The crystal
domain size was estimated using the Scherrer equation [6.3]
𝐾𝜆

𝜏 = 𝛽𝑐𝑜𝑠𝛩

[6.3]

where τ is the mean size of the ordered (crystalline) domains K is a dimensionless shape factor with
a value close to unity (0.8396 for iron oxide), λ is the X-ray wavelength, β is the line broadening
at half the maximum intensity (FWHM) in radians after subtracting the instrumental line
broadening, and θ is the Bragg angle (17.72 °).
Fourier transform infrared (FTIR) spectra. Attenuated total reflectance FTIR (ATR-FTIR) was
used to determine surface functionalization with a Varian Inc. 7000e spectrometer. Dried samples
were placed on the diamond ATR crystal and the spectrum was obtained between 700 and 4000
cm−1 for 32 scans.
6.2.9 Cell Culture
A549 and H358 cells were cultured between passages 5-11 in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% of Fetal Bovine Serum (FBS), 1mM sodium pyruvate, 4 mM Lglutamine, Pen-Strep (100 µg /mL penicillin and 100 µg/mL streptomycin), and 10 μg/ml of
Fungizone. Cells incubated at 37 °C and 5% CO2.
6.2.10 Iron oxide nanoparticle uptake
A549 and H358 cells were seeded into 6 well plates at a density of 100,000 cells/mL and 2 mL/well.
After 24 hours, cells were exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH,
or Fe3O4+TAT) at a concentration of 500 µg/mL for 2 hours. After two hours, the nanoparticles
were removed and the cells were washed twice with PBS to remove any nanoparticles not
internalized within the cells. Cells were then detached from the 6 well plates and counted using a
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Nexcelom Cellometer to determine the cell concentration in each well. Cells were then centrifuges
and the media supernatant was removed. The cell pellets were dried overnight then dissolved in
6M HCl for 72 hours. After 72 hours, 10 µL of the dissolved cell pellet was transferred to a new
microcentrifuge tube and the iron concentration assay was completed (Section 2.7). The iron
concentration was then normalized to the number of cells in the sample.
6.2.11 Reactive Oxygen Species (ROS) Generation
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well in 6 well plates. After 24
hours of growth, the cells were exposed to various nanoparticle systems (uncoated Fe3O4,
Fe3O4+Dx-ECH, or Fe3O4+TAT) at a concentration of 500 μg/mL iron oxide for 2 hours. After 2
hours of exposure to the nanoparticles, the nanoparticle solutions were removed and cells were
washed 2 times with PBS, prior to trypsinizing and transferring the cells to microcentrifuge tubes.
The cells were then centrifuged and re-suspended in 1 mL of 50 μM carboxy-DCF solution. The
cells were incubated in the carboxy-DCF solution for 30 minutes to facilitate internalization of the
dye. Half of the samples were then exposed to an alternating magnetic field (AMF) (292 kHz, 56
kA/m) for 30 minutes or 1 hour with 30 minutes post incubation. Carboxy-DCF fluorescence was
measured using an Accuri Flow Cytometer in FL-1.
6.2.12 Acridine orange lysosomal permeabilization experiments
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not
associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were
exposed to an AMF (292 kHz, 56 kA/m) for one hour, then the cells were stained with acridine
orange (10 µg/mL) for ten minutes at 37 °C prior to analysis using an Accuri Flow Cytometer (FL3).
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6.2.13 Mitochondrial membrane depolarization studies (JC-1)
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not
associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were
exposed to an AMF (292 kHz, 56kA/m) for one hour, then the cells were centrifuged, re-suspended
in PBS, and stained with JC-1 (2 µM) for 30 minutes at 37 °C prior to analysis using an Accuri
Flow Cytometer (FL-1 and FL-3).
6.2.14 Caspase 3/7 apoptosis studies
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not
associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were
exposed to an AMF (292 kHz, 56kA/m) for one hour. At 12 or 24 hours post AMF treatment, the
cells were centrifuged, re-suspended in PBS, and stained with CellEvent per manufacturer’s
instructions (1 µL CellEvent/mL cell solution (500 nM)) for 30 minutes at 37 °C prior to analysis
using an Accuri Flow Cytometer (FL-1). Cells were gated into two populations: non-apoptotic and
apoptotic, with the apoptotic group being higher in FL-1 fluorescence and decreased in forward
scatter as confirmed by a CDDP (100 µM) positive control population.
6.2.15 Viability studies
A549 and H358 cells were seeded at 150,000 cells/mL and 2 mL/well into 6 well plates. Cells were
exposed to the nanoparticle systems (uncoated Fe3O4, Fe3O4+Dx-ECH, or Fe3O4+TAT) for two
hours at a concentration of 500 µg/mL iron oxide then rinsed to remove any nanoparticles not
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associated with the cells. The cells were trypsinized, the trypsin was neutralized with cell culture
media, and then the cells were transferred to 1.5 mL microcentrifuge tubes. Half the cells were
exposed to an AMF (292 kHz, 56kA/m) for one hour. The cells were then re-seeded into black
walled 96 well plates at 15,000 cells/mL and 100 µL/well and allowed to grow for 48 hours prior
to staining the cells with 2 µM calcein AMF and reading fluorescence on a plate reader (ex/em:
485/528 nm). Fluorescence was normalized to the fluorescence of the control (no nanoparticles and
no AMF treatment).
6.3 Results and Discussion
6.3.1 Iron oxide nanoparticle characterization
Iron oxide nanoparticles were synthesized via a one-pot co-precipitation method using a 2:1
molar ratio of iron salts and 30% ammonium hydroxide as the reducing agent. Figure 6.2 depicts
the subsequent surface functionalization strategy to conjugate the TAT peptide to the nanoparticle
surface via EDC/sulfo-NHS crosslinking. Size and zeta potential measurements are summarized in
Table 6.1. The number average hydrated diameter of the nanoparticles ranged from 127 nm for the
Fe3O4 + TAT to 177 nm for the Fe3O4 + Dx-ECH in water. The crosslinked dextran coating on the
nanoparticle surface stabilizes the nanoparticles at physiological pH by introducing steric
interactions and a relatively neutral surface charge, as indicated by the zeta potential (Lewin,
Carlesso et al. 2000, Ayala, Herrera et al. 2013). The decrease in size between the Fe3O4 + DxECH and Fe3O4 + TAT is a result of the additional washing steps required to remove unconjugated
TAT peptide after the reaction, which also removes loosely attached dextran which was not
crosslinked or removed in previous washing steps. The size of these nanoparticle systems is
appropriate for cell internalization while being above the cut-off of renal excretion (Ogawara,
Yoshida et al. 1999, Petters, Bulcke et al. 2014). DLS was also completed in cell culture media to
gauge nanoparticle sizes during cell culture studies. The nanoparticles were stored suspended in DI
water at 4 °C, diluted in cell culture media and bath sonicated for five minutes prior to recording
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DLS measurements over ten minutes. The larger size associated with uncoated Fe3O4 and Fe3O4 +
Dx-ECH-Amine nanoparticles in cell culture medium is an indication that agglomeration of the
nanoparticles during storage is not easily reversible. In addition, protein adsorption to the
nanoparticle surface likely caused the nanoparticles to increase in size and agglomerate. There is a
slight increase in size of the Fe3O4 + Dx-ECH and Fe3O4 + TAT nanoparticles when suspended in
cell culture media compared to DI water likely due to protein adsorption. However, the
nanoparticles are stabilized by the dextran crosslinked coating and charge repulsion from the TAT
peptide which allows the nanoparticles to be easily re-suspended upon bath sonication. The increase
in zeta potential between the Fe3O4 + Dx-ECH-Amine (-7.45 mV) and Fe3O4 + TAT (14.8 mV)
indicates successful attachment of the TAT peptide to the surface of the nanoparticle (Rao, Reddy
et al. 2008).
FTIR was also completed on the Fe3O4 + Dx-ECH-Amine and Fe3O4 + TAT systems to confirm
TAT attachment to the surface (Li, Dong et al. 2014). As shown in Figure 6.3a, there are slight
changes in the FTIR spectra, most notably a change in the N-H peak at 3300 cm-1 indicating a
decrease in primary amines in the coating due to conjugation of the TAT peptide using EDC/sulfoNHS crosslinking. TEM and XRD were used to determine iron oxide crystal size. Example TEM
images of the dextran coated iron oxide nanoparticles are shown in Figure 6.3b. The images shown
depict multiple nanoparticle crystals of approximately 8.9 ± 2 nm (average ± standard deviation as
determined by ten images at 60 nanoparticles per image) in size encapsulated within the dextran
coating. The crystalline size is not expected to change with further functionalization of the surface.
XRD (Figure 6.3c) confirmed the crystalline structure of the nanoparticles to be iron oxide (likely
a combination of magnetite and maghemite due to oxidation), and the Scherrer equation (Equation
6.3) and the (311) peak was used to calculate the average crystal length to be approximately 12.1
± 0.2 nm (n=3 individual batches), which is comparable to the crystal length determined via TEM
imaging. Although bulk heating was not the focus of this work, the specific absorption rate (SAR)
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is an indication of how the nanoparticles interact with an AMF. Previous characterization of the
crosslinked-dextran coated iron oxide nanoparticles indicated a SAR value of 211.0 ± 46.6 W/g (58
kA/m, 292 kHz), confirming the ability of the nanoparticles to respond to an AMF (Hauser, Mathias
et al. 2015).

Figure 6.2. Iron oxide nanoparticle synthesis and functionalization of the TAT peptide.
Table 6.1. Iron oxide nanoparticle size from dynamic light scattering in DI water and cell culture
media and zeta potential represented as average ± standard deviation (n=3).
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Figure 6.3 Nanoparticle characterization. a. FTIR spectra of amine functionalized and TAT
conjugated iron oxide nanoparticles. b. TEM images of dextran coated iron oxide nanoparticles to
confirm Fe3O4 crystalline structure. c. X-ray diffraction pattern of dextran coated iron oxide
nanoparticles.
6.3.2 Cellular uptake of iron oxide nanoparticles
A549 and H358 lung cancer cells were exposed to three nanoparticle systems of interest at a
concentration of 500 µg/mL for two hours. This exposure time and concentration were kept
constant throughout the studies completed. As shown in Figure 6.4, Fe3O4 + TAT uptake was
significantly greater than the other nanoparticle systems in both cell lines due to the TAT peptide
being a cell penetrating peptide and positively charged, which enhances internalization of its
attached cargo (Thorek and Tsourkas 2008, Torchilin 2008, Villanueva, Canete et al. 2009, Wang,
Qiao et al. 2012, Ayala, Herrera et al. 2013). The uncoated Fe3O4 nanoparticles were internalized
to a significantly greater extent than Fe3O4 + Dx-ECH in A549 cells and slightly greater in H358
cells. This is likely due to the positive zeta potential associated with uncoated Fe 3O4 (Osaka,
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Nakanishi et al. 2009). The Fe3O4 + Dx-ECH system did not result in significant uptake, as the iron
concentration is not different from that of the control, and this is likely a result of the slightly
negative surface charge which limits uptake (Villanueva, Canete et al. 2009). It was expected that
the effects of Fe3O4 + TAT nanoparticles in the presence of an AMF will be greater than the other
nanoparticle systems studied due to increased intracellular concentrations.

Figure 6.4 Uptake of Fe3O4 nanoparticles into a.) A549 and b.) H358 lung cancer cells. Error bars
represent standard error (n=3) and significant differences are indicated by * (p<0.05) and **
(p<0.01) via a one-way ANOVA.
6.3.3 Intracellular reactive oxygen species formation
Iron oxide nanoparticles have the ability to catalyze the formation of the hydroxyl radical via
Fenton chemistry. It has been previously shown that hydroxyl radical formation is enhanced in the
presence of an AMF due to energy dissipation by Brownian rotation and Neél relaxation resulting
in cellular stress (Wydra, Oliver et al. 2015). Figure 6.5a shows carboxy-DCF fluorescence of A549
lung carcinoma exposed to the three nanoparticle systems and a control followed by 30 minutes or
one hour AMF treatment, which did not result in a measureable temperature rise. AMF treatment
for 30 minutes significantly enhanced ROS production in A549 cells exposed to uncoated Fe 3O4
and Fe3O4 + TAT. The surface of uncoated Fe3O4 is not shielded and therefore can interact with the
cell environment and catalyze hydroxyl radical formation through Fenton chemistry. Enhancement
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of ROS generation via uncoated Fe3O4 in the presence of an AMF was previously shown by Wydra
et al., where methylene blue decolorization was enhanced in the presence of uncoated Fe 3O4 and
an AMF compared to the theoretical degradation associated with bulk temperature rise (Wydra,
Oliver et al. 2015).
Fe3O4 + TAT nanoparticles are potentially inducing local heating effects or frictional effects
from Brownian rotation and therefore causing cell stress and increasing ROS production. Only the
Fe3O4 + TAT increased ROS production in A549 lung carcinoma when exposed to an AMF for
both 30 minutes and one hour, which is likely due to the increased concentration of intracellular
nanoparticles and, therefore, greater local heating and frictional effects. Although not significant,
uncoated Fe3O4 combined with one hour AMF exposure slightly increased intracellular ROS
production. The convergence in ROS production between uncoated Fe3O4 and uncoated Fe3O4 with
one hour AMF can be explained by the inherent ability of the nanoparticle to increase intracellular
ROS production through Fenton chemistry at the surface even without local energy dissipation
(Wydra, Oliver et al. 2015). The longer AMF exposure time increased the amount of time that the
internalized nanoparticles were able to interact intracellularly, which could cause a convergence in
ROS generation between the no AMF and one hour AMF treatments for cells exposed to uncoated
Fe3O4.
It should also be noted that the A549 control cells, which were not exposed to iron oxide
nanoparticles, still generate ROS through natural cellular respiration. By increasing AMF exposure
time, carboxy-DCF exposure time also increased resulting in increased fluorescence being
associated with the longer AMF exposure. By doubling the AMF exposure time, the carboxy-DCF
exposure nearly doubled, resulting in a near two-fold increase in fluorescence of control A549 cells.
However, this was not observed in H358 cells as shown in Figure 6.5b. Increased H358 incubation
time with carboxy-DCF did not show the same increase in fluorescence indicating that the cells
were potentially operating at their maximal ROS generation rate. The difference in inherent ROS
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production between A549 and H358 cells was determined by incubating the cells with 50 µM
carboxy-DCF for two hours and then measuring the raw fluorescence of the cells via flow
cytometry. As shown in Figure 6.6, H358 cells operated at a higher level of reactive oxygen species
than A549 cells. Previous work by Trachootham, et al. in 2006 showed that increased oxidative
stress in cancer cells is associated with oncogenic transformation by transfecting T72 ovarian cells
with the Ras gene (Trachootham, Zhou et al. 2006). Oncogenic transformation resulted in increased
oxidative stress as well as increased sensitivity to ROS inducing agents. Therefore, increased
oxidative stress results in greater dependence upon antioxidant systems causing the cells to be more
sensitive to exogenous agents, which threaten this delicate balance (Trachootham, Zhou et al. 2006,
Wang and Yi 2008, Klein, Sommer et al. 2012, Huang, Chen et al. 2013).

Figure 6.5 Normalized carboxy-DCF fluorescence of a.) A549 and b.) H358 lung cancer cells after
treatment with Fe3O4 nanoparticles with and without 30 minutes or 1 hour AMF exposure. Error
bars represent standard error (n=3) and significant difference is indicated by * (p<0.05) via a twoway ANOVA.
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Figure 6.6 Average fluorescence of A549 and H358 cells after 2 hours of exposure to 50 µM
carboxy-DCF. Error bars represent standard error (n=5) and * indicates a significant difference
(p<0.05) via a t-test.
6.3.4 Intracellular effects of internalized iron oxide nanoparticles and AMF exposure
There are a multitude of intracellular properties and pathways that can be affected by increased
ROS production. Therefore, we have evaluated lysosomal permeability, mitochondrial membrane
permeability, apoptosis via the Caspase 3/7 pathway, and cell viability of A549 and H358 lung
cancer cells after exposure to the nanoparticle systems with and without one hour of AMF exposure.
AMF exposure did not result in a measurable temperature rise.
An increase in lysosome permeability is associated with several apoptosis pathways.
Destabilization of the lysosomal membranes releases lysosomal contents such as proteolytic
enzymes (e.g., cathepsins) into the cytosol, which then induces mitochondrial damage by enhancing
the production of superoxide radicals and hydrogen peroxide, further increasing lysosome
permeability, resulting in an amplifying feedback loop (Zhao, Antunes et al. 2003). Acridine orange
(AO) is a metachromatic fluorophore which gives a distinct red fluorescence at high lysosomal
concentrations and a weakly green fluorescence at the low cytosolic concentration and can therefore
be used to measure lysosomal membrane permeability, with a decrease in the red fluorescence
channel corresponding to an increase in lysosome permeability (Terman, Kurz et al. 2006). AO red
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fluorescence was measured for A549 (Figure 6.7a) and H358 (Figure 6.7b) immediately following
iron oxide nanoparticle internalization and one hour of AMF exposure, and these fluorescence
intensities were then normalized to the control with no AMF exposure. Lysosome permeability
increased with Fe3O4 + TAT treatment in both A549 and H358 cells. However, the permeability
was not further increased by AMF exposure. This could be a result of saturating the assay as the
Fe3O4 + TAT nanoparticles permeabilized the lysosomal membranes to the same extent as the 100
µM hydrogen peroxide positive control (data not shown), and thus, the effects of the AMF could
not increase the permeability further. In A549 lung carcinoma, all of the nanoparticles significantly
increased lysosome permeability. This could be due to the uncoated Fe3O4 nanoparticles generating
ROS within the lysosome, leading to destabilization of the membrane (Terman, Kurz et al. 2006).

Figure 6.7 Relative acridine orange (AO) fluorescence of a.) A549 and b.) H358 lung cancer cells
after treatment with Fe3O4 nanoparticles with and without 1 hour AMF exposure. Error bars
represent standard error (n=3) and significant difference from the control is indicated by * (p<0.05)
via a two-way ANOVA.
The JC-1 assay employs a cationic dye that exhibits potential dependent accumulation in
mitochondria. At high concentrations, such as those in the mitochondria, the JC-1 dye aggregates
to form red-fluorescent J-aggregates. Depolarization of the mitochondrial membrane results in
lower JC-1 concentrations and therefore the formation of green-fluorescent monomers.
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Mitochondrial membrane potential can be monitored using the JC-1 ratio (red/green fluorescence).
A decrease in the red/green fluorescence ratio is the result of mitochondrial membrane
depolarization, which occurs in the early stages of apoptosis (Ly, Grubb et al. 2003). Figure 6.8
shows the percentage of cells with mitochondrial membrane depolarization, which resulted in a
decreased JC-1 ratio. In A549 lung carcinoma, Fe3O4 + TAT treatment resulted in a significant
increase in the percentage of the cell population with depolarized mitochondrial membranes.
However, this was not significantly increased with the addition of AMF treatment. As previously
mentioned, mitochondrial integrity can be compromised by increases in lysosomal permeability
due to the escape of toxins and proteolytic enzymes into the cytosol. Therefore, it is hypothesized
that the Fe3O4 + TAT nanoparticles permeabilized the lysosomal membranes which then affected
the mitochondrial integrity of the A549 lung carcinoma. There is also the possibility that the Fe3O4
+ TAT nanoparticles fully escaped the lysosomes, interacted with the mitochondria, and catalyzed
ROS formation at the mitochondria. However, it should be noted that this effect is cell line
dependent as the Fe3O4 + TAT nanoparticles did not disrupt the mitochondrial membrane integrity
in H358 lung carcinoma.

Figure 6.8 Percentage of a.) A549 and b.) H358 cells with depolarized mitochondrial membranes
as indicated by a decrease in the ratio between FL3/FL1 (JC1 ratio). Error bars represent standard
error (n=3) and * indicates a significant difference (p<0.05) compared to the control as determined
via a two-way ANOVA.
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An increase in lysosome membrane permeability and depolarization of the mitochondrial
membrane are both found upstream in many apoptotic pathways (Brunk, Neuzil et al. 2001, Ly,
Grubb et al. 2003). Therefore, the effects of the iron oxide nanoparticle systems and subsequent
AMF exposure on the Caspase 3/7 apoptotic pathway were evaluated. Due to the cells being in
different stages of the cell cycle at the time of treatment, the time between treatment and analysis
of the apoptotic population was delayed to 12 and 24 hours post treatment. These time points were
determined using hydrogen peroxide controls and evaluating the peak times of apoptosis following
treatment (data not shown). Although there were no statistically significant differences between the
percent of apoptotic cells when comparing the nanoparticle systems to one another and the
individual systems with and without AMF treatment, there were trends in the data that are
interesting and warrant further exploration of these potential effects. In Figure 6.9, both A549 lung
carcinoma and H358 bronchi alveolar appeared to increase in apoptosis when the nanoparticles
were combined with AMF, although not significant. Additionally, H358 cells appear to have
increased apoptosis compared to A549 in all treatments. This could be a result of the H358 cells
being more sensitive to the treatment as well as the processing procedure of the experiment. It also
appeared as though uncoated Fe3O4 and Fe3O4 + TAT resulted in greater apoptosis than the Fe3O4
+ Dx-ECH in H358 cells which corresponds to the ROS generation data provided previously. The
significant error observed in this assay prevents firm conclusions about differences between the
treatments. However, as previously mentioned, there were notable trends in the data. In future
studies, additional assays, such as Annexin V/Propidium iodide (PI), will be used as the variability
in the current assay limit the conclusions that can currently be made. Additionally, prior work by
Wydra, et al. used the Caspase 3/7 assay to show a significant increase in apoptosis of CT26 colon
cancer cells when uncoated, citric acid coated and glucose functionalized iron oxide nanoparticles
were combined with AMF (292 kHz, 56 kA/m) exposure for 1 hour compared to the nanoparticle
systems alone (Hauser, Wydra et al. , Wydra, Rychahou et al. 2015).The effect was larger in this
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case and found to be statistically significant, which further confirms that the efficacy of MagMED
treatment is cell line dependent as expected.

Figure 6.9 Percentage apoptosis of a.) A549 and b.) H358 lung cancer cells 12 and 24 hours after
treatment with Fe3O4 nanoparticles with and without 1 hour AMF. Error bars represent standard
error (n=3) and significant difference from the control is indicated by * (p<0.05) via a two-way
ANOVA.
A549 and H358 viability 48 hours following treatment with the nanoparticle systems with and
without AMF were evaluated and shown in Figure 6.10. In A549 lung carcinoma, there is no
significant difference between the nanoparticle systems and the control or within a nanoparticle
system with and without AMF treatment. In the H358 cells, only the uncoated Fe3O4 nanoparticles
resulted in a decrease in cell viability compared to the control, but there was no additional decrease
in viability as a result of AMF treatment. Although intracellular effects of the nanoparticle systems
combined with AMF were observed (e.g., especially in intracellular ROS generation), the
intracellular effects were not enough to induce a decrease in cell viability. Previous work by
Creixell et al. showed a significant decrease in cell viability when internalized EGFR targeted iron
oxide nanoparticles were combined with an AMF for 2 hours (Creixell, Bohorquez et al. 2011).
However, there was significant toxicity of the EGFR targeted nanoparticles alone which could have
sensitized the cells to additional treatment with the AMF. Additionally, the AMF treatment time
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was two hours instead of the one hour used in these studies. Another study completed by Domenech
et al. demonstrated that intracellular energy delivery is cell line dependent. MDA-MB 231 and 18485 cells were incubated with EGF targeted, carboxymethyl dextran coated iron oxide nanoparticles
and then exposed to an AMF (233 kHz, 41.75 kA/m) for 1 hour (Domenech, Marrero-Berrios et al.
2013). A decrease in viability of MDA-MB-231 cells was observed with the addition of AMF
treatment however, while 184-85 cell viability was not affected by AMF treatment. Future work
will explore utilizing intracellular energy delivery as a combinational treatment in order to enhance
the efficacy of conventional treatments such as chemotherapy and radiation. It is possible that
intracellular energy delivery can act as a sensitizer to additional treatments resulting in a synergistic
combinational effect.

Figure 6.10 Relative viability of a.) A549 and b.) H358 lung cancer cells 48 hours after treatment
with Fe3O4 nanoparticles with and without 1 hour AMF. Error bars represent standard error (n=3)
and significant difference from the control is indicated by * (p<0.05) via a two-way ANOVA.
6.4 Conclusions
Dextran coated iron oxide nanoparticles were successfully functionalized with the TAT peptide
and characterized for their physicochemical properties. The nanoparticles ranged in size from
approximately 130-180 nm and successful conjugation of the TAT peptide was confirmed by
changes in nanoparticle zeta potential and FTIR spectra. TAT functionalization to dextran coated
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iron oxide nanoparticles resulted in a novel nanoparticle system in that the nanoparticles were
internalized within cells at significantly greater concentrations but were not internalized via
receptor-mediated endocytosis. Uncoated Fe3O4 and Fe3O4 + TAT increased cellular ROS
generation in both A549 and H358 cell lines upon exposure to an AMF. Lysosomal permeability
was increased in both cell lines following treatment with Fe 3O4 + TAT nanoparticles due to the
TAT peptide destabilizing the lysosomal membranes. In A549 cells, the mitochondrial integrity
was compromised by the Fe3O4 + TAT nanoparticles but this was not enhanced by AMF exposure
or observed in H358 cells, indicating a cell dependent response to treatment. Apoptosis response
was also cell line dependent, and although not statistically significant, trends were observed that
suggested an increase in apoptosis when nanoparticle systems were combined with AMF treatment.
However, there was no difference in the treatments when cell viability was analyzed 48 hours post
treatment. Future work will aim to increase consistency of apoptosis assays and increase the scope
of tested cell lines. Targeting the nanoparticles to specific organelles could also improve the
efficacy of MagMED, especially if the particles were targeted to vital organelles such as the
mitochondria.
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Chapter 7 Targeted iron oxide nanoparticles for the enhancement of radiation therapy
Iron oxide nanoparticles have the ability to catalyze the Fenton reaction to generate reactive oxygen
species (ROS). Radiation therapy promotes mitochondrial respiration which leads to increased
superoxide anion production. In the presence of iron oxide nanoparticles, the superoxide anion is
converted to the highly reactive hydroxyl radical. The goal of this chapter was to evaluate the
cellular effects of radiation combined with the peptide functionalized nanoparticles developed in
Chapter 6. The chapter is taken directly or adapted from work recently submitted to Biomaterials.
Used with permissions from Anastasia K. Hauser, Mihail I. Mitov, Emily F. Daley, Kimberly W.
Anderson and J. Zach Hilt, “Targeted iron oxide nanoparticles for the enhancement of radiation
therapy.”
7.0 Abstract
To increase the efficacy of radiation, iron oxide nanoparticles can be utilized for their ability
to produce reactive oxygen species (ROS). Radiation therapy promotes mitochondrial respiration
which is often linked to higher cellular energy production and leads to an increase in mitochondrial
production of the superoxide anion which is converted to hydrogen peroxide by superoxide
dismutase. Iron oxide nanoparticles can then catalyze the reaction from hydrogen peroxide to the
highly reactive hydroxyl radical. Therefore, the overall aim of this project was to utilize iron oxide
nanoparticles conjugated to a cell penetrating peptide, TAT, to escape lysosomal encapsulation
after internalization by cancer cells and catalyze hydroxyl radical formation. It was determined that
TAT functionalized iron oxide nanoparticles and uncoated iron oxide nanoparticles resulted in
permeabilization of the lysosomal membranes. Additionally, mitochondrial integrity was
compromised when A549 cells were treated with both TAT-functionalized nanoparticles and
radiation. Pre-treatment with TAT-functionalized nanoparticles also significantly increased the
ROS generation associated with radiation. A long term viability study showed that TATfunctionalized iron oxide nanoparticles combined with radiation resulted in a synergistic
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combination treatment. This is likely due to the TAT-functionalized nanoparticles sensitizing the
cells to subsequent radiation therapy, because the nanoparticles alone did not result in significant
toxicities.
7.1 Introduction
Iron oxide nanoparticles have been previously studied for their multitude of biological
applications, magnetic properties, and lack of protein adsorption after proper coating (Laurent, Dutz
et al. 2011). Iron oxide nanoparticles have been utilized in magnetically mediated hyperthermia for
the treatment of cancer, contrast agents in magnetic resonance imaging, and treatment of anemia
(Dennis, Jackson et al. 2009, Hu, Ma et al. 2011, Laurent, Dutz et al. 2011, McCormack 2012).
However, recent work suggests that inherent toxicities of the nanoparticles can be utilized to
enhance current cancer treatments via the generation of reactive oxygen species (ROS) (Koenczoel,
Weiss et al. 2013, Luo, Li et al. 2015).
Cancer cells are more susceptible to oxidative insults compared to normal cells due to fast cell
proliferation and metabolism so additional ROS stress induced by exogenous agents can
overwhelm the relatively low antioxidant capacity and disrupt the redox homeostasis inside cancer
cells leading to selective tumor cell toxicity (Huang, Chen et al. 2013, Luo, Li et al. 2015).
Trachootham et al. transfected T72 cells with the Ras gene and showed that oncogenic cells
containing the Ras gene operated at increased ROS stress compared to non-transfected cells
(Trachootham, Zhou et al. 2006). This increased oxidative stress caused the T72 Ras cells to be
more sensitive to PEITC, an exogenous ROS generating agent. ROS have the ability to result in
DNA and lipid damage and disturb signal transduction, which can lead to cell death if the damage
is severe enough that it cannot be repaired (Kehrer 2000). Therefore, sensitization of cancer cells
to radiation by inducing oxidative stress has the potential to synergistically increase treatment
efficacy.
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The Haber-Weiss reaction results in generation of the highly reactive hydroxyl radical from the
reaction between superoxide and hydrogen peroxide. This reaction is thermodynamically unfavorable in biologic systems, and with a second order rate constant of zero in aqueous solution, it
was found to require a catalyst to proceed (Kehrer 2000). The iron catalyzed Haber-Weiss reaction,
which makes use of Fenton chemistry, is now considered the major mechanism by which the highly
reactive radical is generated in biological systems (Kehrer 2000). The Fenton chemistry reaction
set is shown as Equation 7.1, and the Haber-Weiss reaction (net reaction) is shown as Equation 7.2.
Fe3+ + O2· - → Fe2+ + O2
Fe2+ +H2O2 → Fe3+ + OH- + OH·

[7.1]

O2· - + H2O2 → O2 + OH- + OH·

[7.2]

Under normal conditions, only trace amounts of iron exist outside of physiologic sinks such as
transferrin or ferritin. Proteins sequester iron ions so that the ions circulate bound to transferrin and
accumulate within cells in the form of ferritin. The absorption of iron is finely regulated to prevent
an excess storage and oxidative attack (Emerit, Beaumont et al. 2001). Iron oxide nanoparticles
have been previously studied for their multitude of biological applications, and recent work
suggests that the uptake of iron oxide nanoparticles can lead to a concentration increase of
intracellular unbound iron which may result in cell injury or death (Weissleder, Stark et al. 1989,
Klein, Sommer et al. 2012, Alarifi, Ali et al. 2014), especially when combined with additional
therapies (Klein, Sommer et al. 2012, Huang, Chen et al. 2013, Klein, Sommer et al. 2014, Luo, Li
et al. 2015). When iron oxide nanoparticles are taken up by a cell, they stimulate the generation of
ROS via one of two pathways: the release of ions into the cytosol where chelation by citrate or
adenosine phosphate takes place resulting in the iron ions participating in the Haber-Weiss cycle
or the surface of the iron oxide nanoparticle may act as a catalyst for the Haber-Weiss cycle and
the Fenton reaction (Auffan, Achouak et al. 2008, Lewinski, Colvin et al. 2008, Voinov, Pagan et
al. 2011, Klein, Sommer et al. 2012). Both pathways result in the formation of the highly reactive
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hydroxyl radical. Iron oxide nanoparticles can exist in many forms with two of the most common
forms of iron oxide nanoparticles being magnetite (Fe3O4) and maghemite (Fe2O3). It was suggested
by Aranda et al. that magnetite nanoparticles would lead to greater ROS formation and oxidative
stress due to iron being present as both Fe3+ and Fe2+ ions within magnetite while maghemite has
mostly ferric iron ions (Aranda, Sequedo et al. 2013). Therefore, these studies focus on magnetite
iron oxide nanoparticles for the generation of intracellular ROS.
There are multiple pathways within the cell that naturally generate ROS. The pathway of
particular interest is mitochondrial respiration which produces the superoxide anion (Kehrer 2000).
The superoxide anion is converted to hydrogen peroxide through natural superoxide dismutase, and
in the presence of iron ions, the conversion of hydrogen peroxide to the highly reactive hydroxyl
radical is catalyzed (Koenczoel, Weiss et al. 2013). Although the exact mechanism remains unclear,
radiation promotes mitochondrial respiration and therefore increases production of the superoxide
anion (Kam and Banati 2013). Yamamori et al. showed that A549 lung carcinoma exhibited
increased oxygen consumption rates as well as increased rates of mitochondrial ROS production at
6 and 12 hours following 5 Gy radiation (Yamamori, Yasui et al. 2012). If the intracellular
concentration of the superoxide anion is increased following radiation and iron oxide nanoparticles
are present to catalyze hydroxyl radical formation, it is hypothesized that the hydroxyl radical
concentration will subsequently be increased, resulting in increased toxicity.
Iron oxide nanoparticles are usually taken up by cells through endocytosis resulting in the
nanoparticles being encapsulated in endosomes/lysosomes. Due to the acidic nature of these
subcellular compartments, the nanoparticles can be degraded prior to fulfilling their purpose.
However, if a cell penetrating peptide (CPP) is conjugated to the surface of the iron oxide
nanoparticle, the nanoparticle can avoid receptor mediated endocytosis (Vives, Brodin et al. 1997).
In this work, the CPP of particular interest is the TAT peptide (sequence: YGRKKRRQRRR),
which contains a characteristic lysine and arginine sequence. Biomolecules with this tag are known
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to bind to importin α and β in the cytoplasm allowing for active transportation to the nuclear pore
complex (NPC) and, if small enough, through the NPC into the nucleus (Austin, Kang et al. 2011).
Several studies have utilized the TAT peptide as a cell internalization mechanism (Josephson, Tung
et al. 1999, Lewin, Carlesso et al. 2000, Rao, Reddy et al. 2008, Torchilin 2008, Wang, Qiao et al.
2012) as well as a nuclear targeting moiety (Vives, Brodin et al. 1997, de la Fuente and Berry 2005,
Oyelere, Chen et al. 2007, Xu, Xie et al. 2008, Yang, Neshatian et al. 2014).
Although lysosomes may eventually uptake TAT-conjugated nanoparticles residing in the
cytosol, the TAT peptide is positively charged and can destabilize lysosomal membranes leading
to release of lysosomal contents, including proteolytic enzymes and the nanoparticles (Terman,
Kurz et al. 2006). An increase in lysosome membrane permeability is an upstream event in many
apoptotic pathways, as the proteolytic enzymes lead to mitochondrial damage by enhancing the
production of superoxide radicals and hydrogen peroxide, which in turn increases lysosomal
membrane permeability, resulting in an amplifying feedback loop (Zhao, Antunes et al. 2003,
Kirkegaard and Jaattela 2009). Due to the size of our iron oxide nanoparticles being larger than the
upper limit of the nuclear pore complex (20―70 nm), it was of particular interest to escape
endosome/lysosomes in order to interact with other organelles such as the mitochondria (Pan, He
et al. 2012).
In this study, dextran coated iron oxide nanoparticles were functionalized with the TAT peptide
and this nanoparticle system was used to enhance the efficacy of radiation. The TAT peptide
increased intracellular concentrations of the nanoparticles compared to uncoated nanoparticles as
shown by transmission electron microscopy (TEM). TEM images also indicate that uncoated iron
oxide nanoparticles were encapsulated within lysosomes after cell internalization. However, TATfunctionalized nanoparticles were found in the cytoplasm as well as in lysosomes with destabilized
membranes. Lysosomal membrane permeability studies confirmed the ability of the TAT peptide
to destabilize the lysosomes, and cell respiration studies indicated that TAT-functionalized
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nanoparticles combined with radiation resulted in a loss of mitochondrial integrity, causing the cells
to operate at lower metabolic levels. When combined with radiation, the TAT-functionalized
nanoparticles increased reactive oxygen species generation to a greater extent than radiation alone.
The combined treatment also resulted in synergistic cytotoxic effects on A549 lung carcinoma, as
shown by a long term viability study. Therefore, it has been concluded that TAT-conjugated iron
oxide nanoparticles have the ability to destabilize lysosomal membranes, releasing their toxic
contents into the cytosol and causing the cells to be more sensitive to radiation therapy.
Additionally, after radiation therapy when the mitochondria have increased respiration levels and
are producing greater amounts of the superoxide anion, the iron oxide nanoparticles can catalyze
the formation of the highly reactive hydroxyl radical. This hypothesis is depicted in Figure 7.1.

Figure 7.1 TAT-conjugated iron oxide nanoparticles are internalized into the cell, followed by
lysosomal membrane permeabilization. This results in release of proteolytic enzymes as well as the
nanoparticles into the cytoplasm where they can interact with organelles such as the nucleus and
mitochondria and catalyze the formation of the hydroxyl radical.
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7.2 Materials and Methods
7.2.1 Materials
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran,
epichlorohydrin (ECH) were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). Phosphate buffered saline
solution (PBS) (10X) was purchased from EMD Millipore (Billerica, MA). The activation buffer
2-[N-morpholino] ethane sulfonic acid (MES), N-hydroxysulfosuccinimide (sulfo-NHS) and 1ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) were purchased from
Thermo scientific (Rockford, IL). The TAT peptide was purchased custom from Biomatik.
Phosphate buffered saline (PBS), Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, Lglutamine, Fungizone®, sodium pyruvate, and calcein AM were obtained from Invitrogen
(Frederick, MD). Acridine orange was purchased from Nexcelom Bioscience (Lawrence, MA) and
A549 lung carcinoma and trypsin were purchased from American Type Culture Collection (ATCC,
Manassas, VA). All materials were used as received.
7.2.2 Synthesis of uncoated iron oxide nanoparticles (uncoated Fe3O4)
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 60 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. The reaction solution was heated to 85 °C at
which 5 ml of NH4OH was diluted to 40 mL with DI water and the combined solution was injected
dropwise into the vessel. The reaction was carried out for 1 hour at 85 °C. The particles were
magnetically decanted and washed three times with DI water. The nanoparticles were then resuspended in DI water and dialyzed against DI water for 24 hours (100 kDa molecular weight
cutoff). After dialysis, the nanoparticles were probe sonicated for 10 minutes and then centrifuged
at 1000 rpm for 5 minutes to remove large agglomerates.
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7.2.3 Synthesis of dextran coated iron oxide nanoparticles (Fe3O4 + Dx)
FeCl3·6H2O and FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams,
respectively) and dissolved in 40 mL deionized (DI) water and sealed in a three-neck flask under
vigorous stirring and an inert nitrogen environment. 5 grams of dextran was solubilized in 20 mL
of DI water. The reaction solution was heated to 85 °C at which 5 ml of NH4OH was added to the
dextran solution and the combined solution was injected dropwise into the vessel. The reaction was
carried out for 1 hour at 85 °C. The particles were magnetically decanted and washed three times
with DI water. The nanoparticles were then re-suspended in DI water and dialyzed against DI water
for 24 hours (100 kDa molecular weight cutoff). After dialysis, the nanoparticles were probe
sonicated for 10 minutes and then centrifuged at 1000 rpm for 5 minutes to remove large
agglomerates.
7.2.4 Epichlorohydrin (ECH) crosslinking of dextran coated iron oxide nanoparticles (Fe3O4 +
Dx-ECH)
Dextran coated iron oxide nanoparticles were crosslinked using ECH for increased stability
(Palmacci and Josephson 1993). The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M
NaOH and 1.5 mL ECH. The reaction was carried out for 24 hours at room temperature under
continuous agitation. The particles were then magnetically decanted and dialyzed against DI water
(100 kDa molecular weight cutoff) for 24 hours to remove excess ECH.
7.2.5 Amine functionalization of crosslinked dextran coated iron oxide nanoparticles (Fe3O4 +
Dx-ECH-Amine)
An equal volume of ammonium hydroxide to mmol iron from Fe3O4 + Dx-ECH were combined
and placed on the shaker table for 24 hours. After 24 hours, the nanoparticles were dialyzed against
DI H2O for an additional 24 hours, with their water changed 3 times during this time period.
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7.2.6 TAT peptide conjugation to iron oxide nanoparticles (Fe3O4 + TAT)
10 mg of the TAT-peptide was dissolved in 10 mL MES buffer (2-[N-morpholino] ethane sulfonic
acid). 4 mg EDC and 11 mg sulfo-NHS were also added to the solution. Solution was reacted for
15 minutes with continuous agitation after which 14 µL of 2- mercaptoethanol was added to the
reaction in order to quench excess EDC. Amine-functionalized iron oxide nanoparticles were
diluted to 1 mg Fe3O4/mL with PBS. The iron oxide suspension was added to the TAT-peptide
solution and reacted over night under continuous agitation. After the TAT-iron oxide nanoparticle
reaction was complete, and particles were washed with PBS via magnetic decanting until the
washing solution was clear.
7.2.7 Iron Concentration Assay
Between each step of synthesizing a new system of iron oxide nanoparticles, an iron assay was
used to determine the iron concentration of the nanoparticles. 20x, 50x, and 100x dilutions of the
iron oxide nanoparticles were made in DI water and 10 µL of each dilution was added to 10 µL 6M
HCl and allowed to sit for 3 hours. After this time, 500 µL of 1M acetic acid, 100 µL of
hydroxylamine hydrochloride, 100 µL of 1, 10 phenanthroline, and 280 µL of DI water were added
to each dilution. Solutions were left overnight. After 24 hours, the absorbance of each solution (λ
= 511 nm) was used to calculate the iron concentration based on a standard curve.
7.2.8 Cell Culture
A549 cells were cultured between passages 5-11 in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% of Fetal Bovine Serum (FBS), 1mM sodium pyruvate, 4 mM L-glutamine,
Pen-Strep (100 µg /mL penicillin and 100 µg/mL streptomycin), and 10 μg/ml of Fungizone. Cells
incubated at 37 °C and 5% CO2.
7.2.9 Transmission electron microscopy
A549 cells were seeded into 6 well plates at 13,000 cells/cm2 and grown for 24 hours. Cells were
then exposed to 500 µg/mL iron oxide of either uncoated iron oxide nanoparticles or Fe3O4 + TAT
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for 24 hours. After 24 hours, the nanoparticles suspensions were removed and the cells were rinsed
with media to remove non-internalized nanoparticles. Half of the samples were then exposed to 5
Gy radiation. After treatment, the cells were washed with PBS to remove media then fixed in 3.5%
glutaraldehyde in 0.1 M Sorenson’s buffer for 75 minutes at 4 °C. Cells were then washed 4 times
with 0.1 M Sorenson’s containing 5% sucrose, post fixed with 1% osmium tetraoxide for 45
minutes at 4 °C, then washed again with 0.1 M Sorenson’s. Cells were dehydrated in graded
ethanols (50-100%) then absolute ethanol twice at 4 °C. Cells were then embedded in Eponate 12
resin and polymerized at 60 °C prior to slicing and mounting for imaging (Philips BioTwin 12
Transmission Electron Microscope).
7.2.10 Acridine orange lysosomal permeabilization experiments
A549 lung carcinoma cells were seeded at 80,000 cells/mL and 2 mL/well into 6 well plates. Cells
were exposed to the nanoparticle systems for three hours at a concentration of 500 µg/mL iron
oxide then rinsed to remove any nanoparticles not associated with the cells. Half the cells were
exposed to 5 Gy radiation then the cells were stained with acridine orange (10 µg/mL) for ten
minutes at 37 °C prior to analysis via flow cytometry (FL-3).
7.2.11 Mitochondrial stress test
A549 lung carcinoma cells were seeded at densities of 30,000 per well in Seahorse XF96
microplates and allowed to grow overnight. The cells were then exposed to the nanoparticle systems
for 3 hours at 500 µg/mL iron oxide then rinsed to remove any nanoparticles not associated with
the cells. Half of the samples were then treated with 5 Gy radiation. Mitochondrial stress was then
measured using the Seahorse XF 96 Extracellular Flux Analyzer to measure in vitro oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR). The bioenergetic baseline
profiles can be determined by plotting the ECAR vs OCR signal for the last measurement of base
line (or just before adding Oligomycin A to the cells as shown in Figure 7.2). To expand, cells were
incubated for one hour prior to the start of analysis at 37 °C in XF modified assay medium
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containing 25mM Glucose and 1mM Pyruvate. Three baseline OCR and ECAR values were taken
over 16 minutes representing the basal respiration rate, which is the total base line OCR minus the
non-mitochondrial respiration. The next three measurements were taken for a period over 20
minutes, after the addition of an ATP synthase inhibitor (Oligomycin 1uM) which helps to calculate
the amount of oxygen used for ATP turnover. Next, mitochondrial uncoupler, FCCP (0.6 µM) was
added to force the cells to operate at their maximal respiration rates for 3 measurements over 20
minutes. Finally, antimycin A and rotenone were added to inhibit the electron transport chain of
oxidative phosphorylation and therefore disrupt the formation of the proton gradient across the
inner membrane, leading to complete cessation of oxygen consumption by the mitochondria, after
which three values were taken in 14 minutes. All measurements were normalized to protein using
bicinchoninic acid (BCA) assay. Analysis of the effects of Fe3O4 nanoparticle systems combined
with radiation on each component of the OCR profile can be found in the supplementary
information section.

Figure 7.2 Bioenergetic profile of control A549 cells over time. Error bars represent standard error
(n=12).
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7.2.12 Reactive Oxygen Species (ROS) Generation
A549 human lung carcinoma cells were seeded at 40,000 cells/mL and 100 µL/well in black walled
96 well plates. After 24 hours of growth, the cells were exposed to various iron oxide nanoparticle
systems (uncoated Fe3O4, Fe3O4+Dx-ECH, Fe3O4+ Dx-ECH-Amine, or Fe3O4 + TAT) at
concentrations of 100 μg/mL or 500 μg/mL iron oxide for 24 hours. After 24 hours of exposure,
the nanoparticle solutions were removed and cells were washed 2 times with media, and 100 μL of
50 μM carboxy-DCF solution was added to each well followed by 20 minutes of incubation to
facilitate internalization of the dye. Half of the samples were then irradiated with 5 Gy radiation.
Carboxy-DCF fluorescence was measured using a plate reader (ex/em: 485/528 nm) followed by
staining with HOESCHT 33342 nuclear stain to normalize data back to the number of cells present.
7.2.13 Viability studies
A549 human lung carcinoma cells were seeded at 5,000 cells/mL and 100 µL/well in black walled
96 well plates. After 24 hours of growth, the cells were exposed to various nanoparticle systems
(uncoated, Fe3O4 + Dx-ECH, Fe3O4 + Dx-ECH-Amine, or Fe3O4 + TAT) at a concentration of 500
μg/mL iron oxide for 24 hours. After 24 hours of exposure, the nanoparticle solutions were removed
and cells were washed 2 times with media and half of the samples were then irradiated with 5 Gy
radiation. Cell viability was analyzed 3, 5, and 7 days after treatment using a calcein AM assay.
Calcein AM fluorescence was measured on a plate reader and the fluorescence of each treatment
was normalized to the fluorescence of the control on that day.
7.3 Results and Discussion
Iron oxide nanoparticle systems were previously synthesized and characterized for
physicochemical properties (see Chapter 6). TEM images of A549 lung carcinoma after exposure
to uncoated Fe3O4 or Fe3O4 + TAT with and without 5 Gy radiation treatment are shown in Figure
7.3. Uncoated Fe3O4 nanoparticles with and without radiation are localized within lysosomes. No
uncoated Fe3O4 nanoparticles were found to be interacting with the mitochondria or to have
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penetrated the nuclear membrane. Uncoated Fe3O4 nanoparticles are taken up via non-specific
endocytosis and do not have the ability to sufficiently destabilize lysosome membranes and escape
into the cytosol (Terman, Kurz et al. 2006). Similarly, Könczöl et al. found that uncoated iron oxide
nanoparticles were encapsulated in vesicles of A549 lung carcinoma after 24 hours of incubation
(Koenczoel, Weiss et al. 2013). There was significantly greater uptake of the Fe3O4 + TAT
nanoparticles into A549 cells as the TAT peptide facilitates cell penetration and escapes receptor
mediated endocytosis. Fe3O4 + TAT nanoparticles could be found both in lysosomes as well as in
the cytosol. The nanoparticles appeared to surround the nuclear membrane, but they did not
penetrate it due to size restraints of the nuclear pore complex (Pan, He et al. 2012). When combined
with radiation, the Fe3O4 + TAT nanoparticles appeared to destabilize the lysosomal membranes
even more and greater interaction with surrounding mitochondria was observed. Similar lysosomal
escape into the cytosol by nanoparticles conjugated with a cell penetrating peptide or nuclear
localizing signal, such as TAT, has been previously observed (Xu, Xie et al. 2008, Austin, Kang et
al. 2011).

Figure 7.3 Internalization of Uncoated or TAT-conjugated iron oxide nanoparticles by A549 lung
carcinoma, with and without radiation treatment. Scale bars represent 200 nm.
Lysosomal membrane permeabilization is an upstream event in many apoptosis pathways as
destabilization of the lysosomal membranes releases lysosomal contents such as proteolytic
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enzymes (cathepsins, etc.) into the cytosol, which then induce mitochondrial damage by enhancing
the production of superoxide radicals and hydrogen peroxide, further increasing lysosome
permeability, resulting in an amplifying feedback loop (Zhao, Antunes et al. 2003). Acridine
Orange (AO) is a metachromatic fluorophore which gives a distinct red fluorescence at high
lysosomal concentrations and a weakly green fluorescence at low cytosolic concentrations and can
therefore be used to measure lysosomal membrane permeability, with a decrease in the red
fluorescence channel corresponding to an increase in lysosome permeability (Terman, Kurz et al.
2006). This method was used by Domenech et al. to prove that targeted iron oxide nanoparticles
have the ability to disrupt lysosomal membranes via mechanical forces actuated by an alternating
magnetic field (Domenech, Marrero-Berrios et al. 2013). Therefore, AO was used to quantify
lysosomal permeabilization by the Fe3O4 nanoparticle systems with and without radiation. As
shown in Figure 7.4, uncoated Fe3O4 and Fe3O4 + TAT nanoparticles significantly decreased AO
fluorescence compared to the control, but no further decrease was observed with the addition of
radiation. Hydrogen peroxide was used as a positive control and there was no difference between
hydrogen peroxide treatment and Fe3O4 + TAT nanoparticles indicating lysosomal membrane
permeabilization. As previously shown, the TAT peptide on the nanoparticle surface destabilizes
lysosomal membranes due to its highly positive charge (Kornhuber, Henkel et al. 2010). Uncoated
Fe3O4 nanoparticles can catalyze the formation of the hydroxyl radical inside the lysosomes leading
to lysosome membrane destabilization (Guicciardi, Leist et al. 2004, Kirkegaard and Jaattela 2009,
Koenczoel, Weiss et al. 2013). Both Fe3O4 + Dx-ECH and Fe3O4 + Dx-ECH-Amine nanoparticles
have protective coatings on their surfaces preventing the formation of ROS by surface reaction,
which explains why these systems do not result in lysosomal membrane permeabilization.
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Figure 7.4 Normalized acridine orange (AO) fluorescence of A549 lung carcinoma after 2 hour
treatment with Fe3O4 nanoparticle systems with and without radiation. Error bars represent standard
error (n=3) and ** indicates a significant difference from the control (p<0.01) via a two-way
ANOVA.
As previously mentioned, lysosomal permeability and toxicity of iron oxide nanoparticles can
lead to toxic mitochondrial effects. The effects of the combined Fe3O4 nanoparticle treatments with
radiation on mitochondrial function were analyzed using a XF96 Seahorse instrument, which
measures oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) over time.
Figure 7.5 represents the basal respiration associated with A549 lung carcinoma cells following
Fe3O4 nanoparticle treatment with and without 5 Gy radiation treatment. Control A549 cells, which
had not been exposed to Fe3O4 nanoparticles, had significantly increased basal respiration rates
after radiation treatment, which is consistent with previous studies (Yamamori, Yasui et al. 2012).
Uncoated Fe3O4 and Fe3O4 + TAT nanoparticles significantly decreased basal respiration rates
when combined with radiation compared to radiation alone and no increase in respiration was
observed following radiation treatment, indicating that mitochondrial integrity was compromised
by the presence of the nanoparticles. Figure 7.6 represents the maximal respiration levels associated
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with A549 lung carcinoma cells following Fe3O4 nanoparticle treatment with and without radiation.
At the maximal respiration levels, there was a significant interaction between the nanoparticle
system and radiation, indicating that the effects of the nanoparticle system were dependent on
radiation expoure. An increase in respiration rate after radiation treatment was observed in both the
control and Fe3O4+Dx-ECH-Amine nanoparticles. Additionally, the nanoparticle systems
decreased the maximal respiration of the cells compared to the control, both with and without
radiation treatment, indicating that the nanoparticles compromised the integrity of the
mitochondria. Mitochondrial DNA is highly susceptible to damage by ROS and other agents
because it is not as well protected by histones as is nuclear DNA (Hervouet, Simonnet et al. 2007).
Therefore, additional ROS stress by the uncoated Fe3O4 nanoparticles, or ROS stress induced by
release of lysosomal contents, can lead to significant toxicities to the mitochondria.
The overall metabolism of the cells can be depicted by plotting OCR versus ECAR. Figure 7.7
represents the metabolic energy associated with A549 lung carcinoma cells after treatment with
Fe3O4 nanoparticle systems with and without radiation and after FCCP stimulation so the cells were
operating at their total maximal respiration levels. All cells treated with the Fe3O4 nanoparticle
systems only were operating at approximately the same ECAR levels but decreased OCR compared
to the control. The initial decrease in OCR associated with Fe3O4 + TAT nanoparticle treatment
suggests that these nanoparticles can sensitize the cells to subsequent radiation therapy. The cells
treated with both the Fe3O4 + TAT nanoparticles and radiation operated at a significantly lower
energy level than cells treated with nanoparticles alone. This is an indication that cells treated with
Fe3O4 + TAT nanoparticles and radiation do not have the ability to respond to external stimuli, such
as FCCP, indicating a decrease in substrate availability or that mitochondrial mass or integrity has
been compromised (Hill, Benavides et al. 2012, Chacko, Kramer et al. 2014). Previous studies have
shown that various iron oxide nanoparticle systems can adversely affect mitochondrial integrity.
Khan et al. evaluated the effects of iron oxide nanoparticle concentration on the mitochondrial
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membrane potential (MMP) of HeLa cells and found that, with increasing nanoparticle
concentration, the percentage of cells with loss of MMP increased as well (Khan, Mohammad et
al. 2012).

Figure 7.5 Basal oxygen consumption rates of A549 lung carcinoma cells after Fe3O4 nanoparticle
treatment with and without radiation. Error bars represent standard error (n=12). * indicates a
significant difference between the no radiation and radiation treatments within a nanoparticle
system (p<0.05), † indicates a significant difference compared to the control without radiation
(p<0.05) and ‡ indicates a significant difference from the control with radiation (p<0.05), via a
two-way ANOVA with an interaction term.
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Figure 7.6 Maximal oxygen consumption rates of A549 lung carcinoma cells after Fe3O4
nanoparticle treatment with and without radiation. Error bars represent standard error (n=12). *
indicates a significant difference between the no radiation and radiation treatments within a
nanoparticle system (p<0.05), † indicates a significant difference compared to the control without
radiation (p<0.05) and ‡ indicates a significant difference from the control with radiation (p<0.05),
via a two-way ANOVA with an interaction term.
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Figure 7.7 Oxygen consumption rate vs. extracellular acidification rate of A549 lung carcinoma
after exposure to Fe3O4 nanoparticle systems with and without radiation and FCCP stimulation.
Error bars represent standard error (n=12) and ** indicates a significant difference in both OCR
and ECAR from no-radiation Fe3O4 nanoparticle.
Cancer cells are highly sensitive to exogenous ROS inducing agents due to increased inherent
ROS production being associated with oncogenic transformation making the cells highly dependent
upon their antioxidant systems (Huang, Chen et al. 2013, Luo, Li et al. 2015). Therefore, the ROS
production associated with the nanoparticle systems with and without radiation was analyzed. As
shown in Figure 7.8, ionizing radiation treatment alone significantly increased ROS production in
A549 lung carcinoma, and this was further increased by pre-treatment with uncoated Fe3O4, Fe3O4
+ Dx-ECH-Amine and Fe3O4 + TAT at a concentration of 500 µg/mL. Additionally, the Fe3O4 +
TAT increased ROS generation to a significantly greater extent than the other systems. It is
hypothesized that uncoated Fe3O4 nanoparticles increase ROS by surface catalysis of the hydroxyl
radical which is the main form of ROS measured by carboxy-DCF (Cohn, Simon et al. 2008,
Koenczoel, Weiss et al. 2013). Significant work has been completed to link oxidative stress induced
by uncoated iron oxide nanoparticles to nanoparticle toxicity (Ahamed, Alhadlaq et al. 2013,
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Cochran, Wattamwar et al. 2013, Alarifi, Ali et al. 2014, Park, Umh et al. 2014, Luo, Li et al. 2015).
Ahamed et al. and Khan et al. both showed that uncoated iron oxide nanoparticles induced oxidative
stress in A549 lung carcinoma, which increased with increasing concentration and increasing
exposure time (Khan, Mohammad et al. 2012, Ahamed, Alhadlaq et al. 2013). The positive charge
associated with primary amines functionalized to the nanoparticle surface could slightly increase
lysosomal permeability, although this was not observed in the AO studies, resulting in the release
of some lysosomal contents and inducing ROS associated toxicities. Fe3O4 + TAT nanoparticles
destabilized lysosomal membranes and facilitated release of toxic components, as well as the
nanoparticles, which compromised mitochondrial integrity and increased ROS production.
Therefore, ROS generation was significantly increased when radiation was combined with the
Fe3O4 + TAT nanoparticles.

Figure 7.8 Relative carboxy-DCF fluorescence in A549 lung carcinoma following 24 hour
treatment with Fe3O4 nanoparticle systems with and without 5 Gy radiation treatment. Error bars
represent standard error (n=12) and * indicates a significant difference compared to radiation alone
and † indicates a significant difference compared to 500 µg/mL uncoated and 500 µg/mL amine
functionalized Fe3O4 nanoparticles.
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To determine whether the nanoparticle systems combined with radiation treatment had an effect
on cell viability, a long term viability study was completed. A549 cells were treated for 24 hours
with the nanoparticle systems to facilitate uptake, followed by treatment with 5 Gy radiation. Cells
were then re-seeded and allowed to grow for 3, 5 or 7 days post treatment. Figure 7.9 displays the
relative viability of A549 lung carcinoma 3, 5 and 7 days post treatment with Fe 3O4 nanoparticles
alone, radiation alone, and the combined treatment. When combined with radiation, uncoated Fe3O4
nanoparticles resulted in a delayed effect, as only at day 7 was the combined treatment significantly
different from radiation alone. The uncoated Fe3O4 nanoparticles increased lysosomal permeability
and increased intracellular ROS production, but the toxic effects were delayed. The Fe3O4 + DxECH nanoparticles did not significantly enhance the efficacy of radiation treatment. This was
expected as this nanoparticle system did not induce lysosomal permeabilization, decrease
mitochondrial integrity, nor increase ROS generation. The Fe3O4 + Dx-ECH-Amine nanoparticles
did increase the efficacy of radiation treatment in the short term, but the effects did not continue
through the analysis times. This could be due to the Fe3O4 + Dx-ECH-Amine nanoparticles having
the ability to increase ROS generation upon exposure to radiation, but the nanoparticles did not
cause other cellular effects. Therefore, the slight increase in ROS when combined with radiation
by the Fe3O4 + Dx-ECH-Amine nanoparticles was enough to induce increased toxicities in short
time frames, but as the cells continued to grow for the longer time points, they were able to
overcome the toxicities induced by the slight increases in exogenous ROS. Fe3O4 + TAT
nanoparticles significantly enhanced the effect of radiation when cell viability was analyzed 3, 5
and 7 days post treatment, indicating that the Fe3O4 + TAT nanoparticles successfully sensitized
A549 lung carcinoma cells to radiation therapy. Fe3O4 + TAT nanoparticles increased lysosomal
membrane permeabilization, releasing toxic contents into the cytosol, which then compromised
mitochondrial integrity and sensitized the cells to radiation treatment. The efficacy of the combined
treatment was analyzed using a set of equations established by Babincova et al. (Babincova,
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Altanerova et al. 2008). These equations are displayed in Table 7.1, and the calculations for the
Fe3O4 + TAT nanoparticles are shown in Table 7.2. On each day of analysis following treatment,
the combined treatment of Fe3O4 + TAT nanoparticles and radiation therapy on A549 lung
carcinoma was significantly greater than the expected outcome of combining the two treatments,
indicating that it was a synergistic treatment.

Figure 7.9 Relative viability of A549 lung carcinoma 3, 5 or 7 days following a) uncoated b) DxECH c) amine functionalized or d) TAT-conjugated Fe3O4 nanoparticle treatment with and
without 5 Gy radiation. Error bars represent standard error (n=12) and * indicates a significant
difference (p<0.05) via a one-way ANOVA.
Table 7.1 Equations developed by Babincova et al. for analysis of combinational treatments.

Synergistic: [Fe3O4 + Radiation] < [Fe3O4] x [Radiation]/100
Additive:
[Fe3O4 + Radiation] = [Fe3O4] x [Radiation]/100
Sub-additive: [Fe3O4] x [Radiation]/100 < [Fe3O4 + Radiation] < [Fe3O4]; if [Fe3O4] <
[Radiation]
Interference: [Fe3O4] < [Fe3O4+ Radiation] < [Radiation], if [Fe3O4] < [Radiation]
Antagonistic: [Radiation] < [Fe3O4 + Radiation], if [Fe3O4] < [Radiation]
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Table 7.2 Calculations to analyze the effects of combined Fe3O4 + TAT nanoparticles and radiation
treatments. Values represent viability average ± standard error (n=12) on days 3, 5 and 7 post
treatment. * (p<0.05) and ** (p<0.01) indicate a significant difference from the [Fe3O4 +
TAT]x[Radiation]/100 group on the same day.

Day 3
Day 5
Day 7

Fe3O4 + TAT
105.4 ± 4.5
95.6 ± 3.2
90.4 ± 2.0

Radiation [Fe3O4 + TAT]x[Radiation]/100 [Radiation + Fe3O4 + TAT]
86.4 ± 6.1
92.5 ± 9.2
68.7 ± 3.6 *
86.4 ± 4.6
81.8 ± 3.8
66.2 ± 3.4 **
72.6 ± 2.6
65.5 ± 2.4
48.0 ± 2.6 **

7.4 Conclusions
The cell penetrating peptide, TAT, was successfully conjugated to dextran-coated iron oxide
nanoparticles. Electron microscopy of A549 lung carcinoma after uptake of Fe3O4 + TAT
nanoparticles showed the nanoparticles interacting with mitochondria and membrane
destabilization of lysosomes containing Fe3O4 + TAT nanoparticles. Lysosomal permeability was
confirmed and quantified using the AO assay. Both the uncoated Fe3O4 and Fe3O4 + TAT
nanoparticles had the ability to permeabilize lysosomal membranes after cellular uptake due to
ROS generation and the positive charge of the TAT peptide, respectively. Fe 3O4 + TAT
nanoparticles combined with radiation also affected mitochondrial integrity of the cells. When
mitochondria were uncoupled with FCCP, cells that had been previously treated with Fe3O4 + TAT
nanoparticles combined with radiation showed significantly lower capability to meet ATP demands
than the nanoparticle only treatment, indicating a loss of metabolic potential. ROS generation was
also predicted to play a role in the additional toxicities associated with radiation when the cells
were pre-treated with the nanoparticle systems. When combined with radiation, uncoated Fe 3O4,
Fe3O4 + Dx-ECH-Amine, and Fe3O4 + TAT nanoparticles significantly increased ROS production
compared to radiation alone in A549 lung carcinoma. Due to this increase in ROS generation, in
lysosomal permeability, and the loss of mitochondrial integrity and function, the combined
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treatment of Fe3O4 + TAT nanoparticles and radiation resulted in a synergistic decrease in cell
viability.

Copyright © Anastasia Kruse Hauser 2016
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Chapter 8 Conclusions
In this dissertation, peptide-conjugated iron oxide magnetic nanoparticles were synthesized,
characterized, and evaluated for their cancer therapy applications via magnetically mediated
hyperthermia, intra-cellular localized energy delivery, and catalysis of reactive oxygen species.
Both magnetically mediated hyperthermia and intra-cellular localized energy delivery rely upon
the ability of the magnetic nanoparticles to respond to an alternating magnetic field, while catalysis
of reactive oxygen species generation utilizes the capability of the nanoparticles to catalyze the
Haber-Weiss reaction via Fenton chemistry. First, an iron oxide nanoparticle system conjugated
with a tumor-homing peptide, CREKA, was developed for magnetically mediated hyperthermia
treatment of A549 lung carcinoma. The physicochemical properties of the nanoparticle system were
fully characterized and revealed their ability to target tumor extracellular matrix components and
generate sufficient heat to induce hyperthermia conditions. Additionally, in a proof-of-concept
study, magnetically mediated hyperthermia was combined with a chemotherapeutic, cisplatin, and
the combined treatment resulted in an additive toxic effect.
Although the heating properties of the previously developed magnetic nanoparticles were
sufficient to induce hyperthermia conditions, their specific absorption rate was significantly lower
than other magnetic nanoparticle systems reported in literature. Therefore, the method of
synthesizing dextran-coated iron oxide magnetic nanoparticles was altered, as it was determined
that the time of dextran addition into the synthesis reaction dramatically changed the
physicochemical properties of the magnetic nanoparticles. By manipulating the synthesis
conditions, it was demonstrated that nanoparticles could be formed with various size, stability, and
crystallinity properties for biological applications.
After improving the synthesis method of dextran-coated iron oxide nanoparticles, the magnetic
nanoparticles were functionalized with a cell penetrating peptide, TAT, to increase the intracellular
concentration of the magnetic nanoparticles. This magnetic nanoparticle system was used to locally
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deliver energy upon activation by a magnetic field. It was demonstrated that TAT-functionalization
to the magnetic nanoparticles increased cell uptake by A549 and H358 lung cancer cell lines and
permeabilized lysosomal membranes, sensitizing the cells to the damaging effects of localized
energy delivery upon exposure to an alternating magnetic field. Although not statistically
significant, there was an observable trend illustrating increasing apoptosis when lung cancer cells
were treated with the TAT-functionalized magnetic nanoparticles and an alternating magnetic field
compared to the nanoparticles alone.
The last portion of this dissertation evaluated the intracellular effects of TAT-functionalized
iron oxide nanoparticles combined with radiation on lung cancer cells. Studies indicated that the
TAT-functionalized nanoparticles sensitized the cells to further treatment with radiation by
permeabilizing lysosomal membranes, damaging mitochondrial integrity, and catalyzing
production of the highly reactive hydroxyl radical. While the TAT peptide can also serve as a
nuclear localizing signal, electron microscopy images indicated that the targeted magnetic
nanoparticles were located within destabilized lysosomes or in the cytoplasm, but at significantly
greater concentrations than uncoated nanoparticles. Future work in this area should focus on
targeting the magnetic nanoparticles to specific organelles such as the mitochondria or the nucleus
in an effort to enhance nanoparticle effects and associated therapy.
8.1 Significant Findings
There are several findings in this work that contribute to the scientific community’s
understanding of peptide-functionalized iron oxide nanoparticles for cancer therapy applications.
Research in magnetically mediated hyperthermia for cancer therapy has grown significantly over
the past decade with minimal clinical translation. Magnetically mediated energy delivery is a
growing alternative to magnetically mediated hyperthermia, so this research directly impacts an
important aspect of magnetic nanoparticle research. Although this work was specific to cancer
therapy, there are a wide variety of other biological and environmental remediation applications.
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Dextran-coated iron oxide magnetic nanoparticles can be synthesized by a one-pot coprecipitation method and have properties consistent with those required for tumor targeting
in vivo.



CREKA-conjugated magnetic nanoparticles can be used for magnetically mediated
hyperthermia treatment of lung cancer and combination with cisplatin results in an additive
effect.



Timing of dextran addition to the synthesis reaction of dextran-coated iron oxide
nanoparticles significantly effects the physical and chemical properties of the material
likely due to the viscosity of the dextran solution retarding crystal growth.



Functionalization of the cell penetrating TAT peptide to iron oxide nanoparticles increases
the intracellular iron concentration within lung cancer cells.



Internalized, TAT-functionalized iron oxide nanoparticles increases reactive oxygen
species production within lung cancer cells upon exposure to an alternating magnetic field
and increased lysosomal permeability.



Although not statistically significant, trends were observed that suggest an increase in cell
apoptosis when the TAT-functionalized iron oxide nanoparticle system is combined with
alternating magnetic field treatment.



When combined with radiation, TAT-functionalized iron oxide nanoparticles significantly
increase reactive oxygen species production compared to radiation alone in A549 lung
carcinoma.



Treatment with TAT-functionalized iron oxide nanoparticles and radiation significantly
reduces the metabolic energy of lung cancer cells indicating compromise of mitochondrial
integrity or a decrease in substrate availability.



Dual treatment with TAT-functionalized iron oxide nanoparticles and radiation results in a
synergistic therapy for A549 lung carcinoma.
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Appendix A Combination treatment of multi-cellular tumor spheroids
In this study, multicellular tumor spheroids were fabricated and used to analyze the effects of
anti-cancer treatments as three-dimensional models more accurately represent avascular tumors in
vivo compared to traditional monolayer cell cultures. The main limitation of using multicellular
tumor spheroids as a screen for treatment efficacy is the difficulty in analyzing spheroid viability
via a high throughput assay. Therefore, in this study, three viability assays were screened for
accuracy in determining spheroid viability. A single assay was then selected to evaluate the efficacy
of radiation and chemotherapy combined with hyperthermia treatment. This work was completed
in conjunction with Kendall Huddleston Murphy, Jonathan Colburn, and Sarah Patterson as a part
of the NSF Research Experience for Undergraduates at the University of Kentucky.
A.1 Introduction
Monolayer cell cultures have been the traditional form of in vitro screening for drugs and novel
therapies. However, 2-dimensional (2D) cultures lack many of the physiological properties of cells
in vivo. In vivo, cells reside in a 3-dimentional (3D) matrix complete with an extracellular matrix
(ECM) made up of various macromolecules (collagens, proteoglycans, and laminin). 2D cell
cultures grown on slides coated with substrata do not form an extra-cellular matrix, leading to
several drawbacks of monolayer cultures: 1. lack of molecular gradients which play a vital role in
cell differentiation, determination of cell fate, and signal transduction, 2. alterations in gene
expression patterns and metabolism, and 3. morphological and phenotypic changes due to altering
production of their own ECM proteins (Hutmacher, Horch et al. 2009). 3D cell cultures can be used
to better mimic tumor cell growth and responses to drugs and therapies to in vivo tumors.
Multicellular tumor spheroids (MCTS) 200-500 µm in diameter mimic avascular tumors in that
they have diffusion limitations of oxygen and other nutrients resulting in a proliferation gradient: a
necrotic core surrounded by a layer of quiescent cells, followed by a viable outer rim (Mueller-
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Klieser, Vaupel et al. 1987). Diffusion limitations out of the spheroid result in waste accumulation
within the core of the spheroid and contribute to the necrotic core.
Physical properties of MCTS also hinder drug penetration. Nirmalanandhan et al. reported cellline dependent differences in response to multiple drugs between spheroid and monolayer cell
cultures (Nirmalanandhan, Duren et al. 2010). The proximity of cells as well as the presence of an
extracellular matrix in MCTS is thought to effect MCTS response to various treatments as well
(Minchinton and Tannock 2006). Due to these characteristics and suitability for high throughput
studies, MCTS have been applied in various cancer therapy studies. Khoei et al. reported superior
hyperthermic resistance of spheroids compared to cell monolayers in DU 145 human prostate
carcinoma cells (Khoei, Goliaei et al. 2004) and interestingly enough, Yamauchi et al. demonstrated
the opposite result in HT29 colon adenocarcinoma cells with different experimental methods
(Yamauchi, Asao et al. 2011). Senavirathna et al. successfully applied a MCTS model to study the
effects of proton beam radiotherapy and doxorubicin-loaded temperature-sensitive liposomes
(Senavirathna, Fernando et al. 2013).
Coinciding with the increased complexity of MCTS culture, is increased difficulty of analysis.
For example, many traditional analysis techniques used in monolayer cell culture studies cannot be
applied for MCTS analysis due to assay penetration limitations. Variability in spheroid
compactness and shape can also affect results. A popular method of analyzing MCTS is to measure
volume over time (Friedrich, Ebner et al. 2007). Other studies dissociate the spheroids and either
analyze the dissociated cells directly (Ivascu and Kubbies 2006, Mattix, Olsen et al. 2014), or apply
a colony formation assay to analyze the ability of the cells to replicate (Khoei, Goliaei et al. 2004,
Yamauchi, Asao et al. 2011). However, the dissociation process is labor-intensive and can cause
damage or a decrease in the cell population (Friedrich, Ebner et al. 2007). Neither of these methods
provides a basis for determining the viability of intact MCTS. Thus, viability assays appropriate to
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MCTS culture must be further developed and validated to increase MCTS use as a translational
research method.
Hyperthermia, the heating of tissue to 41 - 45 ˚C, induces cell apoptosis, or controlled cell
death, primarily by denaturing nucleolic, cytoplasmatic, or membrane proteins. In vitro tumor cells
do no exhibit hyperthermia sensitivity compared to healthy cells however, in vivo, tumor tissue is
particularly sensitive to hyperthermia treatment due to properties such as hypoxia and low pH levels
(Issels 2008). At temperatures above the hyperthermia range, cell death occurs through necrosis
with lower selectivity between healthy and tumor tissues (Hildebrandt, Wust et al. 2002). However,
high temperatures are difficult to achieve in vivo and are generally avoided in clinical application
due to the negative effects of necrosis.
Hyperthermia has been previously demonstrated to interact synergistically with radiation and
chemotherapy but hyperthermia treatment alone has proved insufficient to result in major effects
(Wust, Hildebrandt et al. 2002, Issels 2008). In combination with chemotherapy, hyperthermia is
generally most effective when administered simultaneously with drug administration. Mechanisms
involved in the interaction between hyperthermia and drugs include increase of blood flow,
vascular permeability, and cellular membrane fluidity, all of which enable increased tumor and
cellular uptake of drug (Issels 2008). Hyperthermia can also increase the reaction rate of the drug
with the cellular target (Halamikova, Vrana et al. 2007) and has been used to overcome drug
resistance in some cell lines (Hildebrandt, Wust et al. 2002).
When combined with radiation therapy, hyperthermia has been shown to decrease the repair
rate of sub-lethal DNA strand break, and therefore increase the efficacy of radiation. In vivo, mild
hyperthermia treatment increases tumor oxygenation by increasing blood perfusion to the tumor
and therefore increasing reactive oxygen species production upon radiation treatment. On the
contrary, studies have indicated that physical clamping or the use of physiological modifiers to
reduce blood flow to the tumor can enhance the efficacy of hyperthermia by reducing the
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convective cooling effects (Overgaard and Nielsen 1980). The results of radiation combined with
hyperthermia studies vary greatly and are also highly dependent on cell line, order of treatment,
and tumor size. A study completed by Sapareto et al. showed that timing of irradiation and thermal
therapy has dramatic effects on the efficacy of the combined treatment and is also cell line
dependent. Irradiating HA-1 cells immediately prior to thermal therapy had the greatest toxic effect,
while the opposite was true for EMT6 cells. Therefore, the consensus is that thermal therapy during
radiation treatment is most effective (Sapareto, Raaphorst et al. 1979). Larger tumors have been
shown to be more sensitive to the combined therapy compared to smaller tumors due to having a
higher cell population of radio resistant, yet heat sensitive cells (Vaupel, Kallinowski et al. 1989).
Despite some success in clinical application, hyperthermia therapy faces several key
challenges. Due to lack of heat perfusion and the deep location of metastatic tumors, conventional
hyperthermia methods such as water baths, microwaves, radiotherapy, and limb perfusion make it
difficult to target to tumor tissue without harming healthy tissue. Additionally, hyperthermia
temperatures may be difficult to reach and maintain for sufficient time periods (Wust, Hildebrandt
et al. 2002). A relatively new hyperthermia treatment, magnetically-mediated hyperthermia
(MMH), also known as magnetic fluid hyperthermia, utilizes magnetic nanoparticles in the
presence of an alternating magnetic field (AMF) to locally generate heat. Upon activation by an
AMF, magnetic nanoparticles convert the field energy into heat through Brownian rotation and
Néel paramagnetic switching. Because an AMF can be applied with minimal effect on bodily
tissue, MMH is a promising alternative to current hyperthermia treatments (Laurent, Dutz et al.
2011). A clinical trial by Maier-Hauff et al. demonstrated the feasibility of intracranial MMH using
aminosilane coated iron oxide nanoparticles and a sophisticated dosing software (Maier-Hauff,
Rothe et al. 2007).
There has been significant progress in MMH research (see Chapter 3), but with limited clinical
translation due to the lack of consistency between in vitro studies, preliminary in vivo studies, and
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clinical trials. By applying the MCTS model to MMH studies at the in vitro screening stage, it
should enable a more thorough screening of MMH techniques compared to cell monolayers. First,
however, a standard protocol for analysis must be developed in order to use MCTS to try to bridge
the gap between in vitro and in vivo studies. Specifically, an assay is needed that will accurately
report spheroid viability in a high throughput manner.
The first objective of this study was to evaluate the efficacy and consistency of selected
viability assays on A549 lung carcinoma MCTS. Three viability assays were selected: resazurin,
acid phosphatase (APH), and calcein AM/ethidium homodimer-1. Based on experiments by
Friedrich et al., it was expected that the APH assay would provide an accurate and consistent
method for assaying the A549 lung carcinoma MCTS (Friedrich, Eder et al. 2007). Assays were
investigated for accuracy and consistency by varying the number of MCTS analyzed as well as the
seeding density of spheroids assayed. The effect of spheroid dissociation was also analyzed for
each assay. Secondly, a feasible assay was chosen for a proof of concept study to demonstrate the
interaction between cisplatin (CDDP), a common chemotherapeutic, and hyperthermia in the
MCTS model. The third objective combined radiation therapy with hyperthermia treatment on
MCTS in a proof of concept study.
A.2 Materials and Methods
A.2.1 Materials
Fetal bovine serum (FBS) and Type 1 rat tail collagen were obtained from Fisher Scientific
(Florence, KY), and Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine,
Fungizone®, sodium pyruvate, calcein AM, and ethidium homodimer-1 were obtained from
Invitrogen (Grand Island, NY). Trypsin (0.25% trypsin/0.53 mM EDTA) and A549 lung cancer
cells were purchased from American Type Culture Collection (Manassas, VA). Nunc Sphera 96well plates and p-nitrophenyl phosphate (pNPP), disodium salt, were obtained from Thermo
Scientific (Rochester, NY). Sodium acetate trihydrate, resazurin, and cisplatin were purchased
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from Sigma Aldrich (St. Louis, MO). Phosphate buffered saline solution (PBS) was obtained from
EMD Millipore (Billerica, MA).
A.2.2 Cell culture
Cell culture media was prepared by adding 10% FBS, 1 mM sodium pyruvate, 4 mM L-glutamine,
pen-strep (100 U/mL penicillin and 100 µg/mL streptomycin), and 10 μg/ml Fungizone ® to 500
mL DMEM. The media mixture was sterile filtered. A549 lung carcinoma cells were cultured
between passages 4 and 24.
A.2.3 MCTS formation
A549 cells were seeded at 50,000 cells/mL (unless otherwise specified) at 100 µL/well into Nunc
Sphera 96-well plates and collagen was added to the cell solution at a concentration of 20 µg/mL
to aid spheroid formation. The round bottom 96-well plates were centrifuged at 1250 rpm for 15
min to aggregate the cells. Cells were incubated to allow spheroid compaction and growth at 37 ˚C
and 5% CO2 for 48 hours. Figure A.1 depicts the MCTS formation process over time.

Figure A.1 Chronological images of three different A549 MCTS during formation.
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A.2.4 MCTS dissociation
Plates were centrifuged for 5 min at 1250 rpm, and 140 µL per well of supernatant was carefully
removed. 0.25% trypsin-EDTA was diluted with PBS to obtain 0.1% trypsin and 160 µL was
added per well. Plates were again centrifuged and 160 µL of supernatant was replaced with 0.1%
trypsin. Spheroids were disassociated in wells by rapid pipetting and immediately returned to
incubator. Disassociation via shear stress was repeated five times (every 20 min) and if spheroids
were not yet dissociated, further shear stress was applied with a 20-guage needle. Cell suspensions
were transferred to a well plate coated for regular cell culture to avoid re-aggregation and the trypsin
was neutralized with cell culture media.
A.2.5 Acid phosphatase assay
Plates were centrifuged and supernatant was replaced with PBS due to potential interference of cell
culture media with APH signal (amount of supernatant replaced was adjusted based on
corresponding volumes and wells). Plates were centrifuged again, and supernatant was removed
to obtain half the desired volume. The desired volume was obtained by adding APH buffer (0.1 M
sodium acetate, 0.1% (v/v) Triton X-100, and 8 mg/mL pNPP in deionized water before dilution;
use 2 mg/mL pNPP for dissociated cells). Spheroids were incubated with APH buffer (final
concentrations of 4 mg/mL and 1 mg/mL for MCTS and dissociated MCTS, respectively) for 6 h
and dissociated cells for 90 min. Plates were placed on an incubator shaker for the initial and final
15 min of incubation. After the incubation period, the absorbance of the wells was read at 405 nm
by a Biotek SynergyMx microplate reader.
A.2.6 Resazurin assay
Resazurin (10 mM) was added to each well for a 10% (v/v) solution. Plates were incubated for 6
h at 37 ˚C to allow resazurin to be metabolized. The plates were placed on an incubator shaker for
the initial and final 15 min of this period. The fluorescence of each well was read by a Biotek
SynergyMx microplate reader at an excitation of 530 nm and an emission of 590 nm.
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A.2.7 Calcein AM/Ethidium homodimer-1 (live/dead) assay
Two spheroids per treatment group were transferred with 200 µL media per spheroid to a 12-well
plate. One row was filled with 400 µL of media to obtain background fluorescence. PBS was
supplemented with 2 µM calcein AM and 4 µg/mL ethidium homodimer-1 before addition at 400
µL/well. Plates were incubated for 1 h. Following incubation, one live and one dead image per
spheroid were obtained and combined using a Nikon Eclipse LV 100 microscope. The first control
spheroid was used to focus the microscope and to set auto-exposure times, which remained
consistent throughout the imaging process. This first spheroid was not included in the data, and all
other images were obtained within 5 s to prevent bleaching of fluorescence. Mean intensity values
of images were exported for data analysis.
Dissociated spheroids were transferred to a 96-dark-well plate as described in the dissociation
procedure; each dissociated spheroid was transferred to a different well. Cells were allowed to
attach and to grow for 48 h, at which point media was removed from wells. PBS supplemented
with 2 µM calcein was added at 100 µL. After 25 min incubation, mean relative fluorescence values
were obtained by a Biotek SynergyMx microplate reader using an area scan (ex: 495/em: 515 nm).
After reading fluorescence values, qualitative images were also obtained as described above.
A.2.8 Assay validation studies
The APH and resazurin assays were tested for response to varying numbers of spheroids. Between
one and five spheroids were transferred to each well of a 48-well plate and excess media was
removed to a final volume of 200 µL/well. The remainder of the APH assay was completed as
described above, with the exception that the spheroids were only incubated for 90 min. For the
resazurin assay, between one and five spheroids were transferred to a 48-well plate with 100 µL
media/spheroid; additional media was added as necessary to reach a final volume of 500 µL in all
wells. Then the resazurin assay was carried out as described above. For all viability assays, the
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appropriate background samples were prepared to correct for background absorption and
fluorescence.
The APH and resazurin assays were also tested for response to varying seeding density of
spheroids. MCTS were seeded at concentrations between 2,500 and 15,000 cells per spheroid and
were allowed to grow for 24 h before performing APH and resazurin assays.
All assays were applied to MCTS treated with 0, 20, and 2000 µM CDDP dissolved in media for
72 h. These concentrations were chosen because they represent a concentration near and a
concentration far greater than the IC50. Following 72 h of incubation, some spheroids were
dissociated, and APH, resazurin, and live/dead assays were performed on intact and dissociated
spheroids. All values were normalized to the average value of the controls not treated with CDDP.
And for ethidium staining, reported values are one less than the normalized values to give the
controls a relative cell death of zero.
A.2.9 Incubator-induced hyperthermia with CDDP
After 48 h of growth, MCTS were treated with CDDP in media at concentrations between 0 and
2000 µM. Immediately following the addition of CDDP, half of the spheroids in each treatment
group were returned to an incubator at 37 ˚C while the remaining spheroids were placed in an
incubator set to 43 ˚C. In order to efficiently raise well temperature, the well plate was placed on
a hot pad resting on a hot plate set to 60 ˚C. When the well temperature reached 43 ˚C, the well
plate was removed from the hot pad and maintained between 42.5 and 43 ˚C. The well plate
remained in the incubator for 30 min after reaching 41.5 ˚C, which was deemed the effective
starting point of hyperthermia treatment. The temperature was continuously monitored through the
use of a fiber optic temperature sensor (Luxtron FOT Lab Kit from LumaSense) inserted into a
central well through a small hole drilled through a well plate lid. After hyperthermia treatment, the
well plate was returned to an incubator at 37 ˚C. IC50 values and regression curves were obtained
using SigmaPlot to fit the data to a four parameter logistic curve.
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A.2.10 Incubator induced hyperthermia with radiation
Following the 48-hour growth period, MCTS were subjected to gamma irradiation. A cesium-137
irradiator was used to administer doses of 0, 2, 4, and 6 Gy at room temperature. Immediately
following radiation, a subset of the irradiated spheroids were exposed to hyperthermia. The time
delay between treatments could not be reduced to less than 15 minutes due to differing treatment
locations. In order to efficiently raise well temperature, the well plate was placed on a hot pad
resting on a hot plate set to 60 ˚C. When the well temperature reached 43 ˚C, the well plate was
removed from the hot pad and maintained between 42.5 and 43 ˚C. The well plate remained in the
incubator for 60 min after reaching 41.5 ˚C, which was deemed the effective starting point of
hyperthermia treatment. The temperature was continuously monitored through the use of a fiber
optic temperature sensor (Luxtron FOT Lab Kit from LumaSense) which was inserted into a central
well through a small hole drilled through a well plate lid. After hyperthermia treatment, the well
plate was returned to an incubator at 37 ˚C. Viability was analyzed 5 and 7 days post-treatment
using the APH assay and live/dead assay as previously described.
A.3 Results and discussion
A.3.1 MCTS assay validation
Spheroids were analyzed by the APH and resazurin assays and the number of spheroids per
well varied from one to five. The response of the assay to this setup can indicate the consistency in
signal generation of the assay for a single spheroid as well as its ability to handle increasingly large
quantities of cells. Results are portrayed in Figure A.2 and R2 values are given for each assay based
on linear regression of the data. The live/dead assay was not applied in this study due to the
difficulty of obtaining images that encompass all the spheroids in a given well. Although neither
assay responded linearly, the APH assay displayed a clearer trend compared to the resazurin assay.
It could be suggested that the APH assay responded in an exponential manner to increasing number

163

of spheroids however, this was deemed unlikely as the signal is expected to follow a logarithmic
rather than exponential increase in signal at sufficiently high numbers of spheroids.

Figure A.2 Results of APH and resazurin assays of wells containing one to five MCTS after 24
hours of formation. Bars represent standard error (n≥3).
The APH and resazurin assays were further validated by varying MCTS seeding density in
order to conclude whether the assay effectively penetrated spheroids and to determine how spheroid
size affected assay results. In the case of perfect penetration of an entirely viable spheroid, the
assay would respond linearly to an increase in seeding density. If the assay does not penetrate
beyond the spheroid surface, the assay response would be expected to resemble a fractional power
curve. In reality, the response is likely to lie somewhere in between due to the growth of the
spheroids after seeding, death of innermost cells and imperfect penetration of the assay. As
demonstrated in Figure A.3, no substantial difference in trend was observed between the APH and
resazurin assays. Wells seeded with 2,500 cells per well did not form spheroids but remained
largely dispersed throughout the wells. Interestingly, the average fluorescence returned by the
resazurin assay of these wells far exceeded all the values for formed spheroids, whereas the average
absorbance returned by the APH assay fell below the linear trend. This indicates a much stronger
response of resazurin than pNPP to dissociated cells. If this is the case, minor imperfections in
spheroid formation could affect the resazurin assay more strongly than the APH assay.
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Figure A.3 Results of APH and resazurin assays of spheroids seeded at various densities and grown
for 24 hours. Bars represent standard error (n≥4).
In validation studies with CDDP, there was no accurate standard for determining the response
of A549 MCTS to varying concentrations of CDDP. Instead, simply a reasonable decrease in
viability due to CDDP treatment was expected. Spheroid dissociation was used to compare
response of the assay to tightly packed and dispersed cells, since each assay used is generally
accepted as accurate in cell monolayers. Each treatment was normalized to the control to give the
relative viability. Results are given in Figure A.4. The APH assay returned consistent relative
viability results between intact and dissociated spheroids after exposure to 20 or 2000 µM CDDP.
The resazurin assay presented large discrepancies between intact and dissociated spheroids at the
same CDDP concentration suggesting that its use for MCTS analysis is limited.
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Figure A.4 APH and resazurin assays of intact and dissociated spheroids, and calcein assay of
dissociated spheroids. Dissociation and assay were performed following 72 hours of treatment
with CDDP. Each group was separately normalized to its own control. Bars represent standard
error (n≥5).
The live/dead assay of intact spheroids was displayed separately in Figure A.5. The calcein
AM stain of intact spheroids indicated no trend in viability in response to CDDP, suggesting that it
is a poor indicator of spheroid viability. The ethidium stain of intact spheroids demonstrated a
reasonable trend however, relative cell death cannot be directly compared with relative viability.
As demonstrated by the upper row of Figure A.6, the images associated with the live/dead assay
provide a useful means of qualitative analysis of spheroid response to treatment. Besides a general
trend in viability, these images suggested that 20 µM CDDP inhibits growth of the spheroid and
2000 µM CDDP was strong enough to begin to disperse cells, causing the spheroid to appear larger
than after 20 µM CDDP treatment.
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Figure A.5 Live/dead assay of intact spheroids, performed following 72 hours of treatment with
CDDP. Each group was separately normalized to its own control. Bars represent standard error
(n≥5).

Figure A.6 Representative images of intact spheroids stained with calcein AM and ethidium
homodimer-1 (upper), and of dissociated spheroids stained with calcein AM (lower). Staining was
performed after 72 hours of treatment with CDDP for intact spheroids and an additional attachment
period of 48 hours preceded stain of dissociated spheroids. Scale bars represent 200 µm.
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A.3.2 Cisplatin combined with hyperthermia on MCTS
Based on the consistency of the APH assay and on its ease of application, this assay was chosen
for a proof of feasibility study investigating the interaction between incubator-induced
hyperthermia and CDDP (Figure A.7). CDDP has been previously shown to be more effective
when administered at elevated temperatures (Urano, Kuroda et al. 1999) and a sigmoidal response
with increasing concentration of CDDP has been previously observed on monolayer cell cultures.
This same trend was observed for MCTS treated with CDDP with and without 30 minutes of
hyperthermia. The IC50 value, the concentration of CDDP that results in 50% cell death, was
compared to CDDP alone with the combined treatment. A decrease in the IC50 value from 54 to
34 µM was observed upon application of hyperthermia with CDDP on A549 MCTS. Live/dead
images obtained in parallel with this experiment confirm qualitatively that a sharp decrease in
viability was observed at about 40 µM CDDP. However, this study was completed as a single trial
(n≥5) and should be repeated to assess consistency of the treatment.
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Figure A.7 Relative viabilities of MCTS treated with varying concentrations of CDDP for 72 hours
with and without hyperthermia for 30 minutes at 43 ˚C immediately following CDDP exposure.
Error bars represent standard error (n≥5). Corresponding live/dead images and IC50 values are
included.
A.3.3 Radiation combined with hyperthermia on MCTS
The third objective of this study was to analyze the effects of radiation combined with
hyperthermia treatment on A549 MCTS. Various radiation treatments of 0, 2, 4, and 6 Gy were
dosed to MCTS, and following radiation exposure half of the MCTS were treated with 60 minutes
of incubator-induced hyperthermia. Normalized viability was determined by the APH assay and
live/dead staining 5 and 7 days following treatment. Both 5 and 7 days post treatment, radiation
treatment alone effected the relative viability of A549 MCTS however, hyperthermia treatment did
not further decrease the relative viability of the MCTS (Figures A.8 and A.11). Additionally, upon
analysis of the reported dead fluorescence values, there was a greater increase in dead fluorescence
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as radiation treatment increased, but no additional enhancement was observed by hyperthermia
treatment (Figures A.9 and A.12).
Analyzing MCTS viability as well as the relative dead fluorescence, there was no difference
between the control and hyperthermia treatment alone. This is consistent with previous studies
suggesting that hyperthermia is not powerful enough by itself to effectively treat cancer. Traditional
monolayer studies suggest that hyperthermia combined with radiation does often result in a
synergistic effect (Horsman and Murata 2002) however, this was not observed when treating
MCTS. Radiation was combined with hyperthermia to treat MCTS because MCTS work to bridge
the gap between traditional monolayer cell culture and in vivo animal studies. Most traditional
monolayer cell culture used with hyperthermia in literature administer a single treatment of
hyperthermia. Since the MCTS are more representative of in vivo studies, the protocols may need
to be altered to better represent treatments which would be administered in vivo, such as
fractionated radiation. By fractionating the radiation dosage and exposing the MCTS to cyclic
hyperthermia treatments, a synergistic therapy may result however, significant optimization needs
to occur.

Figure A.8 Relative viability of A549 lung carcinoma 5 days after radiation treatment (0, 2, 4, 6
Gy) with and without 60 minutes incubator induced hyperthermia, measured using APH assay.
Error bars represent standard error (n=9).
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Figure A.9 Relative dead fluorescence of A549 lung carcinoma MCTS 5 days after radiation
treatment (0, 2, 4, 6 Gy) with and without 60 minutes incubator induced hyperthermia. Error bars
represent standard error (n=6).

Figure A.10 Live/Dead images of A549 MCTS 5 days following radiation treatment with and
without hyperthermia exposure.
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Figure A.11 Relative viability of A549 lung carcinoma 7 days after radiation treatment (0, 2, 4, 6
Gy) with and without 60 minutes incubator induced hyperthermia, measured using APH assay.
Error bars represent standard error (n=9).

Figure A.12 Relative dead fluorescence of A549 lung carcinoma MCTS 7 days after radiation
treatment (0, 2, 4, 6 Gy) with and without 60 minutes incubator induced hyperthermia. Error bars
represent standard error (n=6).
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Figure A.13 Live/Dead images of A549 MCTS 7 days following radiation treatment with and
without hyperthermia exposure.
A.4 Conclusions
Cancer therapy research using MCTS poses significant challenges due to difficulty in analyzing
the MCTS post treatment. However, there are significant benefits to utilizing MCTS for analysis
prior to expensive in vivo studies as MCTS more accurately represent physiological conditions
compared to monolayer cell cultures. In this work, three assays were analyzed to determine the
most consistent and accurate analysis method of MCTS viability. The APH assay appeared to be
more consistent and accurate at determining the relative viability of MCTS compared to the
resazurin assay. Although the live/dead assay was not studied as extensively as the APH and
resazurin assays, it was determined that due to the associated costs, time sensitivity, and labor
intensity, the live/dead assay is not suitable for use in high throughput studies but rather provides
images as a verification of results obtained by other assays. Although several previous studies
involving MCTS perform a viability assay after dissociation of spheroids, this option is impractical
for high throughput due the level of associated labor. Additionally, the dissociation process
provides significant opportunity for inconsistency in working volumes and may cause damage or
loss of cells.
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After determining the appropriate viability assay, two proof of concept studies were completed
to analyze the effects of hyperthermia combined with chemotherapy or radiation on A549 lung
carcinoma MCTS. When cisplatin was combined with 30 minutes of incubator-induced
hyperthermia, the IC50 value decreased, suggesting that the combined treatment was more effective
than the CDDP alone. When radiation was combined with 60 minutes of incubator hyperthermia
on MCTS, there was no enhancement of radiation therapy. This could be due to a variety of reasons
including the cell line, hyperthermia time and temperature, delay between radiation and
hyperthermia treatment, order of the treatments, etc. Previous work has indicated the variability in
treatment efficacy by combining hyperthermia and radiation and this study further confirms these
results. Future work with MCTS and hyperthermia should address magnetically mediated
hyperthermia in combination with a chemotherapeutic. MCTS would allow for evaluation of
nanoparticle uptake and penetration into the spheroid as well as analysis of the effects of
magnetically mediated hyperthermia on an in vitro three-dimensional model.

Copyright © Anastasia K Hauser

174

References
Abakumov, M., N. V. Nukolova, M. Sokolsky-Papkov, S. A. Shein, T. O. Sandalova, H. M.
Vishwasrao, N. F. Grinenko, I. L. Gubsky, A. M. Abakumov, A. V. Kabanov and V. P. Chekhonin
(2015). "VEGF-targeted magnetic nanoparticles for MRI visualization of brain tumor."
Nanomedicine-Nanotechnology Biology and Medicine 11(4): 825-833.
ACS (2013). Cancer Facts and Figures, American Cancer Society.
Agemy, L., K. N. Sugahara, V. R. Kotamraju, K. Gujraty, O. M. Girard, Y. Kono, R. F. Mattrey,
J.-H. Park, M. J. Sailor, A. I. Jimenez, C. Cativiela, D. Zanuy, F. J. Sayago, C. Aleman, R. Nussinov
and E. Ruoslahti (2010). "Nanoparticle-induced vascular blockade in human prostate cancer."
Blood 116(15): 2847-2856.
Ahamed, M., H. A. Alhadlaq, J. Alam, M. Khan, D. Ali and S. Alarafi (2013). "Iron Oxide
Nanoparticle-induced Oxidative Stress and Genotoxicity in Human Skin Epithelial and Lung
Epithelial Cell Lines." Current Pharmaceutical Design 19(37): 6681-6690.
Ahamed, M., H. A. Alhadlaq, M. A. M. Khan and M. J. Akhtar (2013). "Selective killing of cancer
cells by iron oxide nanoparticles mediated through reactive oxygen species via p53 pathway."
Journal of Nanoparticle Research 15(1).
Alarifi, S., D. Ali, S. Alkahtani and M. S. Alhader (2014). "Iron Oxide Nanoparticles Induce
Oxidative Stress, DNA Damage, and Caspase Activation in the Human Breast Cancer Cell Line."
Biological Trace Element Research 159(1-3): 416-424.
Alvarez-Berrios, M. P., A. Castillo, J. Mendez, O. Soto, C. Rinaldi and M. Torres-Lugo (2013).
"Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an
increase in cell membrane fluidity." International Journal of Nanomedicine 8: 1003-1013.
Alvarez-Berríos, M. P., A. Castillo, J. Mendéz, O. Soto, C. Rinaldi and M. Torres-Lugo (2013).
"Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an
increase in cell membrane fluidity." International Journal of Nanomedicine 8: 1003-1013.
Alvarez-Berrios, M. P., A. Castillo, F. Merida, J. Mendez, C. Rinaldi and M. Torres-Lugo (2015).
"Enhanced proteotoxic stress: one of the contributors for hyperthermic potentiation of the
proteasome inhibitor bortezomib using magnetic nanoparticles." Biomaterials Science 3(2): 391400.
Alvarez-Berrios, M. P., A. Castillo, C. Rinaldi and M. Torres-Lugo (2014). "Magnetic fluid
hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines."
International Journal of Nanomedicine 9: 145-153.
Amin, M. L., J. Y. Joo, D. K. Yi and S. S. A. An (2015). "Surface modification and local
orientations of surface molecules in nanotherapeutics." Journal of Controlled Release 207: 131142.
Amstad, E., J. Kohlbrecher, E. Mueller, T. Schweizer, M. Textor and E. Reimhult (2011).
"Triggered Release from Liposomes through Magnetic Actuation of Iron Oxide Nanoparticle
Containing Membranes." Nano Letters 11(4): 1664-1670.

175

Amstad, E., M. Textor and E. Reimhult (2011). "Stabilization and functionalization of iron oxide
nanoparticles for biomedical applications." Nanoscale 3(7): 2819-2843.
Andrade, A. L., D. M. Souza, M. C. Pereira, J. D. Fabris and R. Z. Domingues (2010). "pH EFFECT
ON THE SYNTHESIS OF MAGNETITE NANOPARTICLES BY THE CHEMICAL
REDUCTION-PRECIPITATION METHOD." Quimica Nova 33(3): 524-527.
Aranda, A., L. Sequedo, L. Tolosa, G. Quintas, E. Burello, J. V. Castell and L. Gombau (2013).
"Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: A quantitative method for oxidative
stress assessment of nanoparticle-treated cells." Toxicology in Vitro 27(2): 954-963.
Arbain, R., M. Othman and S. Palaniandy (2011). "Preparation of iron oxide nanoparticles by
mechanical milling." Minerals Engineering 24(1): 1-9.
Atkinson, W. J., I. A. Brezovich and D. P. Chakraborty (1984). "USABLE FREQUENCIES IN
HYPERTHERMIA WITH THERMAL SEEDS." Ieee Transactions on Biomedical Engineering
31(1): 70-75.
Auerbach, M. (2008). "Ferumoxytol as a New, Safer, Easier-to-Ad minister Intravenous Iron: Yes
or No?" American Journal of Kidney Diseases 52(5): 826-829.
Auffan, M., W. Achouak, J. Rose, M.-A. Roncato, C. Chaneac, D. T. Waite, A. Masion, J. C.
Woicik, M. R. Wiesner and J.-Y. Bottero (2008). "Relation between the redox state of iron-based
nanoparticles and their cytotoxicity toward Escherichia coli." Environmental Science &
Technology 42(17): 6730-6735.
Austin, L. A., B. Kang, C. W. Yen and M. A. El-Sayed (2011). "Nuclear Targeted Silver
Nanospheres Perturb the Cancer Cell Cycle Differently than Those of Nanogold." Bioconjugate
Chemistry 22(11): 2324-2331.
Ayala, V., A. P. Herrera, M. Latorre-Esteves, M. Torres-Lugo and C. Rinaldi (2013). "Effect of
surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron
oxide nanoparticles." Journal of Nanoparticle Research 15(8).
Babincova, M., V. Altanerova, C. Altaner, C. Bergemann and P. Babinec (2008). "In vitro analysis
of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and
electromagnetic hyperthermia." Ieee Transactions on Nanobioscience 7(1): 15-19.
Bae, K. H., M. Park, M. J. Do, N. Lee, J. H. Ryu, G. W. Kim, C. Kim, T. G. Park and T. Hyeon
(2012). "Chitosan Oligosaccharide-Stabilized Ferrimagnetic Iron Oxide Nanocubes for
Magnetically Modulated Cancer Hyperthermia." Acs Nano 6(6): 5266-5273.
Bahrami, B., M. Mohammadnia-Afrouzi, P. Bakhshaei, Y. Yazdani, G. Ghalamfarsa, M. Yousefi,
S. Sadreddini, F. Jadidi-Niaragh and M. Hojjat-Farsangi (2015). "Folate-conjugated nanoparticles
as a potent therapeutic approach in targeted cancer therapy." Tumor Biology 36(8): 5727-5742.
Balasubramanian, S., A. R. Girija, Y. Nagaoka, S. Iwai, M. Suzuki, V. Kizhikkilot, Y. Yoshida, T.
Maekawa and S. D. Nair (2014). "Curcumin and 5-Fluorouracil-loaded, folate- and transferrindecorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach,
accelerated by magnetic hyperthermia." International Journal of Nanomedicine 9.

176

Barbaro, D., L. Di Bari, V. Gandin, C. Evangelisti, G. Vitulli, E. Schiavi, C. Marzano, A. M. Ferretti
and P. Salvadori (2015). "Glucose-Coated Superparamagnetic Iron Oxide Nanoparticles Prepared
by Metal Vapour Synthesis Are Electively Internalized in a Pancreatic Adenocarcinoma Cell Line
Expressing GLUT1 Transporter." Plos One 10(4).
Bautista, M. C., O. Bomati-Miguel, M. D. Morales, C. J. Serna and S. Veintemillas-Verdaguer
(2005). "Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser
pyrolysis and coprecipitation." Journal of Magnetism and Magnetic Materials 293(1): 20-27.
Bee, A., R. Massart and S. Neveu (1995). "SYNTHESIS OF VERY FINE MAGHEMITE
PARTICLES." Journal of Magnetism and Magnetic Materials 149(1-2): 6-9.
Berry, C. C. (2009). "Progress in functionalization of magnetic nanoparticles for applications in
biomedicine." Journal of Physics D-Applied Physics 42(22): 9.
Berry, C. C. and A. S. G. Curtis (2003). "Functionalisation of magnetic nanoparticles for
applications in biomedicine." Journal of Physics D-Applied Physics 36(13): R198-R206.
Bertrand, N., J. Wu, X. Xu, N. Kamaly and O. C. Farokhzad (2014). "Cancer nanotechnology: The
impact of passive and active targeting in the era of modern cancer biology." Advanced Drug
Delivery Reviews 66: 2-25.
Bloemen, M., C. Denis, M. Peeters, L. De Meester, A. Gils, N. Geukens and T. Verbiest (2015).
"Antibody-modified iron oxide nanoparticles for efficient magnetic isolation and flow cytometric
determination of L-pneumophila." Microchimica Acta 182(7-8): 1439-1446.
Bolhassani, A. (2011). "Potential efficacy of cell-penetrating peptides for nucleic acid and drug
delivery in cancer." Biochimica Et Biophysica Acta-Reviews on Cancer 1816(2): 232-246.
Bonini, M., D. Berti and P. Baglioni (2013). "Nanostructures for magnetically triggered release of
drugs and biomolecules." Current Opinion in Colloid & Interface Science 18(5): 459-467.
Bouras, A., M. Kaluzova and C. G. Hadjipanayis (2015). "Radiosensitivity enhancement of
radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide
nanoparticles." Journal of Neuro-Oncology 124(1): 13-22.
Brazel, C. S. (2009). "Magnetothermally-responsive Nanomaterials: Combining Magnetic
Nanostructures and Thermally-Sensitive Polymers for Triggered Drug Release." Pharmaceutical
Research 26(3): 644-656.
Brunk, U. T., J. Neuzil and J. W. Eaton (2001). "Lysosomal involvement in apoptosis." Redox
Report 6(2): 91-97.
Brusentsov, N. A., T. N. Brusentsova, E. Y. Filinova, N. Y. Jurchenko, D. A. Kupriyanov, Y. A.
Pirogov, A. I. Dubina, M. N. Shumskikh, L. I. Shumakov, E. N. Anashkina, A. A. Shevelev and A.
A. Uchevatkin (2007). "Magnetohydrodynamic thermochemotherapy and MRI of mouse tumors."
Journal of Magnetism and Magnetic Materials 311(1): 176-180.
Butour, J.-L., P. Alvinerie, J.-P. Souchard, P. Colson, C. Houssier and N. P. Johnson (1991). "Effect
of the amine non-leaving group on the structure and stability of DNA complexes with cis-[Pt(RNH2)2(NO3)2]." European Journal of Biochemistry 202(3): 975-980.
177

Buyukhatipoglu, K. and A. M. Clyne (2010). "Controlled flame synthesis of alpha Fe2O3 and
Fe3O4 nanoparticles: effect of flame configuration, flame temperature, and additive loading."
Journal of Nanoparticle Research 12(4): 1495-1508.
Cavalli, S., D. Carbajo, M. Acosta, S. Lope-Piedrafita, A. P. Candiota, C. Arus, M. Royo and F.
Albericio (2012). "Efficient gamma-amino-proline-derived cell penetrating peptidesuperparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as
bimodal imaging nanoagents." Chemical Communications 48(43): 5322-5324.
Chacko, B. K., P. A. Kramer, S. Ravi, G. A. Benavides, T. Mitchell, B. P. Dranka, D. Ferrick, A.
K. Singal, S. W. Ballinger, S. M. Bailey, R. W. Hardy, J. Zhang, D. Zhi and V. M. Darley-Usmar
(2014). "The Bioenergetic Health Index: a new concept in mitochondrial translational research."
Clinical Science 127(5-6): 367-373.
Charras, G. T., M. Coughlin, T. J. Mitchison and L. Mahadevan (2008). "Life and times of a cellular
bleb." Biophysical Journal 94(5): 1836-1853.
Chen, G. J., Y. Z. Su, C. Hsu, Y. L. Lo, S. J. Huang, J. H. Ke, Y. C. Kuo and L. F. Wang (2014).
"Angiopep-pluronic F127-conjugated superparamagnetic iron oxide nanoparticles as
nanotheranostic agents for BBB targeting." Journal of Materials Chemistry B 2(34): 5666-5675.
Chen, Q.-Y., G.-P. Tao, Y.-Q. Liu and X. Yang (2012). "Synthesis, characterization, cell imaging
and anti-tumor activity of multifunctional nanoparticles." Spectrochimica Acta Part a-Molecular
and Biomolecular Spectroscopy 96: 284-288.
Chen, W. H., X. W. Zheng, S. L. Li, W. Z. Zhang, X. Wen, L. D. Yue and J. L. Wang (2015). "Onepot synthesis of FePt/CNTs nanocomposites for efficient cellular imaging and cancer therapy."
Journal of Nanoparticle Research 17(11): 444-444.
Choi, W. I., J. H. Lee, J. Y. Kim, S. U. Heo, Y. Y. Jeong, Y. H. Kim and G. Tae (2015). "Targeted
antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2
trastuzumab." Nanomedicine-Nanotechnology Biology and Medicine 11(2): 359-368.
Chou, L. Y. T., K. Ming and W. C. W. Chan (2011). "Strategies for the intracellular delivery of
nanoparticles." Chemical Society Reviews 40(1): 233-245.
Chu, X., J. Yu and Y.-L. Hou (2015). "Surface modification of magnetic nanoparticles in
biomedicine." Chinese Physics B 24(1).
Cleal, K., L. He, P. D. Watson and A. T. Jones (2013). "Endocytosis, Intracellular Traffic and Fate
of Cell Penetrating Peptide Based Conjugates and Nanoparticles." Current Pharmaceutical Design
19(16): 2878-2894.
Cochran, D. B., P. P. Wattamwar, R. Wydra, J. Z. Hilt, K. W. Anderson, R. E. Eitel and T. D.
Dziubla (2013). "Suppressing iron oxide nanoparticle toxicity by vascular targeted antioxidant
polymer nanoparticles." Biomaterials 34(37): 9615-9622.
Cohn, C. A., S. R. Simon and M. A. A. Schoonen (2008). "Comparison of fluorescence-based
techniques for the quantification of particle-induced hydroxyl radicals." Particle and Fibre
Toxicology 5.

178

Connord, V., P. Clerc, N. Hallali, D. E. H. Diab, D. Fourmy, V. Gigoux and J. Carrey (2015).
"Real-Time Analysis of Magnetic Hyperthermia Experiments on Living Cells under a Confocal
Microscope." Small 11(20): 2437-2445.
Corchero, J. and A. Villaverde (2009). "Biomedical applications of distally controlled magnetic
nanoparticles." Trends in Biotechnology 27(8): 468-476.
Creixell, M., A. C. Bohorquez, M. Torres-Lugo and C. Rinaldi (2011). "EGFR-Targeted Magnetic
Nanoparticle Heaters Kill Cancer Cells without a Perceptible Temperature Rise." Acs Nano 5(9):
7124-7129.
Daou, T. J., J. M. Greneche, G. Pourroy, S. Buathong, A. Derory, C. Ulhaq-Bouillet, B. Donnio,
D. Guillon and S. Begin-Colin (2008). "Coupling agent effect on magnetic properties of
functionalized magnetite-based nanoparticles." Chemistry of Materials 20(18): 5869-5875.
de la Fuente, J. M. and C. C. Berry (2005). "Tat peptide as an efficient molecule to translocate gold
nanoparticles into the cell nucleus." Bioconjugate Chemistry 16(5): 1176-1180.
Delaviz, N., P. Gill, A. Ajami and M. Aarabi (2015). "Aptamer-conjugated magnetic nanoparticles
for the efficient removal of HCV particles from human plasma samples." Rsc Advances 5(97):
79433-79439.
Deng, S., W. Zhang, B. Zhang, R. Hong, Q. Chen, J. Dong, Y. Chen, Z. Chen and Y. Wu (2015).
"Radiolabeled cyclic arginine-glycine-aspartic (RGD)-conjugated iron oxide nanoparticles as
single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI)
dual-modality agents for imaging of breast cancer." Journal of Nanoparticle Research 17(1).
Dennis, C. L., A. J. Jackson, J. A. Borchers, P. J. Hoopes, R. Strawbridge, A. R. Foreman, J. v.
Lierop, C. Grüttner and R. Ivkov (2009). "Nearly complete regression of tumors via collective
behavior of magnetic nanoparticles in hyperthermia." Nanotechnology 20(39): 395103.
Di Corato, R., A. Espinosa, L. Lartigue, M. Tharaud, S. Chat, T. Pellegrino, C. Ménager, F. Gazeau
and C. Wilhelm (2014). "Magnetic hyperthermia efficiency in the cellular environment for different
nanoparticle designs." Biomaterials 35(24): 6400-6411.
Dolores, R., S. Raquel and G. L. Adianez (2015). "Sonochemical synthesis of iron oxide
nanoparticles loaded with folate and cisplatin: Effect of ultrasonic frequency." Ultrasonics
Sonochemistry 23: 391-398.
Domenech, M., I. Marrero-Berrios, M. Torres-Lugo and C. Rinaldi (2013). "Lysosomal Membrane
Permeabilization by Targeted Magnetic Nanoparticles in Alternating Magnetic Fields." Acs Nano
7(6): 5091-5101.
Du, B., S. P. Han, H. Y. Li, F. F. Zhao, X. J. Su, X. H. Cao and Z. Z. Zhang (2015). "Multifunctional liposomes showing radiofrequency-triggered release and magnetic resonance imaging
for tumor multi-mechanism therapy." Nanoscale 7(12): 5411-5426.
Duguet, E., S. Vasseur, S. Mornet and J. M. Devoisselle (2006). "Magnetic nanoparticles and their
applications in medicine." Nanomedicine 1(2): 157-168.

179

Easo, S. L. and P. V. Mohanan (2013). "Dextran stabilized iron oxide nanoparticles: Synthesis,
characterization and in vitro studies." Carbohydrate Polymers 92(1): 726-732.
Emerit, J., C. Beaumont and F. Trivin (2001). "Iron metabolism, free radicals, and oxidative
injury." Biomedicine & Pharmacotherapy 55(6): 333-339.
Farkhani, S. M., A. Valizadeh, H. Karami, S. Mohammadi, N. Sohrabi and F. Badrzadeh (2014).
"Cell penetrating peptides: Efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic
and diagnostic molecules." Peptides 57: 78-94.
Feest, T. G. (1976). "LOW-MOLECULAR WEIGHT DEXTRAN - A CONTINUING CAUSE OF
ACUTE RENAL-FAILURE." British Medical Journal 2(6047): 1300-1300.
Fortin, J. P., C. Wilhelm, J. Servais, C. Menager, J. C. Bacri and F. Gazeau (2007). "Size-sorted
anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia." Journal of the
American Chemical Society 129(9): 2628-2635.
Fox, M. E., F. C. Szoka and J. M. J. Frechet (2009). "Soluble Polymer Carriers for the Treatment
of Cancer: The Importance of Molecular Architecture." Accounts of Chemical Research 42(8):
1141-1151.
Friedrich, J., R. Ebner and L. A. Kunz-Schughart (2007). "Experimental anti-tumor therapy in 3D: Spheroids - old hat or new challenge?" International Journal of Radiation Biology 83(11-12):
849-871.
Friedrich, J., W. Eder, J. Castaneda, M. Doss, E. Huber, R. Ebner and L. A. Kunz-Schughart (2007).
"A reliable tool to determine cell viability in complex 3-D culture: The acid phosphatase assay."
Journal of Biomolecular Screening 12(7): 925-937.
Frimpong, R. A., J. Dou, M. Pechan and J. Z. Hilt (2010). "Enhancing remote controlled heating
characteristics in hydrophilic magnetite nanoparticles via facile co-precipitation." Journal of
Magnetism and Magnetic Materials 322(3): 326-331.
Frimpong, R. A. and J. Z. Hilt (2010). "Magnetic nanoparticles in biomedicine: synthesis,
functionalization and applications." Nanomedicine 5(9): 1401-1414.
Gao, F. P., Z. X. Yan, J. Zhou, Y. Y. Cai and J. T. Tang (2012). "Methotrexate-conjugated magnetic
nanoparticles for thermochemotherapy and magnetic resonance imaging of tumor." Journal of
Nanoparticle Research 14(10).
Gautier, J., E. Allard-Vannier, E. Munnier, M. Soucé and I. Chourpa "Recent advances in
theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles." Journal of
Controlled Release 169(1–2): 48-61.
Genet, S. C., Y. Fujii, J. Maeda, M. Kaneko, M. D. Genet, K. Miyagawa and T. A. Kato (2013).
"Hyperthermia inhibits homologous recombination repair and sensitizes cells to ionizing radiation
in a time- and temperature-dependent manner." J Cell Physiol 228(7): 1473-1481.
Glickson, J. D., S. Lund-Katz, R. Zhou, H. Choi, I. W. Chen, H. Li, I. Corbin, A. V. Popov, W. G.
Cao, L. P. Song, C. Z. Qi, D. Marotta, D. S. Nelson, J. Chen, B. Chance and G. Zheng (2009).
LIPOPROTEIN NANOPLATFORM FOR TARGETED DELIVERY OF DIAGNOSTIC AND
180

THERAPEUTIC AGENTS. Oxygen Transport to Tissue Xxx. P. Liss, P. Hansell, D. F. Bruley and
D. K. Harrison. New York, Springer. 645: 227-239.
Gordon, R. T., J. R. Hines and D. Gordon (1979). "INTRACELLULAR HYPERTHERMIA BIOPHYSICAL APPROACH TO CANCER-TREATMENT VIA INTRACELLULAR
TEMPERATURE AND BIOPHYSICAL ALTERATIONS." Medical Hypotheses 5(1): 83-102.
Goya, G. F., V. Grazu and M. R. Ibarra (2008). "Magnetic nanoparticles for cancer therapy."
Current Nanoscience 4(1): 1-16.
Gruettner, C., K. Mueller, J. Teller and F. Westphal (2013). "Synthesis and functionalisation of
magnetic nanoparticles for hyperthermia applications." International Journal of Hyperthermia
29(8): 777-789.
Gruettner, C., K. Mueller, J. Teller, F. Westphal, A. Foreman and R. Ivkov (2007). "Synthesis and
antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for
alternating magnetic field cancer therapy." Journal of Magnetism and Magnetic Materials 311(1):
181-186.
Guicciardi, M. E., M. Leist and G. J. Gores (2004). "Lysosomes in cell death." Oncogene 23(16):
2881-2890.
Gupta, A. K. and M. Gupta (2005). "Synthesis and surface engineering of iron oxide nanoparticles
for biomedical applications." Biomaterials 26: 3995-4021.
Gupta, A. K. and M. Gupta (2005). "Synthesis and surface engineering of iron oxide nanoparticles
for biomedical applications." Biomaterials 26(18): 3995-4021.
Gupta, A. K., R. R. Naregalkar, V. D. Vaidya and M. Gupta (2007). "Recent advances on surface
engineering of magnetic iron oxide nanoparticles and their biomedical applications."
Nanomedicine 2: 23-39.
Hajshafiei, P., S. Fatahian and K. Shahanipoor (2014). "In Vivo Toxicity Assessment of Bovine
Serum Albumin and Dimercaptosuccinic Acid Coated Fe3O4 Nanoparticles." Iranian Journal of
Biotechnology 12(2).
Halamikova, A., D. Vrana, J. Kasparkova and V. Brabec (2007). "Biochemical studies of the
thermal effects on DNA modifications by the antitumor cisplatin and their repair." Chembiochem
8(16): 2008-2015.
Hauser, A. K., R. Mathias, K. W. Anderson and J. Z. Hilt (2015). "The effects of synthesis method
on the physical and chemical properties of dextran coated iron oxide nanoparticles." Materials
Chemistry and Physics 160: 177-186.
Hauser, A. K., R. J. Wydra, R. Bhandari, P. G. Rychahou, B. M. Evers, K. W. Anderson, T. D.
Dziubla and J. Z. Hilt "Corrigendum to “The role of ROS generation from magnetic nanoparticles
in an alternating magnetic field on cytotoxicity” [Acta Biomater. 25 (2015) 284–290]." Acta
Biomaterialia.

181

Herea, D. D., H. Chiriac, N. Lupu, M. Grigoras, G. Stoian, B. A. Stoica and T. Petreus (2015).
"Study on iron oxide nanoparticles coated with glucose-derived polymers for biomedical
applications." Applied Surface Science 352: 117-125.
Hergt, R., R. Hiergeist, I. Hilger, W. A. Kaiser, Y. Lapatnikov, S. Margel and U. Richter (2004).
"Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia."
Journal of Magnetism and Magnetic Materials 270(3): 345-357.
Hervault, A. and N. n. T. K. Thanh (2014). "Magnetic nanoparticle-based therapeutic agents for
thermo-chemotherapy treatment of cancer." Nanoscale 6(20): 11553-11573.
Hervouet, E., H. Simonnet and C. Godinot (2007). "Mitochondria and reactive oxygen species in
renal cancer." Biochimie 89(9): 1080-1088.
Hettinga, J. V. E., W. Lemstra, E. G. E. Devries, A. W. T. Konings and H. H. Kampinga (1995).
"SENSITIZATION TO CISPLATIN ACTION BY STEP-DOWN HEATING IN CDDPSENSITIVE AND CDDP-RESISTANT CELLS." International Journal of Cancer 61(5): 722-726.
Hettinga, J. V. E., W. Lemstra, C. Meijer, W. A. Dam, D. R. A. Uges, A. W. T. Konings, E. G. E.
DeVries and H. H. Kampinga (1997). "Mechanism of hyperthermic potentiation of cisplatin action
in cisplatin-sensitive and -resistant tumour cells." British Journal of Cancer 75(12): 1735-1743.
Hetzel, F. W. and J. A. Dunn (1984). "Hyperthermia and radiation in cancer therapy: a review."
Radiat. Phys. Chem. 24(3/4): 337-345.
Hildebrandt, B., P. Wust, O. Ahlers, A. Dieing, G. Sreenivasa, T. Kerner, R. Felix and H. Riess
(2002). "The cellular and molecular basis of hyperthermia." Critical Reviews in Oncology
Hematology 43(1): 33-56.
Hill, B. G., G. A. Benavides, J. R. Lancaster, Jr., S. Ballinger, L. Dell'Italia, J. Zhang and V. M.
Darley-Usmar (2012). "Integration of cellular bioenergetics with mitochondrial quality control and
autophagy." Biological Chemistry 393(12): 1485-1512.
Ho, D., X. L. Sun and S. H. Sun (2011). "Monodisperse Magnetic Nanoparticles for Theranostic
Applications." Accounts of Chemical Research 44(10): 875-882.
Hola, K., Z. Markova, G. Zoppellaro, J. Tucek and R. Zboril (2015). "Tailored functionalization of
iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of
biosubstances." Biotechnology Advances 33(6): 1162-1176.
Horsman, M. R. and R. Murata (2002). "Combination of vascular targeting agents with thermal or
radiation therapy." International Journal of Radiation Oncology Biology Physics 54(5): 1518-1523.
Horsman, M. R. and J. Overgaard (2007). "Hyperthermia: a potent enhancer of radiotherapy."
Clinical Oncology 19(6): 418-426.
Hu, R., S. Ma, H. Li, X. Ke, G. Wang, D. Wei and W. Wang (2011). "Effect of magnetic fluid
hyperthermia on lung cancer nodules in a murine model." Oncology Letters 2(6): 1161-1164.

182

Hu, R. L., S. L. Ma, H. Li, X. F. Ke, G. Q. Wang, D. S. Wei and W. Wang (2011). "Effect of
magnetic fluid hyperthermia on lung cancer nodules in a murine model." Oncology Letters 2(6):
1161-1164.
Hu, Y., L. D. Li and L. Guo (2015). "The sandwich-type aptasensor based on gold
nanoparticles/DNA/magnetic beads for detection of cancer biomarker protein AGR2." Sensors and
Actuators B-Chemical 209: 846-852.
Huang, G., H. B. Chen, Y. Dong, X. Q. Luo, H. J. Yu, Z. Moore, E. A. Bey, D. A. Boothman and
J. M. Gao (2013). "Superparamagnetic Iron Oxide Nanoparticles: Amplifying ROS Stress to
Improve Anticancer Drug Efficacy." Theranostics 3(2): 116-126.
Huang, H., S. Delikanli, H. Zeng, D. M. Ferkey and A. Pralle (2010). "Remote control of ion
channels and neurons through magnetic-field heating of nanoparticles." Nature Nanotechnology
5(8): 602-606.
Huang, J. Y., M. H. Chen, W. T. Kuo, Y. J. Sun and F. H. Lin (2015). "The characterization and
evaluation of cisplatin-loaded magnetite-hydroxyapatite nanop articles (mHAp/CDDP) as dual
treatment of hyperthermia and chemotherapy for lung cancer therapy." Ceramics International
41(2): 2399-2410.
Hurwitz, M. D., J. L. Hansen, S. Prokopios-Davos, J. Manola, Q. A. Wang, B. A. Bornstein, K.
Hynynen and I. D. Kaplan (2011). "Hyperthermia Combined With Radiation for the Treatment of
Locally Advanced Prostate Cancer Long-Term Results From Dana-Farber Cancer Institute Study
94-153." Cancer 117(3): 510-516.
Hutmacher, D. W., R. E. Horch, D. Loessner, S. Rizzi, S. Sieh, J. Reichert, C., J. A. Clements, J.
P. Beier, A. Arkudus, O. Bleiziffer and U. Kneser (2009). "Translating tissue engineering
technology platforms into cancer research." Journal of Cellular and Molecular Medicine 13(8A):
1417-1427.
Ilkhani, H., M. Sarparast, A. Noori, S. Z. Bathaie and M. F. Mousavi (2015). "Electrochemical
aptamer/antibody based sandwich immunosensor for the detection of EGFR, a cancer biomarker,
using gold nanoparticles as a signaling probe." Biosensors & Bioelectronics 74: 491-497.
Imren, D., M. Gumusderelioglu and A. Guner (2006). "Synthesis and characterization of dextran
hydrogels prepared with chlor- and nitrogen-containing crosslinkers." Journal of Applied Polymer
Science 102(5): 4213-4221.
Issels, R. D. (2008). "Hyperthermia adds to chemotherapy." European Journal of Cancer 44(17):
2546-2554.
Itoh, Y., Y. Yamada, Y. Kazaoka, T. Ishiguchi and N. Honda (2010). "Combination of
chemotherapy and mild hyperthermia enhances the anti-tumor effects of cisplatin and adriamycin
in human bladder cancer T24 cells in vitro." Experimental and Therapeutic Medicine 1(2): 319323.
Ivascu, A. and M. Kubbies (2006). "Rapid generation of single-tumor spheroids for highthroughput cell function and toxicity analysis." Journal of Biomolecular Screening 11(8): 922-932.

183

Ivkov, R., S. J. DeNardo, W. Daum, A. R. Foreman, R. C. Goldstein, V. S. Nemkov and G. L.
DeNardo (2005). "Application of high amplitude alternating magnetic fields for heat induction of
nanoparticles localized in cancer." Clinical Cancer Research 11(19): 7093S-7103S.
Jaattela, M. (2004). "Multiple cell death pathways as regulators of tumour initiation and
progression." Oncogene 23(16): 2746-2756.
Jacobin-Valat, M.-J., J. Laroche-Traineau, M. Lariviere, S. Mornet, S. Sanchez, M. Biran, C.
Lebaron, J. Boudon, S. Lacomme, M. Cerutti and G. Clofent-Sanchez (2015). "Nanoparticles
functionalised with an anti-platelet human antibody for in vivo detection of atherosclerotic plaque
by magnetic resonance imaging." Nanomedicine-Nanotechnology Biology and Medicine 11(4):
927-937.
Jafari, A., M. Salouti, S. F. Shayesteh, Z. Heidari, A. B. Rajabi, K. Boustani and A. Nahardani
(2015). "Synthesis and characterization of Bombesin-superparamagnetic iron oxide nanoparticles
as a targeted contrast agent for imaging of breast cancer using MRI." Nanotechnology 26(7): 11.
Jafari, S., S. M. Dizaj and K. Adibkia (2015). "Cell-penetrating peptides and their analogues as
novel nanocarriers for drug delivery." Bioimpacts 5(2): 103-111.
Janot, R. and D. Guerard (2002). "One-step synthesis of maghemite nanometric powders by ballmilling." Journal of Alloys and Compounds 333(1-2): 302-307.
Jarzyna, P. A., L. H. Deddens, B. H. Kann, S. Ramachandran, C. Calcagno, W. Chen, A. Gianella,
R. M. Dijkhuizen, A. W. Griffioen, Z. A. Fayad and W. J. M. Mulder (2012). "Tumor Angiogenesis
Phenotyping by Nanoparticle-facilitated Magnetic Resonance and Near-infrared Fluorescence
Molecular Imaging." Neoplasia 14(10): 964-973.
Jhaveri, A., P. Deshpande and V. Torchilin (2014). "Stimuli-sensitive nanopreparations for
combination cancer therapy." Journal of Controlled Release 190(0): 352-370.
Jiang, S., K. Y. Win, S. H. Liu, C. P. Teng, Y. G. Zheng and M. Y. Han (2013). "Surfacefunctionalized nanoparticles for biosensing and imaging-guided therapeutics." Nanoscale 5(8):
3127-3148.
Jin, R., B. Lin, D. Li and H. Ai (2014). "Superparamagnetic iron oxide nanoparticles for MR
imaging and therapy: design considerations and clinical applications." Current Opinion in
Pharmacology 18: 18-27.
Johannsen, M., U. Gneueckow, B. Thiesen, K. Taymoorian, C. H. Cho, N. Waldofner, R. Scholz,
A. Jordan, S. A. Loening and P. Wust (2007). "Thermotherapy of prostate cancer using magnetic
nanoparticles: Feasibility, imaging, and three-dimensional temperature distribution." European
Urology 52(6): 1653-1662.
Johannsen, M., U. Gneveckow, K. Taymoorian, B. Thiesen, N. Waldoefner, R. Scholz, K. Jung, A.
Jordan, P. Wust and S. A. Loening (2007). "Morbidity and quality of life during thermotherapy
using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I
trial." International Journal of Hyperthermia 23(3): 315-323.

184

Johannsen, M., A. Jordan, R. Scholz, M. Koch, M. Lein, S. Deger, J. Roigas, K. Jung and S.
Loening (2004). "Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate
cancer." Journal of Endourology 18(5): 495-500.
Johannsen, M., B. Thiesen, U. Gneveckow, K. Taymoorian, N. Waldofner, R. Scholz, S. Deger, K.
Jung, S. A. Loening and A. Jordan (2006). "Thermotherapy using magnetic nanoparticles combined
with external radiation in an orthotopic rat model of prostate cancer." Prostate 66(1): 97-104.
Johannsen, M., B. Thiesen, A. Jordan, K. Taymoorian, U. Gneveckow, N. Waldofner, R. Scholz,
M. Koch, M. Lein, K. Jung and S. A. Loening (2005). "Magnetic fluid hyperthermia (MFH) reduces
prostate cancer growth in the orthotopic dunning R3327 rat model." Prostate 64(3): 283-292.
Johansson, A.-C., H. Appelqvist, C. Nilsson, K. Kagedal, K. Roberg and K. Ollinger (2010).
"Regulation of apoptosis-associated lysosomal membrane permeabilization." Apoptosis 15(5):
527-540.
Jordan, A., R. Scholz, K. Maier-Hauff, F. K. H. van Landeghem, N. Waldoefner, U. Teichgraeber,
J. Pinkernelle, H. Bruhn, F. Neumann, B. Thiesen, A. von Deimling and R. Felix (2006). "The
effect of thermotherapy using magnetic nanoparticles on rat malignant glioma." Journal of NeuroOncology 78(1): 7-14.
Jordan, A., R. Scholz, P. Wust, H. Schirra, T. Schiestel, H. Schmidt and R. Felix (1999).
"Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular
hyperthermia on human mammary carcinoma cells in vitro." Journal of Magnetism and Magnetic
Materials 194(1-3): 185-196.
Josephson, L., C. H. Tung, A. Moore and R. Weissleder (1999). "High-efficiency intracellular
magnetic labeling with novel superparamagnetic-tat peptide conjugates." Bioconjugate Chemistry
10(2): 186-191.
Kallumadil, M., M. Tada, T. Nakagawa, M. Abe, P. Southern and Q. A. Pankhurst (2009).
"Suitability of commercial colloids for magnetic hyperthermia." Journal of Magnetism and
Magnetic Materials 321(10): 1509-1513.
Kallumadil, M., M. Tada, T. Nakagawa, M. Abe, P. Southern and Q. A. Pankhurst (2009).
"Suitability of commercial colloids for magnetic hyperthermia (vol 321, pg 1509, 2009)." Journal
of Magnetism and Magnetic Materials 321(21): 3650-3651.
Kaluzova, M., A. Bouras, R. Machaidze and C. G. Hadjipanayis (2015). "Targeted therapy of
glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide
nanoparticles." Oncotarget 6(11): 8788-8806.
Kam, W. W.-Y. and R. B. Banati (2013). "Effects of ionizing radiation on mitochondria." Free
Radical Biology and Medicine 65: 607-619.
Kanazaki, K., K. Sano, A. Makino, Y. Shimizu, F. Yamauchi, S. Ogawa, N. Ding, T. Yano, T.
Temma, M. Ono and H. Saji (2015). "Development of anti-HER2 fragment antibody conjugated to
iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging." Nanomedicine
: nanotechnology, biology, and medicine 11(8): 2051-2060.

185

Kang, Y. S., S. Risbud, J. F. Rabolt and P. Stroeve (1996). "Synthesis and characterization of
nanometer-size Fe3O4 and gamma-Fe2O3 particles." Chemistry of Materials 8(9): 2209-&.
Karamipour, S., M. S. Sadjadi and N. Farhadyar (2015). "Fabrication and spectroscopic studies of
folic acid-conjugated Fe3O4@Au core-shell for targeted drug delivery application."
Spectrochimica Acta Part a-Molecular and Biomolecular Spectroscopy 148: 146-155.
Kehrer, J. P. (2000). "The Haber-Weiss reaction and mechanisms of toxicity." Toxicology 149(1):
43-50.
Kettering, M., J. Winter, M. Zeisberger, S. Bremer-Streck, H. Oehring, C. Bergemann, C. Alexiou,
R. Hergt, K. J. Halbhuber, W. A. Kaiser and I. Hilger (2007). "Magnetic nanoparticles as bimodal
tools in magnetically induced labelling and magnetic heating of tumour cells: an in vitro study."
Nanotechnology 18(17).
Khan, M. I., A. Mohammad, G. Patil, S. A. H. Naqvi, L. K. S. Chauhan and I. Ahmad (2012).
"Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron
oxide nanoparticles." Biomaterials 33(5): 1477-1488.
Khoei, S., B. Goliaei, A. Neshasteh-Riz and A. Deizadji (2004). "The role of heat shock protein 70
in the thermoresistance of prostate cancer cell line spheroids." Febs Letters 561(1-3): 144-148.
Kievit, F. M., Z. R. Stephen, O. Veiseh, H. Arami, T. Wang, V. P. Lai, J. O. Park, R. G. Ellenbogen,
M. L. Disis and M. Zhang (2012). "Targeting of Primary Breast Cancers and Metastases in a
Transgenic Mouse Model Using Rationally Designed Multifunctional SPIONs." Acs Nano 6(3):
2591-2601.
Kim, Y. S., N. H. A. Raston and M. B. Gu (2016). "Aptamer-based nanobiosensors." Biosensors
& Bioelectronics 76: 2-19.
Kirkegaard, T. and M. Jaattela (2009). "Lysosomal involvement in cell death and cancer."
Biochimica Et Biophysica Acta-Molecular Cell Research 1793(4): 746-754.
Klein, S., A. Sommer, L. V. R. Distel, J. L. Hazemann, W. Kroner, W. Neuhuber, P. Muller, O.
Proux and C. Kryschi (2014). "Superparamagnetic Iron Oxide Nanoparticles as Novel X-ray
Enhancer for Low-Dose Radiation Therapy." Journal of Physical Chemistry B 118(23): 6159-6166.
Klein, S., A. Sommer, L. V. R. Distel, W. Neuhuber and C. Kryschi (2012). "Superparamagnetic
iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation."
Biochemical and Biophysical Research Communications 425(2): 393-397.
Kodama, R. H. (1999). "Magnetic nanoparticles." Journal of Magnetism and Magnetic Materials
200(1-3): 359-372.
Koenczoel, M., A. Weiss, E. Stangenberg, R. Gminski, M. Garcia-Kaeufer, R. Giere, I. Merfort
and V. Mersch-Sundermann (2013). "Cell-Cycle Changes and Oxidative Stress Response to
Magnetite in A549 Human Lung Cells." Chemical Research in Toxicology 26(5): 693-702.
Kolosnjaj-Tabi, J., R. Di Corato, L. Lartigue, I. Marangon, P. Guardia, A. K. A. Silva, N. Luciani,
O. Clement, P. Flaud, J. V. Singh, P. Decuzzi, T. Pellegrino, C. Wilhelm and F. Gazeau (2014).

186

"Heat-Generating Iron Oxide Nanocubes: Subtle
Microenvironment." Acs Nano 8(5): 4268-4283.

"Destructurators"

of

the

Tumoral

Koren, E. and V. P. Torchilin (2012). "Cell-penetrating peptides: breaking through to the other
side." Trends in Molecular Medicine 18(7): 385-393.
Kornhuber, J., A. W. Henkel, T. W. Groemer, S. Staedtler, O. Welzel, P. Tripal, A. Rotter, S. Bleich
and S. Trapp (2010). "Lipophilic Cationic Drugs Increase the Permeability of Lysosomal
Membranes in a Cell Culture System." Journal of Cellular Physiology 224(1): 152-164.
Kozissnik, B., A. C. Bohorquez, J. Dobson and C. Rinaldi (2013). "Magnetic fluid hyperthermia:
Advances, challenges, and opportunity." International Journal of Hyperthermia 29(8): 706-714.
Krpetic, Z., P. Nativo, V. See, I. A. Prior, M. Brust and M. Volk (2010). "Inflicting Controlled
Nonthermal Damage to Subcellular Structures by Laser-Activated Gold Nanoparticles." Nano
Letters 10(11): 4549-4554.
Kruse, A. M., S. A. Meenach, K. W. Anderson and J. Z. Hilt (2014). "Synthesis and characterization
of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications." Acta Biomaterialia
10(6): 2622-2629.
Kumar, C. and F. Mohammad (2011). "Magnetic nanomaterials for hyperthermia-based therapy
and controlled drug delivery." Advanced Drug Delivery Reviews 63(9): 789-808.
Kumar, C. S. S. R. and F. Mohammad (2011). "Magnetic nanomaterials for hyperthermia-based
therapy and controlled drug delivery." Advanced Drug Delivery Reviews 63: 789-808.
Kumar, M., Z. Medarova, P. Pantazopoulos, G. P. Dai and A. Moore (2010). "Novel MembranePermeable Contrast Agent for Brain Tumor Detection by MRI." Magnetic Resonance in Medicine
63(3): 617-624.
Kumar, M., M. Yigit, G. P. Dai, A. Moore and Z. Medarova (2010). "Image-Guided Breast Tumor
Therapy Using a Small Interfering RNA Nanodrug." Cancer Research 70(19): 7553-7561.
Kut, C., Y. Zhang, M. Hedayati, H. Zhou, C. Cornejo, D. Bordelon, J. Mihalic, M. Wabler, E.
Burghardt, C. Gruettner, A. Geyh, C. Brayton, T. L. Deweese and R. Ivkov (2012). "Preliminary
study of injury from heating systemically delivered, nontargeted dextran-superparamagnetic iron
oxide nanoparticles in mice." Nanomedicine 7(11): 1697-1711.
Lartigue, L., P. Hugounenq, D. Alloyeau, S. P. Clarke, M. Levy, J.-C. Bacri, R. Bazzi, D. F.
Brougham, C. Wilhelm and F. Gazeau (2012). "Cooperative Organization in Iron Oxide MultiCore Nanoparticles Potentiates Their Efficiency as Heating Mediators and MRI Contrast Agents."
Acs Nano 6(12): 10935-10949.
Laurent, S., S. Dutz, U. O. Haefeli and M. Mahmoudi (2011). "Magnetic fluid hyperthermia: Focus
on superparamagnetic iron oxide nanoparticles." Advances in Colloid and Interface Science 166(12): 8-23.
Laurent, S., S. Dutz, U. O. Hafeli and M. Mahmoudi (2011). "Magnetic fluid hyperthermia: Focus
on superparamagnetic iron oxide nanoparticles." Advances in Colloid and Interface Science 166:
8-23.
187

Laurent, S., S. Dutz, U. O. Hafeli and M. Mahmoudi (2011). "Magnetic fluid hyperthermia: Focus
on superparamagnetic iron oxide nanoparticles." Advances in Colloid and Interface Science 166(12): 8-23.
Le, B., M. Shinkai, T. Kitade, H. Honda, J. Yoshida, T. Wakabayashi and T. Kobayashi (2001).
"Preparation of tumor-specific magnetoliposomes and their application for hyperthermia." Journal
of Chemical Engineering of Japan 34(1): 66-72.
Lee, J.-H., J.-t. Jang, J.-s. Choi, S. H. Moon, S.-h. Noh, J.-w. Kim, J.-G. Kim, I.-S. Kim, K. I. Park
and J. Cheon (2011). "Exchange-coupled magnetic nanoparticles for efficient heat induction."
Nature Nanotechnology 6(7): 418-422.
Lee, J. S., H. L. Rodriguez-Luccioni, J. Mendez, A. K. Sood, G. Lpez-Berestein, C. Rinaldi and M.
Torres-Lugo (2011). "Hyperthermia Induced by Magnetic Nanoparticles Improves the
Effectiveness of the Anticancer Drug cis-Diamminedichloroplatinum." Journal of Nanoscience and
Nanotechnology 11(5): 4153-4157.
Lee, Y., J. Lee, C. J. Bae, J. G. Park, H. J. Noh, J. H. Park and T. Hyeon (2005). "Large-scale
synthesis of uniform and crystalline magnetite nanoparticles using reverse micelles as nanoreactors
under reflux conditions." Advanced Functional Materials 15(3): 503-509.
Lee, Y. T., K. Woo and K. S. Choi (2008). "Preparation of water-dispersible and biocompatible
iron oxide nanoparticles for MRI agent." Ieee Transactions on Nanotechnology 7(2): 111-114.
Lewin, M., N. Carlesso, C. H. Tung, X. W. Tang, D. Cory, D. T. Scadden and R. Weissleder (2000).
"Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor
cells." Nature Biotechnology 18(4): 410-414.
Lewinski, N., V. Colvin and R. Drezek (2008). "Cytotoxicity of nanoparticles." Small 4(1): 26-49.
Li, H., K. Yan, Y. L. Shang, L. Shrestha, R. F. Liao, F. Liu, P. H. Li, H. B. Xu, Z. S. Xu and P. K.
Chu (2015). "Folate-bovine serum albumin functionalized polymeric micelles loaded with
superparamagnetic iron oxide nanoparticles for tumor targeting and magnetic resonance imaging."
Acta Biomaterialia 15: 117-126.
Li, T., H. E. Gendelman, G. Zhang, P. Puligujja, J. M. McMillan, T. K. Bronich, B. Edagwa, X. M.
Liu and M. D. Boska (2015). "Magnetic resonance imaging of folic acid-coated magnetite
nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy." International
Journal of Nanomedicine 10: 3779-3790.
Li, T. J., C. C. Huang, P. W. Ruan, K. Y. Chuang, K. J. Huang, D. B. Shieh and C. S. Yeh (2013).
"In vivo anti-cancer efficacy of magnetite nanocrystal-based system using locoregional
hyperthermia combined with 5-fluorouracil chemotherapy." Biomaterials 34(32): 7873-7883.
Li, Y. H., G. Y. Huang, X. H. Zhang, B. Q. Li, Y. M. Chen, T. L. Lu, T. J. Lu and F. Xu (2013).
"Magnetic Hydrogels and Their Potential Biomedical Applications." Advanced Functional
Materials 23(6): 660-672.
Li, Y. J., M. Dong, F. M. Kong and J. P. Zhou (2015). "Folate-decorated anticancer drug and
magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics." International
Journal of Pharmaceutics 489(1-2): 83-90.
188

Li, Z., K. Dong, S. Huang, E. Ju, Z. Liu, M. Yin, J. Ren and X. Qu (2014). "A Smart Nanoassembly
for Multistage Targeted Drug Delivery and Magnetic Resonance Imaging." Advanced Functional
Materials 24(23): 3612-3620.
Li, Z. F., T. Yang, C. M. Lin, Q. S. Li, S. F. Liu, F. Z. Xu, H. Y. Wang and X. J. Cui (2015).
"Sonochemical Synthesis of Hydrophilic Drug Loaded Multifunctional Bovine Serum Albumin
Nanocapsules." Acs Applied Materials & Interfaces 7(34): 19390-19397.
Lin, M. M., Y. J. Kang, Y. Sohn and D. K. Kim (2015). "Dual targeting strategy of magnetic
nanoparticle-loaded and RGD peptide-activated stimuli-sensitive polymeric micelles for delivery
of paclitaxel." Journal of Nanoparticle Research 17(6).
Lin, R.-Y., K. Dayananda, T.-J. Chen, C.-Y. Chen, G.-C. Liu, K.-L. Lin and Y.-M. Wang (2012).
"Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging." Contrast
Media & Molecular Imaging 7(1): 7-18.
Linder, S. T., H. Erdal, M. Berndtsson and M. Shoshan (2005). "Induction of lysosomal membrane
permeabilization by compounds that activate p53-independent apoptosis." Proceedings of the
American Association for Cancer Research Annual Meeting 46: 1171-1171.
Liu, T. Y., S. H. Hu, D. M. Liu, S. Y. Chen and I. W. Chen (2009). "Biomedical nanoparticle
carriers with combined thermal and magnetic responses." Nano Today 4(1): 52-65.
Low, P. S., W. A. Henne and D. D. Doorneweerd (2008). "Discovery and development of folicacid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases."
Accounts of Chemical Research 41(1): 120-129.
Luo, C., Y. Li, L. Yang, X. Wang, J. Long and J. Liu (2015). "Superparamagnetic iron oxide
nanoparticles exacerbate the risks of reactive oxygen species-mediated external stresses." Archives
of Toxicology 89(3): 357-369.
Luo, Y., J. Yang, Y. Yan, J. Li, M. Shen, G. Zhang, S. Mignani and X. Shi (2015). "RGDfunctionalized ultrasmall iron oxide nanoparticles for targeted T-1-weighted MR imaging of
gliomas." Nanoscale 7(34): 14538-14546.
Ly, J. D., D. R. Grubb and A. Lawen (2003). "The mitochondrial membrane potential (Delta psi
m) in apoptosis; an update." Apoptosis 8(2): 115-128.
Ma, D.-X., N.-Q. Shi and X.-R. Qi (2011). "Distinct transduction modes of arginine-rich cellpenetrating peptides for cargo delivery into tumor cells." International Journal of Pharmaceutics
419(1-2): 200-208.
Ma, Z. Y., Y. P. Liu, L. Y. Bai, J. An, L. Zhang, Y. Xuan, X. S. Zhang and Y. D. Zhao (2015).
"Folic acid-targeted magnetic Tb-doped CeF3 fluorescent nanoparticles as bimodal probes for
cellular fluorescence and magnetic resonance imaging." Dalton Transactions 44(37): 16304-16312.
Maharramov, A. M., M. A. Ramazanov, A. I. Ahadova, M. Kloor, J. Kopitz, M. v. K. Doeberitza,
A. L. Shabanov, Q. M. Eyvazova, Z. A. Agamaliyev, F. V. Hajiyeva, S. B. Veliyeva and U. A.
Hasanova (2014). "PREPARATION OF 2-DEOXY-D-GLUCOSE COATED SPIO
NANOPARTICLES AND CHARACTERIZATION OF THEIR PHYSICAL, CHEMICAL, AND

189

BIOLOGICAL PROPERTIES." Digest Journal of Nanomaterials and Biostructures 9(4): 14611469.
Mahmoudi, M., A. Simchi, A. S. Milani and P. Stroeve (2009). "Cell toxicity of superparamagnetic
iron oxide nanoparticles." Journal of Colloid and Interface Science 336(2): 510-518.
Maier-Hauff, K., R. Rothe, R. Scholz, U. Gneveckow, P. Wust, B. Thiesen, A. Feussner, A. von
Deimling, N. Waldoefner, R. Felix and A. Jordan (2007). "Intracranial thermotherapy using
magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study
on patients with glioblastoma multiforme." Journal of Neuro-Oncology 81(1): 53-60.
Maier-Hauff, K., F. Ulrich, D. Nestler, H. Niehoff, P. Wust, B. Thiesen, H. Orawa, V. Budach and
A. Jordan (2011). "Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide
nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma
multiforme." Journal of Neuro-Oncology 103(2): 317-324.
Mansoori, G. A., K. S. Brandenburg and A. Shakeri-Zadeh (2010). "A comparative study of two
folate-conjugated gold nanoparticles for cancer nanotechnology applications." Cancers 2(4): 19111928.
Massart, R. (1981). "PREPARATION OF AQUEOUS MAGNETIC LIQUIDS IN ALKALINE
AND ACIDIC MEDIA." Ieee Transactions on Magnetics 17(2): 1247-1248.
Mattix, B., T. R. Olsen, Y. Gu, M. Casco, A. Herbst, D. T. Simionescu, R. P. Visconti, K. G.
Kornev and F. Alexis (2014). "Biological magnetic cellular spheroids as building blocks for tissue
engineering." Acta Biomaterialia 10(2): 623-629.
McCarthy, J. R. and R. Weissleder (2008). "Multifunctional magnetic nanoparticles for targeted
imaging and therapy." Advanced Drug Delivery Reviews 60(11): 1241-1251.
McCormack, P. L. (2012). "Ferumoxytol In Iron Deficiency Anaemia in Adults With Chronic
Kidney Disease." Drugs 72(15): 2013-2022.
Medarova, Z., L. Rashkovetsky, P. Pantazopoulos and A. Moore (2009). "Multiparametric
Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging." Cancer Research
69(3): 1182-1189.
Melemenidis, S., A. Jefferson, N. Ruparelia, A. M. Akhtar, J. Xie, D. Allen, A. Hamilton, J. R.
Larkin, F. Perez-Balderas, S. C. Smart, R. J. Muschel, X. Chen, N. R. Sibson and R. P. Choudhury
(2015). "Molecular Magnetic Resonance Imaging of Angiogenesis In Vivo using Polyvalent Cyclic
RGD-Iron Oxide Microparticle Conjugates." Theranostics 5(5): 515-529.
Meng, H. M., L. M. Lu, X. H. Zhao, Z. Chen, Z. L. Zhao, C. Yang, X. B. Zhang and W. H. Tan
(2015). "Multiple Functional Nanoprobe for Contrast-Enhanced Bimodal Cellular Imaging and
Targeted Therapy." Analytical Chemistry 87(8): 4448-4454.
Menichetti, L., L. Manzoni, L. Paduano, A. Flori, C. Kusmic, D. De Marchi, S. Casciaro, F.
Conversano, M. Lombardi, V. Positano and D. Arosio (2013). "Iron Oxide-Gold Core-Shell
Nanoparticles as Multimodal Imaging Contrast Agent." Ieee Sensors Journal 13(6): 2341-2347.

190

Meyn, R. E., P. M. Corry, S. E. Fletcher and M. Demetriades (1980). "THERMAL
ENHANCEMENT OF DNA DAMAGE IN MAMMALIAN-CELLS TREATED WITH CISDIAMMINEDICHLOROPLATINUM(II)." Cancer Research 40(4): 1136-1139.
Minchinton, A. I. and I. F. Tannock (2006). "Drug penetration in solid tumours." Nature Reviews
Cancer 6(8): 583-592.
Montenegro, J. M., V. Grazu, A. Sukhanova, S. Agarwal, J. M. de la Fuente, I. Nabiev, A. Greiner
and W. J. Parak (2013). "Controlled antibody/(bio-) conjugation of inorganic nanoparticles for
targeted delivery." Advanced Drug Delivery Reviews 65(5): 677-688.
Mornet, S., S. Vasseur, F. Grasset and E. Duguet (2004). "Magnetic nanoparticle design for medical
diagnosis and therapy." Journal of Materials Chemistry 14(14): 2161-2175.
Moroz, P., S. K. Jones and B. N. Gray (2002). "Magnetically mediated hyperthermia: current status
and future directions." International Journal of Hyperthermia 18(4): 267-284.
Mu, Q., F. M. Kievit, R. J. Kant, G. Lin, M. Jeon and M. Zhang (2015). "Anti-HER2/neu peptideconjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells."
Nanoscale 7(43): 18010-18014.
Mueller-Klieser, W., P. Vaupel, S. Walenta, F. Kallinowski and W. Paschen (1987).
"IDENTIFICATION OF HETEROGENEOUS SUBSTRATE DISTRIBUTIONS IN TUMORS
AND TUMOR SPHEROIDS USING BIOLUMINESCENCE." Pfluegers Archiv European Journal
of Physiology 408(SUPPL. 1): R84-R84.
Murbe, J., A. Rechtenbach and J. Topfer (2008). "Synthesis and physical characterization of
magnetite nanoparticles for biomedical applications." Materials Chemistry and Physics 110(2-3):
426-433.
Murthy, S. K. (2007). "Nanoparticles in modern medicine: State of the art and future challenges."
International Journal of Nanomedicine 2(2): 129-141.
Mustafa, T., Y. Zhang, F. Watanabe, A. Karmakar, M. P. Asar, R. Little, M. K. Hudson, Y. Xu and
A. S. Biris (2013). "Iron oxide nanoparticle-based radio-frequency thermotherapy for human breast
adenocarcinoma cancer cells." Biomaterials Science 1(8): 870-880.
Nair, B. G., T. Fukuda, T. Mizuki, T. Hanajiri and T. Maekawa (2012). "Intracellular trafficking of
superparamagnetic iron oxide nanoparticles conjugated with TAT peptide: 3-dimensional electron
tomography analysis." Biochemical and Biophysical Research Communications 421(4): 763-767.
Neshasteh-Riz, A., R. Rahdani and A. Mostaar (2014). "Evaluation of The Combined Effects of
Hyperthermia, Cobalt-60 Gamma Rays and IUdR on Cultured Glioblastoma Spheroid Cells and
Dosimetry Using TLD-100." Cell Journal 16(3): 335-342.
Nirmalanandhan, V. S., A. Duren, P. Hendricks, G. Vielhauer and G. S. Sittampalam (2010).
"Activity of Anticancer Agents in a Three-Dimensional Cell Culture Model." Assay and Drug
Development Technologies 8(5): 581-590.

191

Ogawara, K., M. Yoshida, K. Higaki, T. Kimura, K. Shiraishi, M. Nishikawa, Y. Takakura and M.
Hashida (1999). "Hepatic uptake of polystyrene microspheres in rats: Effect of particle size on
intrahepatic distribution." Journal of Controlled Release 59(1): 15-22.
Ohno, S., Z. H. Siddik, Y. Kido, L. A. Zwelling and J. M. C. Bull (1994). "THERMAL
ENHANCEMENT OF DRUG UPTAKE AND DNA-ADDUCTS AS A POSSIBLE
MECHANISM FOR THE EFFECT OF SEQUENCING HYPERTHERMIA ON CISPLATININDUCED CYTOTOXICITY IN L1210 CELLS." Cancer Chemotherapy and Pharmacology
34(4): 302-306.
Osaka, T., T. Nakanishi, S. Shanmugam, S. Takahama and H. Zhang (2009). "Effect of surface
charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein
endothelial cells." Colloids and Surfaces B-Biointerfaces 71(2): 325-330.
Overgaard, J. and O. S. Nielsen (1980). "The role of tissue environmental factors on the kinetics
and morphology of tumor cells exposed to hyperthermia." Annals of the New York Academy of
Sciences 335: 254-280.
Oyelere, A. K., P. C. Chen, X. Huang, I. H. El-Sayed and M. A. El-Sayed (2007). "Peptideconjugated gold nanorods for nuclear targeting." Bioconjugate Chemistry 18(5): 1490-1497.
Palmacci, S. and L. Josephson (1993). Synthesis of polysaccharide covered superparamagnetic
oxide colloids. United States, Advanced Magnetics, Inc.
Pan, L. M., Q. J. He, J. N. Liu, Y. Chen, M. Ma, L. L. Zhang and J. L. Shi (2012). "NuclearTargeted Drug Delivery of TAT Peptide-Conjugated Monodisperse Mesoporous Silica
Nanoparticles." Journal of the American Chemical Society 134(13): 5722-5725.
Pankhurst, Q. A., J. Connolly, S. K. Jones and J. Dobson (2003). "Applications of magnetic
nanoparticles in biomedicine." Journal of Physics D-Applied Physics 36(13): R167-R181.
Pankhurst, Q. A., N. T. K. Thanh, S. K. Jones and J. Dobson (2009). "Progress in applications of
magnetic nanoparticles in biomedicine." Journal of Physics D-Applied Physics 42(22).
Pankhurst, Q. A., N. T. K. Thanh, S. K. Jones and J. Dobson (2009). "Progress in applications of
magnetic nanoparticles in biomedicine." Journal of Physics D-Applied Physics 42(22): 15.
Pardoe, H., W. Chua-anusorn, T. G. St Pierre and J. Dobson (2001). "Structural and magnetic
properties of nanoscale iron oxide particles synthesized in the presence of dextran or polyvinyl
alcohol." Journal of Magnetism and Magnetic Materials 225(1-2): 41-46.
Park, E.-J., H. N. Umh, D.-H. Choi, M. H. Cho, W. Choi, S.-W. Kim, Y. Kim and J.-H. Kim (2014).
"Magnetite- and maghemite-induced different toxicity in murine alveolar macrophage cells."
Archives of Toxicology 88(8): 1607-1618.
Park, J.-H., G. Von Malzahn, L. Zhang, M. P. Schwartz, E. Ruoslahti, S. N. Bhatia and M. J. Sailor
(2008). "Magnetic iron oxide nanoworms for tumor targeting and imaging." Advanced Materials
20: 1630-1635.

192

Park, J., K. J. An, Y. S. Hwang, J. G. Park, H. J. Noh, J. Y. Kim, J. H. Park, N. M. Hwang and T.
Hyeon (2004). "Ultra-large-scale syntheses of monodisperse nanocrystals." Nature Materials 3(12):
891-895.
Park, J. Y., H. Y. Jeong, M. I. Kim and T. J. Park (2015). "Colorimetric Detection System for
Salmonella typhimurium Based on Peroxidase-Like Activity of Magnetic Nanoparticles with DNA
Aptamers." Journal of Nanomaterials: 9.
Parker, N., M. J. Turk, E. Westrick, J. D. Lewis, P. S. Low and C. P. Leamon (2005). "Folate
receptor expression in carcinomas and normal tissues determined by a quantitative radioligand
binding assay." Analytical Biochemistry 338(2): 284-293.
Passemard, S., D. Staedler, L. Ucnova, G. S. Schneiter, P. Kong, L. Bonacina, L. Juillerat-Jeanneret
and S. Gerber-Lemaire (2013). "Convenient synthesis of heterobifunctional poly(ethylene glycol)
suitable for the functionalization of iron oxide nanoparticles for biomedical applications."
Bioorganic & Medicinal Chemistry Letters 23(17): 5006-5010.
Petryk, A. A., A. J. Giustini, R. E. Gottesman, P. A. Kaufman and P. J. Hoopes (2013). "Magnetic
nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment." International
Journal of Hyperthermia 29(8): 845-851.
Petters, C., F. Bulcke, K. Thiel, U. Bickmeyer and R. Dringen (2014). "Uptake of Fluorescent Iron
Oxide Nanoparticles by Oligodendroglial OLN-93 Cells." Neurochemical Research 39(2): 372383.
Phillips, M. A., M. L. Gran and N. A. Peppas (2010). "Targeted nanodelivery of drugs and
diagnostics." Nano Today 5(2): 143-159.
Pierrat, S., I. Zins, A. Breivogel and C. Soennichsen (2007). "Self-assembly of small gold colloids
with functionalized gold nanorods." Nano Letters 7(2): 259-263.
Plouffe, B. D., S. K. Murthy and L. H. Lewis (2015). "Fundamentals and application of magnetic
particles in cell isolation and enrichment: a review." Reports on Progress in Physics 78(1).
Polo-Corrales, L. and C. Rinaldi (2012). "Monitoring iron oxide nanoparticle surface temperature
in an alternating magnetic field using thermoresponsive fluorescent polymers." Journal of Applied
Physics 111(7).
Qiao, R. R., C. H. Yang and M. Y. Gao (2009). "Superparamagnetic iron oxide nanoparticles: from
preparations to in vivo MRI applications." Journal of Materials Chemistry 19(35): 6274-6293.
Rabin, Y. (2002). "Is intracellular hyperthermia superior to extracellular hyperthermia in the
thermal sense?" International Journal of Hyperthermia 18(3): 194-202.
Rao, K. S., M. K. Reddy, J. L. Horning and V. Labhasetwar (2008). "TAT-conjugated nanoparticles
for the CNS delivery of anti-HIV drugs." Biomaterials 29(33): 4429-4438.
Razjouyan, J., H. Zolata, O. Khayat, F. Nowshiravan, N. Shadanpour and M. Mohammadnia
(2015). "Synthesis and evaluation of radiolabeled, folic acid-PEG conjugated, amino silane coated
magnetic nanoparticles in tumor bearing Balb/C mice." Nukleonika 60(3): 497-502.

193

Reimer, P. and T. Balzer (2003). "Ferucarbotran (Resovist): a new clinically approved RESspecific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development,
and applications." European Radiology 13(6): 1266-1276.
Rejinold, N. S., R. Jayakumar and Y.-C. Kim (2015). "Radio frequency responsive nanobiomaterials for cancer therapy." Journal of Controlled Release 204(0): 85-97.
Ridi, F., M. Bonini and P. Baglioni (2014). "Magneto-responsive nanocomposites: Preparation and
integration of magnetic nanoparticles into films, capsules, and gels." Advances in Colloid and
Interface Science 207: 3-13.
Rivet, C. J., Y. Yuan, R. J. Gilbert and D.-A. Borca-Tasciuc (2014). "Effect of magnetic
nanoparticle heating on cortical neuron viability." International Journal of Hyperthermia 30(2): 7985.
Rodriguez-Luccioni, H. L., M. Latorre-Esteves, J. Mendez-Vega, O. Soto, A. R. Rodriguez, C.
Rinaldi and M. Torres-Lugo (2011). "Enhanced reduction in cell viability by hyperthermia induced
by magnetic nanoparticles." International Journal of Nanomedicine 6: 373-380.
Rosen, J. E., L. Chan, D.-B. Shieh and F. X. Gu (2012). "Iron oxide nanoparticles for targeted
cancer imaging and diagnostics." Nanomedicine-Nanotechnology Biology and Medicine 8(3): 275290.
Roy, K., R. K. Kanwar and J. R. Kanwar (2015). "LNA aptamer based multi-modal, Fe3O4saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon
tumor targeting and NIR, MRI and CT imaging." Biomaterials 71: 84-99.
Ruoslahti, E., S. N. Bhatia and M. J. Sailor (2010). "Targeting of drugs and nanoparticles to
tumors." JCB: Review 188(6): 759-768.
Sadhasivam, S., S. Savitha, C. J. Wu, F. H. Lin and L. Stobinski (2015). "Carbon encapsulated iron
oxide nanoparticles surface engineered with polyethylene glycol-folic acid to induce selective
hyperthermia in folate over expressed cancer cells." International Journal of Pharmaceutics 480(12): 8-14.
Sanchez, C., D. E. H. Diab, V. Connord, P. Clerc, E. Meunier, B. Pipy, B. Payre, R. P. Tan, M.
Gougeon, J. Carrey, V. Gigoux and D. Fourmy (2014). "Targeting a G-Protein-Coupled Receptor
Overexpressed in Endocrine Tumors by Magnetic Nanoparticles To Induce Cell Death." Acs Nano
8(2): 1350-1363.
Sapareto, S. A., G. P. Raaphorst and W. C. Dewey (1979). "CELL KILLING AND THE
SEQUENCING OF HYPERTHERMIA AND RADIATION." International Journal of Radiation
Oncology Biology Physics 5(3): 343-347.
Saraswathy, A., S. S. Nazeer, M. Jeevan, N. Nimi, S. Arumugam, V. S. Harikrishnan, P. R. H.
Varma and R. S. Jayasree (2014). "Citrate coated iron oxide nanoparticles with enhanced relaxivity
for in vivo magnetic resonance imaging of liver fibrosis." Colloids and Surfaces B-Biointerfaces
117: 216-224.

194

Saraswathy, A., S. S. Nazeer, N. Nimi, S. Arumugam, S. J. Shenoy and R. S. Jayasree (2014).
"Synthesis and characterization of dextran stabilized superparamagnetic iron oxide nanoparticles
for in vivo MR imaging of liver fibrosis." Carbohydrate Polymers 101: 760-768.
Satarkar, N. S., D. Biswal and J. Z. Hilt (2010). "Hydrogel nanocomposites: a review of
applications as remote controlled biomaterials." Soft Matter 6(11): 2364-2371.
Sawdon, A., E. Weydemeyer and C.-A. Peng (2014). "Antitumor Therapy Using NanomaterialMediated Thermolysis." Journal of Biomedical Nanotechnology 10(9): 1894-1917.
Schleich, N., F. Danhier and V. Preat (2015). "Iron oxide-loaded nanotheranostics: Major obstacles
to in vivo studies and clinical translation." Journal of Controlled Release 198: 35-54.
Schleich, N., C. Po, D. Jacobs, B. Ucakar, B. Gallez, F. Danhier and V. Preat (2014). "Comparison
of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded
nanoparticles for tumor imaging and therapy." Journal of Controlled Release 194: 82-91.
Senavirathna, L. K., R. Fernando, D. Maples, Y. Zheng, J. C. Polf and A. Ranjan (2013). "Tumor
Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam
Radiotherapy and Thermally Sensitive Nanocarriers." Theranostics 3(9): 687-691.
Shan, X. H., H. Hu, F. Xiong, N. Gu, X. D. Geng, W. Zhu, J. Lin and Y. F. Wang (2012). "Targeting
Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-g1ucose modified SPIOs." European
Journal of Radiology 81(1): 95-99.
Shanehsazzadeh, S., C. Gruettner, A. Lahooti, M. Mahmoudi, B. J. Allen, M. Ghavami, F. J. Daha
and M. A. Oghabian (2015). "Monoclonal antibody conjugated magnetic nanoparticles could target
MUC-1-positive cells in vitro but not in vivo." Contrast Media & Molecular Imaging 10(3): 225236.
Sharapova, V. A., M. A. Uimin, A. A. Mysik and A. E. Ermakov (2010). "Heat Release in Magnetic
Nanoparticles in AC Magnetic Fields." Physics of Metals and Metallography 110(1): 5-12.
Shinkai, M., M. Yanase, M. Suzuki, H. Honda, T. Wakabayashi, J. Yoshida and T. Kobayashi
(1999). "Intracellular hyperthermia for cancer using magnetite cationic liposomes." Journal of
Magnetism and Magnetic Materials 194(1-3): 176-184.
Shubayev, V. I., T. R. Pisanic and S. H. Jin (2009). "Magnetic nanoparticles for theragnostics."
Advanced Drug Delivery Reviews 61(6): 467-477.
Simberg, D., T. Duza, J. H. Park, M. Essler, J. Pilch, L. Zhang, A. M. Derfus, M. Yang, R. M.
Hoffman, S. N. Bhatia, M. J. Sailor and E. Ruoslahti (2007). "Biomimetic amplification of
nanoparticle homing to tumors." Proceedings of the National Academy of Sciences 104(3): 932936.
Singh, A. and S. K. Sahoo (2014). "Magnetic nanoparticles: a novel platform for cancer
theranostics." Drug Discovery Today 19(4): 474-481.
Singh, D., J. M. McMillan, A. V. Kabanov, M. Sokolsky-Papkov and H. E. Gendelman (2014).
"Bench-to-bedside translation of magnetic nanoparticles." Nanomedicine 9(4): 501-516.

195

Socaci, C., L. Magerusan, R. Turcu and J. Liebscher (2015). "Developing novel strategies for the
functionalization of core-shell magnetic nanoparticles with folic acid derivatives." Materials
Chemistry and Physics 162: 131-139.
Song, Y., Z. Huang, J. Xu, D. Ren, Y. Wang, X. Zheng, Y. Shen, L. Wang, H. Gao, J. Hou, Z.
Pang, J. Qian and J. Ge (2014). "Multimodal SPION-CREKA peptide based agents for molecular
imaging of microthrombus in a rat myocardial ischemia-reperfusion model." Biomaterials 35(9):
2961-2970.
Soni, S., H. Tyagi, R. A. Taylor and A. Kumar (2014). "Investigation on nanoparticle distribution
for thermal ablation of a tumour subjected to nanoparticle assisted thermal therapy." Journal of
Thermal Biology 43: 70-80.
Sreeja, V. and P. A. Joy (2011). "Effect of inter-particle interactions on the magnetic properties of
magnetite nanoparticles after coating with dextran." International Journal of Nanotechnology 8(1012): 907-915.
Stephen Palmacci, L. J. (1993). Synthesis of polysaccharide covered superparamagnetic oxide
colloids. A. Magnetics. United States. 5,262,176.
Stephen, Z. R., F. M. Kievit, O. Veiseh, P. A. Chiarelli, C. Fang, K. Wang, S. J. Hatzinger, R. G.
Ellenbogen, J. R. Silber and M. Q. Zhang (2014). "Redox-Responsive Magnetic Nanoparticle for
Targeted Convection-Enhanced Delivery of O-6-Benzylguanine to Brain Tumors." Acs Nano
8(10): 10383-10395.
Sun, C., K. Du, C. Fang, N. Bhattarai, O. Veiseh, F. Kievit, Z. Stephen, D. Lee, R. G. Ellenbogen,
B. Ratner and M. Zhang (2010). "PEG-Mediated Synthesis of Highly Dispersive Multifunctional
Superparamagnetic Nanoparticles: Their Physicochemical Properties and Function In Vivo." Acs
Nano 4(4): 2402-2410.
Sun, D., J. Lu, Y. Zhong, Y. Yu, Y. Wang, B. Zhang and Z. Chen (2016). "Sensitive
electrochemical aptamer cytosensor for highly specific detection of cancer cells based on the hybrid
nanoelectrocatalysts and enzyme for signal amplification." Biosensors & Bioelectronics 75: 301307.
Sun, S. H., H. Zeng, D. B. Robinson, S. Raoux, P. M. Rice, S. X. Wang and G. X. Li (2004).
"Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles." Journal of the American Chemical
Society 126(1): 273-279.
Suto, M., Y. Hirota, H. Mamiya, A. Fujita, R. Kasuya, K. Tohji and B. Jeyadevan (2009). "Heat
dissipation mechanism of magnetite nanoparticles in magnetic fluid hyperthermia." Journal of
Magnetism and Magnetic Materials 321(10): 1493-1496.
Suzuki, M., M. Shinkai, H. Honda and T. Kobayashi (2003). "Anticancer effect and immune
induction by hyperthermia of malignant melanoma using magnetite cationic liposomes." Melanoma
Research 13(2): 129-135.
Takahashi, I., Y. Emi, S. Hasuda, Y. Kakeji, Y. Maehara and K. Sugimachi (2002). "Clinical
application of hyperthermia combined with anticancer drugs for the treatment of solid tumors."
Surgery 131(1): S78-S84.

196

Tarn, D., C. E. Ashley, M. Xue, E. C. Carnes, J. I. Zink and C. J. Brinker (2013). "Mesoporous
Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility." Accounts of Chemical
Research 46(3): 792-801.
Tartaj, P., M. D. Morales, S. Veintemillas-Verdaguer, T. Gonzalez-Carreno and C. J. Serna (2003).
"The preparation of magnetic nanoparticles for applications in biomedicine." Journal of Physics DApplied Physics 36(13): R182-R197.
Tassa, C., S. Y. Shaw and R. Weissleder (2011). "Dextran-Coated Iron Oxide Nanoparticles: A
Versatile Platform for Targeted Molecular Imaging, Molecular Diagnostic, and Therapy."
Accounts of Chemical Research 44(10): 842-852.
Terman, A., T. Kurz, B. Gustafsson and U. T. Brunk (2006). "Lysosomal labilization." Iubmb Life
58(9): 531-539.
Thevenot, J., H. Oliveira, O. Sandre and S. Lecommandoux (2013). "Magnetic responsive polymer
composite materials." Chemical Society Reviews 42(17): 7099-7116.
Thorek, D. L. J. and A. Tsourkas (2008). "Size, charge and concentration dependent uptake of iron
oxide particles by non-phagocytic cells." Biomaterials 29(26): 3583-3590.
Toraya-Brown, S., M. R. Sheen, P. Zhang, L. Chen, J. R. Baird, E. Demidenko, M. J. Turk, P. J.
Hoopes, J. R. Conejo-Garcia and S. Fiering (2014). "Local hyperthermia treatment of tumors
induces CD8(+) T cell-mediated resistance against distal and secondary tumors." NanomedicineNanotechnology Biology and Medicine 10(6): 1273-1285.
Torchilin, V. P. (2008). "Tat peptide-mediated intracellular delivery of pharmaceutical
nanocarriers." Advanced Drug Delivery Reviews 60(4-5): 548-558.
Trachootham, D., Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, H. Pelicano, P. J. Chiao, G. Achanta,
R. B. Arlinghaus, J. Liu and P. Huang (2006). "Selective killing of oncogenically transformed cells
through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate." Cancer Cell 10(3): 241252.
Tse, B. W. C., G. J. Cowin, C. Soekmadji, L. Jovanovic, R. S. Vasireddy, M. T. Ling, A. Khatri,
T. Q. Liu, B. Thierry and P. J. Russell (2015). "PSMA-targeting iron oxide magnetic nanoparticles
enhance MRI of preclinical prostate cancer." Nanomedicine 10(3): 375-386.
Tucek, J., R. Zboril and D. Petridis (2006). "Maghemite nanoparticles by view of Mossbauer
spectroscopy." Journal of Nanoscience and Nanotechnology 6(4): 926-947.
Tudisco, C., M. T. Cambria, F. Sinatra, F. Bertani, A. Alba, A. E. Giuffrida, S. Saccone, E.
Fantechi, C. Innocenti, C. Sangregorio, E. Dalcanale and G. G. Condorelli (2015). "Multifunctional
magnetic nanoparticles for enhanced intracellular drug transport." Journal of Materials Chemistry
B 3(20): 4134-4145.
Turcheniuk, K., A. V. Tarasevych, V. P. Kukhar, R. Boukherroub and S. Szunerits (2013). "Recent
advances in surface chemistry strategies for the fabrication of functional iron oxide based magnetic
nanoparticles." Nanoscale 5(22): 10729-10752.

197

Urano, M., M. Kuroda and Y. Nishimura (1999). "For the clinical application of
thermochemotherapy given at mild temperatures." International Journal of Hyperthermia 15(2): 79107.
Vaupel, P., F. Kallinowski and P. Okunieff (1989). "BLOOD-FLOW, OXYGEN AND
NUTRIENT SUPPLY, AND METABOLIC MICROENVIRONMENT OF HUMAN-TUMORS A REVIEW." Cancer Research 49(23): 6449-6465.
Vayssieres, L., C. Chaneac, E. Tronc and J. P. Jolivet (1998). "Size tailoring of magnetite particles
formed by aqueous precipitation: An example of thermodynamic stability of nanometric oxide
particles." Journal of Colloid and Interface Science 205(2): 205-212.
Veiseh, O., J. W. Gunn and M. Q. Zhang (2010). "Design and fabrication of magnetic nanoparticles
for targeted drug delivery and imaging." Advanced Drug Delivery Reviews 62(3): 284-304.
Veiseh, O., F. M. Kievit, C. Fang, N. Mu, S. Jana, M. C. Leung, H. Mok, R. G. Ellenbogen, J. O.
Park and M. Zhang (2010). "Chlorotoxin bound magnetic nanovector tailored for cancer cell
targeting, imaging, and siRNA delivery." Biomaterials 31(31): 8032-8042.
Vertrees, R. A., G. C. Das, V. L. Popov, A. M. Coscio, T. J. Goodwin, R. Logrono, J. B.
Zwischenberger and P. J. Boor (2005). "Synergistic Interation of Hyperthermia and Gemcitabine
in Lung Cancer." Cancer Biology & Therapy 4(10): 1144-1153.
Villanueva, A., M. Canete, A. G. Roca, M. Calero, S. Veintemillas-Verdaguer, C. J. Serna, M. del
Puerto Morales and R. Miranda (2009). "The influence of surface functionalization on the enhanced
internalization of magnetic nanoparticles in cancer cells." Nanotechnology 20(11).
Vives, E., P. Brodin and B. Lebleu (1997). "A truncated HIV-1 Tat protein basic domain rapidly
translocates through the plasma membrane and accumulates in the cell nucleus." Journal of
Biological Chemistry 272(25): 16010-16017.
Voinov, M. A., J. O. S. Pagan, E. Morrison, T. I. Smirnova and A. I. Smirnov (2011). "SurfaceMediated Production of Hydroxyl Radicals as a Mechanism of Iron Oxide Nanoparticle
Biotoxicity." Journal of the American Chemical Society 133(1): 35-41.
Walther, W. and U. Stein (2009). "Heat-responsive gene expression for gene therapy." Advanced
Drug Delivery Reviews 61(7-8): 641-649.
Wang, C., J. Qian, K. Wang, X. Yang, Q. Liu, N. Hao, C. Wang, X. Dong and X. Huang (2016).
"Colorimetric aptasensing of ochratoxin A using Au@Fe3O4 nanoparticles as signal indicator and
magnetic separator." Biosensors & bioelectronics 77: 1183-1191.
Wang, C., L. Qiao, Q. Zhang, H. Yan and K. Liu (2012). "Enhanced cell uptake of
superparamagnetic iron oxide nanoparticles through direct chemisorption of FITC-Tat-PEG(600)b-poly(glycerol monoacrylate)." International Journal of Pharmaceutics 430(1-2): 372-380.
Wang, G. H., D. R. Xu, Q. Chai, X. L. Tan, Y. Zhang, N. Gu and J. T. Tang (2014). "Magnetic
fluid hyperthermia inhibits the growth of breast carcinoma and downregulates vascular endothelial
growth factor expression." Oncology Letters 7(5): 1370-1374.

198

Wang, J. and J. Yi (2008). "Cancer cell killing via ROS To increase or decrease, that is the
question." Cancer Biology & Therapy 7(12): 1875-1884.
Wang, L. F., J. Dong, W. W. Ouyang, X. W. Wang and J. T. Tang (2012). "Anticancer effect and
feasibility study of hyperthermia treatment of pancreatic cancer using magnetic nanoparticles."
Oncology Reports 27(3): 719-726.
Wang, Q. B., J. F. Li, S. An, Y. Chen, C. Jiang and X. L. Wang (2015). "Magnetic resonanceguided regional gene delivery strategy using a tumor stroma-permeable nanocarrier for pancreatic
cancer." International Journal of Nanomedicine 10: 4479-4490.
Wei, Y., G. Yin, C. Ma, Z. Huang, X. Chen, X. Liao, Y. Yao and H. Yin (2013). "Synthesis and
cellular compatibility of biomineralized Fe3O4 nanoparticles in tumor cells targeting peptides."
Colloids and Surfaces B-Biointerfaces 107: 180-188.
Weissleder, R., D. D. Stark, B. L. Engelstad, B. R. Bacon, C. C. Compton, D. L. White, P. Jacobs
and J. Lewis (1989). "SUPERPARAMAGNETIC IRON-OXIDE - PHARMACOKINETICS AND
TOXICITY." American Journal of Roentgenology 152(1): 167-173.
Wu, W., Z. H. Wu, T. Yu, C. Z. Jiang and W. S. Kim (2015). "Recent progress on magnetic iron
oxide nanoparticles: synthesis, surface functional strategies and biomedical applications." Science
and Technology of Advanced Materials 16(2): 43.
Wust, P., B. Hildebrandt, G. Sreenivasa, B. Rau, J. Gellermann, H. Riess, R. Felix and P. M. Schlag
(2002). "Hyperthermia in combined treatment of cancer." Lancet Oncology 3(8): 487-497.
Wydra, R. J., A. M. Kruse, Y. Bae, K. W. Anderson and J. Z. Hilt (2013). "Synthesis and
characterization of PEG-iron oxide core-shell composite nanoparticles for thermal therapy."
Materials Science & Engineering C-Materials for Biological Applications 33(8): 4660-4666.
Wydra, R. J., A. M. Kruse, Y. Bae, K. W. Anderson and J. Z. Hilt (2013). "Synthesis and
characterization of PEG-iron oxide core-shell composite nanoparticles for thermal therapy."
Materials Science and Engineering: C 33(8): 4660-4666.
Wydra, R. J., C. E. Oliver, K. W. Anderson, T. D. Dziubla and J. Z. Hilt (2015). "Accelerated
generation of free radicals by iron oxide nanoparticles in the presence of an alternating magnetic
field." Rsc Advances 5(24): 18888-18893.
Wydra, R. J., P. G. Rychahou, B. M. Evers, K. W. Anderson, T. D. Dziubla and J. Z. Hilt (2015).
"The role of ROS generation from magnetic nanoparticles in an alternating magnetic field on
cytotoxicity." Acta Biomaterialia 25: 284-290.
Xi, Z. J., R. R. Huang, Z. Y. Li, N. Y. He, T. Wang, E. B. Su and Y. Deng (2015). "Selection of
HBsAg-Specific DNA Aptamers Based on Carboxylated Magnetic Nanoparticles and Their
Application in the Rapid and Simple Detection of Hepatitis B Virus Infection." Acs Applied
Materials & Interfaces 7(21): 11215-11223.
Xie, J., K. Chen, J. Huang, S. Lee, J. Wang, J. Gao, X. Li and X. Chen (2010). "PET/NIRF/MRI
triple functional iron oxide nanoparticles." Biomaterials 31(11): 3016-3022.

199

Xie, J., G. Liu, H. S. Eden, H. Ai and X. Chen (2011). "Surface-Engineered Magnetic Nanoparticle
Platforms for Cancer Imaging and Therapy." Accounts of Chemical Research 44(10): 883-892.
Xie, W. and X. Zang (2016). "Immobilized lipase on core-shell structured Fe3O4-MCM-41
nanocomposites as a magnetically recyclable biocatalyst for interesterification of soybean oil and
lard." Food Chemistry 194: 1283-1292.
Xiong, F., Z. Y. Zhu, C. Xiong, X. Q. Hua, X. H. Shan, Y. Zhang and N. Gu (2012). "Preparation,
Characterization of 2-Deoxy-D-Glucose Functionalized Dimercaptosuccinic Acid-Coated
Maghemite Nanoparticles for Targeting Tumor Cells." Pharmaceutical Research 29(4): 1087-1097.
Xu, C., J. Xie, N. Kohler, E. G. Walsh, Y. E. Chin and S. Sun (2008). "Monodisperse magnetite
nanoparticles coupled with nuclear localization signal peptide for cell-nucleus targeting."
Chemistry-an Asian Journal 3(3): 548-552.
Xu, X. Q., H. Shen, Xu, Jr., J. Xu, X. J. Li and X. M. Xiong (2005). "Core-shell structure and
magnetic properties of magnetite magnetic fluids stabilized with dextran." Applied Surface Science
252(2): 494-500.
Xu, Y., A. Karmakar, W. E. Heberlein, T. Mustafa, A. R. Biris and A. S. Biris (2012).
"Multifunctional Magnetic Nanoparticles for Synergistic Enhancement of Cancer Treatment by
Combinatorial Radio Frequency Thermolysis and Drug Delivery." Advanced Healthcare Materials
1(4): 493-501.
Xu, Y., A. Karmakar, D. Y. Wang, M. W. Mahmood, F. Watanabe, Y. B. Zhang, A. Fejleh, P.
Fejleh, Z. R. Li, G. Kannarpady, S. Ali, A. R. Biris and A. S. Biris (2010). "Multifunctional Fe3O4
Cored Magnetic-Quantum Dot Fluorescent Nanocomposites for RF Nanohyperthermia of Cancer
Cells." Journal of Physical Chemistry C 114(11): 5020-5026.
Xue, S., C. Zhang, Y. Yang, L. Zhang, D. Cheng, J. Zhang, H. Shi and Y. Zhang (2015). "99mTcLabeled Iron Oxide Nanoparticles for Dual-Contrast (T-1/T-2) Magnetic Resonance and DualModality Imaging of Tumor Angiogenesis." Journal of Biomedical Nanotechnology 11(6): 10271037.
Yamamori, T., H. Yasui, M. Yamazumi, Y. Wada, Y. Nakamura, H. Nakamura and O. Inanami
(2012). "Ionizing radiation induces mitochondrial reactive oxygen species production accompanied
by upregulation of mitochondrial electron transport chain function and mitochondrial content under
control of the cell cycle checkpoint." Free Radical Biology and Medicine 53(2): 260-270.
Yamauchi, H., T. Asao, S. Yazawa, W. Kigure, H. Morita, T. Kobayashi, T. Kato, R. Yajima, Y.
Tabe, S. Yamaki, T. Fukasawa, T. Fujii, S. Tsutsumi and H. Kuwano (2011). "Cell to Cell
Interaction in Clusters Enhances Thermosensitivity in HT29 Human Colon Cancer Cells." HepatoGastroenterology 58(112): 1958-1962.
Yanase, M., M. Shinkai, H. Honda, T. Wakabayashi, J. Yoshida and T. Kobayashi (1998).
"Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes."
Japanese Journal of Cancer Research 89(7): 775-782.
Yang, C., M. Neshatian, M. van Prooijen and D. B. Chithrani (2014). "Cancer Nanotechnology:
Enhanced Therapeutic Response Using Peptide-Modified Gold Nanoparticles." Journal of
Nanoscience and Nanotechnology 14(7): 4813-4819.
200

Yang, H., Y. Zhuang, Y. Sun, A. Dai, X. Shi, D. Wu, F. Li, H. Hu and S. Yang (2011). "Targeted
dual-contrast T-1- and T-2-weighted magnetic resonance imaging of tumors using multifunctional
gadolinium-labeled superparamagnetic iron oxide nanoparticles." Biomaterials 32(20): 4584-4593.
Yin, C., B. B. Hong, Z. C. Gong, H. Zhao, W. B. Hu, X. M. Lu, J. Li, X. Li, Z. Yang, Q. L. Fan,
Y. Y. Yao and W. Huang (2015). "Fluorescent oligo(p-phenyleneethynylene) contained
amphiphiles-encapsulated magnetic nanoparticles for targeted magnetic resonance and two-photon
optical imaging in vitro and in vivo." Nanoscale 7(19): 8907-8919.
Yin, P. T., B. P. Shah and K.-B. Lee (2014). "Combined Magnetic Nanoparticle-based MicroRNA
and Hyperthermia Therapy to Enhance Apoptosis in Brain Cancer Cells." Small 10(20): 4106-4112.
Yoffe, S., T. Leshuk, P. Everett and F. Gu (2013). "Superparamagnetic Iron Oxide Nanoparticles
(SPIONs): Synthesis and Surface Modification Techniques for use with MRI and Other Biomedical
Applications." Current Pharmaceutical Design 19(3): 493-509.
Yoo, D., H. Jeong, S. H. Noh, J. H. Lee and J. Cheon (2013). "Magnetically Triggered Dual
Functional Nanoparticles for Resistance-Free Apoptotic Hyperthermia." Angewandte ChemieInternational Edition 52(49): 13047-13051.
Zaloga, J., C. Janko, J. Nowak, J. Matuszak, S. Knaup, D. Eberbeck, R. Tietze, H. Unterweger, R.
P. Friedrich, S. Duerr, R. Heimke-Brinck, E. Baum, I. Cicha, F. Doerje, S. Odenbach, S. Lyer, G.
Lee and C. Alexiou (2014). "Development of a lauric acid/albumin hybrid iron oxide nanoparticle
system with improved biocompatibility." International Journal of Nanomedicine 9: 4847-4866.
Zhang, C., M. Jugold, E. C. Woenne, T. Lammers, B. Morgenstern, M. M. Mueller, H. Zentgraf,
M. Bock, M. Eisenhut, W. Semmler and F. Keissling (2007). "Specific targeting of tumor
angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical
1.5-T magnetic resonance scanncer." Cancer Research 67(4): 1555-1562.
Zhang, E., M. F. Kircher, M. Koch, L. Eliasson, S. N. Goldberg and E. Renstrom (2014). "Dynamic
Magnetic Fields Remote-Control Apoptosis via Nanoparticle Rotation." Acs Nano 8(4): 31923201.
Zhang, H., X. Ma, Y. Liu, N. Duan, S. Wu, Z. Wang and B. Xu (2015). "Gold nanoparticles
enhanced SERS aptasensor for the simultaneous detection of Salmonella typhimurium and
Staphylococcus aureus." Biosensors & Bioelectronics 74: 872-877.
Zhao, M., F. Antunes, J. W. Eaton and U. T. Brunk (2003). "Lysosomal enzymes promote
mitochondrial oxidant production, cytochrome c release and apoptosis." European Journal of
Biochemistry 270(18): 3778-3786.
Zhao, Z., D. Huang, Z. Yin, X. Chi, X. Wang and J. Gao (2012). "Magnetite nanoparticles as smart
carriers to manipulate the cytotoxicity of anticancer drugs: magnetic control and pH-responsive
release." Journal of Materials Chemistry 22(31): 15717-15725.
Zwischenberger, J. B., R. A. Vertrees, E. A. Bedell, C. K. McQuitty, J. M. Chernin and L. C.
Woodson (2004). "Percutaneous Venovenous Perfusion-Induced Systemic Hyperthermia for Lung
Cancer: A Phase I Safety Study." Annals of Thoracic Surgery 77: 1916-1925.
Copyright © Anastasia K. Hauser 2016
201

Vita
PERSONAL INFORMATION
Place of Birth: Louisville, Kentucky, United States of America
EDUCATION
University of Kentucky, Lexington, KY, May 2012
BS. Chemical Engineering
RESEARCH EXPERIENCE
NSF Graduate Research Fellow
September 2013-present
University of Kentucky, Lexington, KY
Advisors: Dr. Kimberly W. Anderson and Dr. J. Zach Hilt
NIH Cancer and Nanotechnology Trainee
September 2013 – September 2015
University of Kentucky, Lexington, KY
Advisors: Dr. Kimberly W. Anderson and Dr. J. Zach Hilt
NSF Integrative Graduate Education and Research Traineeship (IGERT) Fellow
May 2012 - August 2013
University of Kentucky, Lexington, KY
Advisors: Dr. Kimberly W. Anderson and Dr. J. Zach Hilt
NSF Research Experience for Undergraduates (REU), Research Assistant
May 2010 - May 2012
University of Kentucky, Lexington, KY
Advisors: Dr. Kimberly W. Anderson and Dr. J. Zach Hilt
Research Intern
May 2011 - August 2011
Alltech, Inc., Nicholasville, KY
Advisor: Dr. Stefan Kwiatkowski
AWARDS/HONORS
Dean’s Award for Outstanding PhD Student
NSF Graduate Research Fellowship Program
Philanthropic Educational Organization (P.E.O.) Scholar Award
Student Travel Allowance Research (STAR) Award - Society for Biomaterials
NIH Cancer and Nanotechnology Training Center Fellowship
NSF IGERT Graduate Fellowship
Dr. Jennifer S. and Mr. Jeffery N. Quinn Graduate Fellowship
Daniel R. Reedy Quality Achievement Fellowship
Maurice A. Clay Leadership Award
Omega Chi Epsilon Outstanding Senior
UK AIChE Outstanding Junior
202

2016
2013 - 2016
2014 - 2015
2014
2013 - 2016
2012 - 2013
2012 - 2015
2012 - 2015
2012
2012
2011

Oswald Research Award
UK AIChE Outstanding Sophomore

2011
2010

PUBLICATIONS
Anastasia K. Hauser, Mihail I. Mitov, Emily F. Daley, Kimberly W. Anderson, J. Zach Hilt.
Targeted iron oxide nanoparticles for the enhancement of radiation therapy. Biomaterials (in
review).
Anastasia K. Hauser, Kimberly W. Anderson, J. Zach Hilt. Peptide conjugated magnetic
nanoparticles for magnetically mediated energy delivery to lung cancer cells. Nanomedicine (in
revision).
Anastasia K. Hauser, Robert J. Wydra, Rohit Bhandari, Piotr G. Rychahou, B. Mark Evers,
Kimberly W. Anderson, Thomas D. Dziubla, and J. Zach Hilt. Corrigendum to The Role of ROS
Generation from Magnetic Nanoparticles in an Alternating Magnetic Field on Cytotoxicity. Acta
Biomaterialia 2015; 25:284-290
Anastasia K. Hauser, Robert J. Wydra, Nathanael A. Stocke, Kimberly W. Anderson, J. Zach
Hilt. Magnetic Nanoparticles and Nanocomposites for Remote Controlled Therapies. America’s
Special Issue of the Journal of Controlled Release 2015; 219: 76-94
Anastasia K. Hauser, Ronita Mathias, Kimberly W. Anderson, J. Zach Hilt. Effects of
nanoparticle synthesis on the physical and chemical properties of dextran coated iron oxide
nanoparticles. Materials Chemistry and Physics 2015; 160:177–186.
Anastasia M. Kruse, Samantha A. Meenach, Kimberly W. Anderson, J. Zach Hilt. Synthesis and
Characterization of CREKA-conjugated Iron Oxide Nanoparticles for the Treatment of Cancer
via Hyperthermia. Acta Biomaterialia 2014; 10:2622-2629
Robert J. Wydra, Anastasia M. Kruse, Younsoo Bae, Kimberly W. Anderson, J. Zach Hilt.
Synthesis and Characterization of PEG-Iron Oxide Core-shell Composite Nanoparticles for
Thermal Therapy Applications. Materials Science and Engineering C: Materials for Biological
Applications 2013; 33:4660-4666
PRESENTATIONS
Anastasia K. Hauser, Emily F. Daley, J. Zach Hilt, Kimberly W. Anderson. Radiation
enhancement via ROS generation catalyzed by peptide-conjugated iron oxide nanoparticles.
American Institute of Chemical Engineers National Meeting, Salt Lake City, UT, November 12,
2015
Anastasia K. Hauser, Emily F. Daley, J. Zach Hilt, Kimberly W. Anderson. Radiation
enhancement via ROS generation catalyzed by iron oxide nanoparticles. MACE Spring
Symposium (Award Presentation), Lexington, KY, May 29th, 2015.
Anastasia K. Hauser, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Development
and Characterization of CREKA-Conjugated Iron Oxide Nanoparticles for Hyperthermia in
Combination with Chemotherapy. American Institute of Chemical Engineers National Meeting,
Atlanta, GA, November 19, 2014
203

Anastasia K. Hauser, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Development
and Characterization of CREKA-Conjugated Iron Oxide Nanoparticles for Hyperthermia in
Combination with Chemotherapy. American Institute of Chemical Engineers National Meeting,
Atlanta, GA, November 18, 2014
*Awarded 2nd place in the Nanoscale Science and Engineering Graduate Student Award Session
Anastasia K. Hauser, J. Zach Hilt, Kimberly W. Anderson. Development of CREKA-conjugated
Iron Oxide Nanoparticles for the Treatment of Cancer via Hyperthermia. UK Biomaterials Day,
Lexington, KY, September 27, 2014
Anastasia M. Kruse, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Synthesis and
Characterization of CREKA-conjugated Iron Oxide Nanoparticles for the Treatment of Cancer
via Hyperthermia. AIChE National Conference, San Francisco, CA, November 8, 2013
Anastasia M. Kruse, Robert J. Wydra, J. Zach Hilt, Kimberly W. Anderson. Biocompatibility
Analysis and Cancer Therapy Application of Core-Shell Composite Magnetic Nanoparticles.
2011 AIChE Southern Region Student Meeting, Atlanta, GA, April 1-3, 2011.
Posters
Anastasia K. Hauser, Emily F. Daley, J. Zach Hilt, Kimberly W. Anderson. Radiation
enhancement via ROS generation catalyzed by iron oxide nanoparticles. Markey Cancer
Research Day, Lexington, KY, May 28, 2015
Anastasia K. Hauser, J. Zach Hilt, Kimberly W. Anderson. Development of CREKA-conjugated
iron oxide nanoparticles for hyperthermia treatment of cancer. Society for Biomaterials Annual
Meeting, Charlotte, NC, April 16, 2015
Anastasia K. Hauser, J. Zach Hilt, Kimberly W. Anderson. The effects of synthesis method on the
physical and chemical properties of dextran coated iron oxide nanoparticles. American Institute
of Chemical Engineers National Meeting, Atlanta, GA, November 18, 2014
Anastasia K. Hauser, J. Zach Hilt, Kimberly W. Anderson. Development of CREKA-conjugated
iron oxide nanoparticles for hyperthermia treatment of cancer. Kentucky Innovation and
Entrepreneurship Conference, Louisville, KY, September 5, 2014
*Awarded 2nd place
Anastasia M. Kruse, J. Zach Hilt, Kimberly W. Anderson. Development of CREKA-conjugated
Iron Oxide Nanoparticles for Hyperthermia Applications. Markey Cancer Day, University of
Kentucky, May 22, 2014
Anastasia M. Kruse, J. Zach Hilt, Kimberly W. Anderson. Development of CREKA-conjugated
Iron Oxide Nanoparticles for Hyperthermia Applications. Graduate Student Poster Session,
University of Kentucky, May 9, 2014
*Awarded 1st place

204

Anastasia M. Kruse, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Synthesis and
Characterization of CREKA-conjugated Iron Oxide Nanoparticles for the Treatment of Cancer
via Hyperthermia. Society for Biomaterials, Denver, CO, April 16-19, 201
Anastasia M. Kruse, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Synthesis and
Characterization of CREKA-conjugated Iron Oxide Nanoparticles for the Treatment of Cancer
via Hyperthermia, Graduate Student Poster Session, University of Kentucky, September 13, 2013
Anastasia M. Kruse, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Synthesis and
characterization of peptide-conjugated dextran coated iron oxide for hyperthermia applications.
2013 Markey Cancer Day, Lexington, KY, April 15, 2013.
Anastasia M. Kruse, Samantha A. Meenach, J. Zach Hilt, Kimberly W. Anderson. Synthesis and
characterization of peptide-conjugated dextran coated iron oxide for hyperthermia applications.
2012 Biomaterials Day, Lexington, KY, September 22, 2012.
Anastasia M. Kruse, Robert J. Wydra, J. Zach Hilt, Kimberly W. Anderson. Biocompatibility
Analysis and Cancer Therapy Application of Core-Shell Composite Magnetic Nanoparticles.
2011 AIChE Student Meeting, Minneapolis, MN, October 14-17, 2011.
Anastasia M. Kruse, Robert J. Wydra, J. Zach Hilt, Kimberly W. Anderson. Biocompatibility
Analysis and Cancer Therapy Application of Core-Shell Composite Magnetic Nanoparticles.
2010 AIChE Student Meeting, Salt Lake City, UT, November 5-8, 2010.
*Awarded 2nd Place in the Food, Pharmaceutical, and Biotechnology Division

205

